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CHAPTER 1 
General introduction 

General introduction 
1.1 Role of FABPs in lipid metabolism 
Cell viability depends on the biosynthesis and uptake of both water-soluble and -insoluble 
metabolites The diffusional processes for lipid-like molecules such as fatty acids between 
and within cells must be controlled. A large number of carrier proteins have been 
identified, that are involved in the transport of lipids or lipid-like molecules in the body. 
They are present in the serum, and in the extra- and intracellular milieu. For over two 
decades the presence of cytoplasmic proteins that associate noncovalently with hydrophobic 
ligands such as fatty acids or retinoids has been appreciated [190]. Since that time, our 
knowledge of the evolutionary and cellular diversity of these proteins has increased via 
molecular cloning and structural studies, but our understanding of their cellular function 
has not kept pace. Before coming to the main subject of this review, the cytoplasmic fatty 
acid-binding proteins (FABPs), we will shortly discuss other proteins which bind fatty 
acids. 
Lipid-binding molecules belong to several unrelated families of proteins which are 
being increasingly characterized and defined The structure of three families of lipid-
binding proteins has been established [281]. Many of these proteins of these families bind 
fatty acids as their main ligand, but also other proteins with quite different structures (e.g. 
fetuin, heat-shock protein, plasma membrane FABP, glutathione S-transferase, sterol-
carrier protein-2 (non-specific lipid-transfer protein)) have affinity to fatty acids [280,281] 
Albumin is the main transporter of free fatty acids in the blood, but in the fetal 
blood α-fetoprotein and fetuin are also involved in fatty acid transport. Serum vitamin D-
binding protein has a low affimty for fatty acids. The structure of the fatty acid-binding 
sites of albumin and human α-fetoprotein have been described [95, 189] Lactoglobulin is 
the only member of the lipocalins which has a rather high affinity for fatty acids, but also 
binds retinol. Heat-shock protein (72 kDa) contains 2 molecules of nonestenfied palmitic 
and oleic acid each per isolated dimer. Glutathione S-transferases bind tatty acid in their 
regulatory domain II at the C-temunal side. Other proteins which bind fatty acids are the 
membrane-associated fatty acid-binding proteins found in Escherichia coli [170] and in the 
plasma membrane of various mammalian cell types as adipocytes, enterocytes, hepatocytes 
and myocytes (fatty acid translocase, fatty acid transport protein)[l, 233]. 
Two evolutionanly distinct but structurally related families of lipid-binding proteins 
have been identified by comparing known crystallographic data [10, 71]. One group, the 
intracellular lipid-binding proteins, uses a 10-stranded and discontinuous ß-structure. A 
second family of proteins typically found extracellularly, the so-called lipocalins, utilizes 
an 8-stranded motif. The 10-stranded ß-barrels have a large, hydrophilic water-filled 
interior cavity that serves as the ligand-binding domain. Hydrophobic lipids such as fatty 
acids and retinoids bind within the cavity, totally sequestered from the external milieu. The 
8-stranded ß-barrel proteins have a hydrophobic pit, which serves as the ligand-binding 
domain for compounds such as bilins and retinoids. 
Together with two other families of ligand-binding proteins, the FABPs and the 
avidins, the lipocalins form part of an overall structural superfamily: the calycins (reviewed 
in [71]). Members of the lipocalin family are characterized by several common molecular-
recognition properties: the ability to bind a range of small hydrophobic molecules, the 
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binding to specific cell-surface receptors and the formation of complexes with soluble 
macromolecules. In the past, the lipocalins have been classified as transport proteins. It is 
now clear, however, that the lipocalins exhibit great functional diversity, with roles in 
retinol transport, invertebrate cryptic coloration, olfaction and pheromone transport, and 
prostaglandin synthesis. 
The structure of the intracellular glycolipid-, phospholipid-, cholesterol-binding 
proteins, and the serum lipid-binding proteins have no resemblance to that of the FABPs. 
Intracellularly, also an acyl-CoA-binding protein is present [68, 90]. This molecule has 
also a completely different structure although the acyl chain is also bound like in FABP in a 
bent conformation near non-polar residues in the interior of the protein [147]. This acyl-
CoA-binding protein does not bind fatty acids, but has a very high affinity to acyl-CoA 
esters [218] and is involved in their intracellular metabolism [68, 90]. Recently, also sterol 
carrier protein-2 was identified as a high-affinity fatty acyl-CoA-binding protein [75]. It 
also appears to bind fatty acids with lower affinity [75]. 
In this introduction the cytoplasmic FABPs form the main subject. Since our group 
and others have recently reviewed structural [10, 280], and functional [33, 79, 82, 83, 
159, 283] aspects of this protein family, we will discuss especially recent data on their 
protein structure, the regulation of their gene expression and their effects on cellular 
function. Fatty acids and FABPs appear to be directly or indirectly involved in modulation 
of several cellular processes including gene expression, growth and differentiation. These 
latter points will also be taken into consideration in this review. 
1.2 Family of FABPs 
Eight types of cytoplasmic FABP have been well identified up to now. They are 14-15 kDa 
proteins of 126-134 amino acids and are named after the first tissue of isolation or 
identification (Table 1). Some tissues contain more types, either in different cell types 
(brain, kidney, stomach)[118, 166, 198], or in the same cell (enterocyte) [242]. 
Table I. Tissue occurence of FABP types' 
Liver type (L) Liver, intestine, kidney, stomach 
Intestinal type (I) Intestine, stomach 
Heart type (H) Heart, kidney, skeletal muscle, aorta, adrenals, 
placenta, brain, testes, ovary, lung, mammary 
gland, stomach 
Adipocyte type (A) Adipose tissue 
Myelin type (My) Peripheral nervous system 
Ileal type (II) Intestine, ovary, adrenals, stomach 
Epidermal type (E) Skin, brain, lens, capillary endothelium, retina 
Brain type (B) Brain (olfactory bulb) 
The indication of a FABP type m a tissue does not mean us presence m all cell types of that tissue; the FABP 
tvpe may be limited to specific cells or may IK present at certain developmental stages. 
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Adipocyte FABP (A-FABP), myelin FABP (My-FABP), and brain FABP (B-FABP) are 
specifically distributed to adipose tissue, peripheral nervous system, and brain, respective­
ly Human heart FABP (H-FABP), and skeletal muscle FABP (M-FABP) appeared to be 
identical proteins [206] H-FABP is the most widely distributed FABP It is present in 
heart, skeletal and smooth muscle [55, 104, 199] The FABP found in lactating mammary 
epithelial cells was reported to be of the heart type [11, 150] Heart FABP was also 
documented in the aorta by using a cDNA probe and polyclonal antibodies [231] H-FABP 
is also present in distal tubules of the kidney, lung, brain, placenta, and ovary [166, 294] 
A testicular FABP was described, but not yet identified and established [194] 
FABPs show 22-73% similarity of ammo acid sequence (Fig 1) Alignment of the 
amino acid sequences of ileal FABP (Il-FABP) and L-FABP with other FABPs shows d 
four-residue gap (six residues when compared to I-FABP) in the C-terminal part, which is 
otherwise highly conserved throughout the protein family On base of primary structure 
and ligand specificity, Il-FABP, also called intestinal Iipid-binding protein or gastrotropin, 
resembles L-FABP more than any other FABP type [82, 280] Extensive literature is 
available on the family of FABPs, reviewing the structure and regulation of genes [280], 
the protein conformation [10], and functional and physiological aspects [33, 82, 281, 283] 
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Fig. 1. Alignment of the amino acid sequences of the members of the FABP family. Alignment of the ammo 
acid sequences of the members of the FABP familv All sequences are for human proteins, except B-FABP 
which is from rat Positions of well conserved ammo acids (identical residues present ¡n at least 5 molecules) 
are shaded Ammo acid sequences were taken from references H-FABP 1206]. В FABP, [20/, My FABP, 
[1001 A-FABP [171. E-FABP, [168]. I FABP. [256]. L FABP, [162]. II FABP [191J 
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Therefore, only few recently identified FABP members will be discussed in more detail 
here. FABP types of many species have been isolated, identified, cloned and characterized 
with the help of the polymerase chain reaction and the availability of conserved FABP 
sequences. A new FABP type was identified, by the authors called psoriasis-associated fatty 
acid-binding protein (PA-FABP)[168], but also known as skin FABP (S-FABP) [149] or 
epidermal FABP (E-FABP) [244]. Its cDNA showed similarity to human H-FABP (48%), 
A-FABP (52%), and My-FABP (58%). Recently a cDNA was cloned and characterized, 
which encoded a novel FABP from rat brain, the so-called brain type FABP (B-FABP) 
[20] B-FABP was also cloned from mouse and the protein appeared to be closely related to 
H-FABP (67% identity) [236]. 
Evolutionary studies have been performed on FABP sequences, and phylogenetic 
trees were constructed [33, 173, 174, 235]. These analyses showed that cellular retinoid-
binding proteins and the subfamily comprising A-FABP, My-FABP, H-FABP, B-FABP, 
and E-FABP has a common progenitor that diverged early from I-FABP and from the L-
FABP/I1-FABP subfamily [33]. All genes of this family analyzed to date contain 4 exons 
and 3 similarly positioned introns of variable size [280]. A calculation by Matarese et al. 
[173] indicated that the different subfamilies diverged from the common ancestral gene 
about 700 million years ago, that is, before the invertebrate-vertebrate divergence 
FABPs have been detected in vertebrates (including fish)[65, 160, 161, 251] as well 
as invertebrates [18, 98, 180, 275]. Intracellular FABP purified and characterized from 
aerobic skeletal muscle of Antarctic icefish Chaenocephalus aceratas, and striped bass 
Morone saxatilis, appeared to be similar to mammalian H-FABP [160, 161]. Invertebrate 
FABPs with high similarities to mammalian H-FABP were isolated from flight muscle of 
locusts [98, 275] and from parasites like schistosomes and Fasciola hepática [18, 180, 
246]. Recently, a 15 kDa FABP was isolated from the cytosol of Yarrowia lipolytica, a 
yeast which is well-adapted to grow on long-chain fatty acids as the sole source of carbon 
and energy [63]. Partial amino acid sequencing revealed no significant homology to the 
FABPs found in higher eukaryotes. 
FABPs are generally considered to be intracellular, cytosolic proteins [82, 280]. 
Based on immuno-electron microscopy, retinal FABP (identical to E-FABP) was also 
located within the nucleus of the chick retina [85], H-FABP within mitochondria [34, 73, 
272] and nuclei [34] of rat and bovine heart cells, and within nuclei but not mitochondria of 
the locust, Schistocerca gregaria, flight muscle [97]. Using anti-H-FABP/MDGI 
antibodies, Muller et al. detected a signal in nuclei of mammary epithelial cells [184] B-
FABP was detected in the nuclei of mouse glial cells and rat astrocytes [69, 309] and II-
FABP in nuclei of rat absorptive epithelial cells [3]. The occurrence of FABP in subcellular 
compartments other than cytosol must have a bearing on the functions of these proteins. In 
a recent study it was shown that extracellular fatty acid enters the hepatocellular nuclei in 
vivo as well as in vitro [88], and this uptake depends on the extracellular and/or cytoplasmic 
fatty acid concentration. FABPs may play an obvious role in this fatty acid transport 
Nuclear occurrence of FABP could be functionally related to the activation of gene 
expression by fatty acids in adipocytes and hepatocytes [66, 126, 176]. The two α-helices 
and a turn of the three-dimensional structure of H-FABP show similarities to the helix-turn-
helix motif [188]. The latter authors proposed that this helical domain of the H-FABP may 
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be involved in DNA binding, and its activity would be modulated by phosphorylation at 
position Tyr-19 No evidence for this hypothesis has been given yet 
Chromosomal mapping of human and mouse FABP genes shows a dispersed pattern 
of loci along the genomes (Table 2) Within these species the genes are located on different 
Table 2. Chromosomal location of genes of members of the FABP family 
Chromosome (region) 
Member 
Liver FABP 
Intestinal FABP 
Heart FABP 
Adipocyte FABP 
Ileal FABP 
Myelin FABP 
Brain FABP 
Epidermal FABP 
Locus * 
FABP1 
FABP2 
FABP3 
FABP4 
PMP2 
FABP5 
Human 
2(pl2 ql l ) 
4(q28q31) 
1 (p32 p33) 
8(q21) 
5 (q23-q35) 
8(q21 3 q22 1) 
7 
·> 
Mouse 
6 
3 
4 
3 
11 
7 
7 
7 
* Name of the locus of the human FABP encoding gene 
chromosomes Synteny exists between the regions where the H-FABP encoding genes ot 
human, mouse, and pig are located (chromosome 1, 4, and 6, respectively) [78, 206, 267, 
270] In these species the H-FABP gene is located in the same region as the loci ENO-1 and 
PGD [219, 307] The genes coding for A-FABP and Il-FABP are also located in chromoso-
mal segments with a syntenic origin [29, 104, 191, 212] The human A-FABP and My-
FABP (peripheral myelin protein 2) encoding genes are mapped to the same chromosomal 
subregion (8q21 3-q22 1) [99, 212] This, together with the high similarity of their coding 
sequences (73%) suggests a common origin Until now, no chromosomal localization 
studies have been described for the recently identified B- and E-FABP Studies of 
chromosomal localization of the FABP-encoding genes should consider the possibility of 
cross-hybridization to other (unknown) FABP genes or to pseudogenes This problem may 
be circumvented using genomic probes, preferably derived from intronic regions, or PCR 
primer sets amplifying introns [212] Until now, processed pseudogenes have been found 
exclusively for H-FABP genes of mouse [104], human [213], and pig [78] 
Polymorphisms of the FABP gene have been identified in man and domestic animals 
(Table 3) Only one of these polymorphisms has been shown to cause a structural defect 
with physiological consequences Thr54Ala substitution in exon 2 of the human I-FABP 
gene has found to be associated with significant increases in body mass index, percent body 
fat, and fasting plasma tnacylglycerol concentration, but not with the presence of insulin 
resistance [9, 101] In an attempt to find deletions or point mutations in the human 
MDGI/H-FABP gene which could account for silencing of this gene in human breast 
neoplasms [114], a Lys53Arg polymorphism was found in 2/90 of control individuals 
[208] This rare exon 2 polymorphic variant was, however, not associated with the 
incidence of breast cancer [208] In bovine heart, two isotypes of H-FABP were reported 
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which only differ in one position, Asp-98 in pi 4 9 H-FABP and Asn-98 in pi 5 1 H-FABP 
[272] Amino acid position 98 of H-FABP is located within a ß-rurn at the surface of 
protein and is exposed to the environment [183, 311] The origin for this H-FABP 
heterogeneity in bovine heart was demonstrated to be caused by distinct mRNA species, 
rather than by post-translational modification (deamination) [13] Whether the distinct 
mRNA species are derived from separate genes, alternative splicing, or RNA editing has to 
be elucidated yet 
Table 3. Polymorphisms in FABP genes 
Species 
human 
bovine 
human 
bovine 
porcine 
Polymorphism 
(TTA)„ repeat 
Ala54Thr 
Taql 
Lys53Arg 
Asn98Asp 
Hinñ 
HaelU 
Msp\ 
Location 
intron 2 
exon 2 
9 
exon 2 
exon 3 
5' UTR 
intron 2 
intron 2 
Reference 
[210] 
[91 
[12] 
[208] 
ИЗ] 
[78] 
5 UTR, upstream noncoding region 
1.3 Structure and ligand binding 
The first secondary structure predictions of FABPs were based on the amino acid sequence 
and circular dichroism (CD) spectra of purified tissue-derived proteins Estimates of 
secondary structure based on the CD studies, indicated a prevalence of ß-structure for L-
and H-FABP [120. 192, 239] Detailed information on the three-dimensional structure of 
apo and holo FABPs have been obtained by high-resolution NMR [108, 109, 164] as well 
as crystallography [10, 228, 229, 311] NMR analysis of different FABP types have been 
performed by one-, two-, and multidimensional NMR spectroscopy [96, 108, 152, 164, 
223] Furthermore, interactions of 13C-enriched fatty acids with L-FABP and I-FABP were 
studied by NMR [51, 52] All FABPs, whose three-dimensional structures have been 
determined by crystallography or NMR thus far, show a common folding motif [10, 280] 
This motif, also called up-and-down ß-barrel [151], consists of a series of 10 extended 
polypeptide segments or ß strands (ßA - ßJ) running antiparallel to each other with a 
relative twist The first and the tenth ß-strand form hydrogen bonds to each other 
completing the ß-barrel motif The bound ligand is found withm the barrel in a central, 
internal water-filled cavity The interior surface of the cavity is formed by the side chains 
of both hydrophobic and polar amino acids The amino acids whose side chains extend into 
the cavity vary between different members of this family It is suggested that the various 
side chains of these buried amino acids determine the volume of the cavity and the 
specificity for the ligand while maintaining a common structural motif used by all family 
16 
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members Internal solvent (water) molecules function in the displacement of fatty acid and 
maintain the electrostatic interactions inside the binding cavity Holo H-FABP contains at 
least 13 ordered water molecules in its binding cavity [308] A hydrophobic patch of amino 
acid residues Phe-4, Trp-8 and Phe-64 is located near the bottom of the gap between the ßD 
and BE strands of the H-FABP structure The role of this conserved cluster of hydrophobic 
residues has to be established but may relate to the stability of the protein 
The three-dimensional structure of ileal FABP, which was recently solved by high-
resolution NMR, is similar to that of other FABPs, but appears to be unusually flexible, 
with a relatively weak hydrogen-bonding network [164] It is likely that this flexibility is 
important in allowing a bile acid, which is larger and more rigid than a fatty acid, to enter 
the central cavity of the protein In contrast to most of the FABPs, the structure of L-FABP 
has not been refined yet Comparative CD and infrared studies of L-FABP and I-FABP or 
L-FABP and H-FABP were used to elucidate changes in secondary structures of L-FABP 
upon heat denaturation or pH shifts of these proteins [51, 182, 258] L-FABP appeared to 
be a predominantly ß-strand protein, like all FABP structures refined yet In contrast to I-
FABP and H-FABP, carboxylate groups of fatty acids bound to L-FABP are solvent-
accessible and located at or near the protein/solvent interface [51] 
Members of the FABP family all have a high affinity for fatty acids [283] I-FABP 
and H-FABP are specific binders of fatty acids [167, 203], whereas L-FABP and II-FABP 
bind more bulky, hydrophobic ligands as lysophospholipids, prostaglandins, bile acids, 
eicosanoids, and some drugs [167, 250, 264] My-FABP has been shown to bind retinol 
(273)(Uyemura, 1984) while A-FABP and My-FABP both bind retinole acid [17, 49, 172, 
273] Ligand-binding properties of B-FABP differ from other FABPs because B-FABP does 
not bind palmitic acid [304] Docosahexaenoic acid (22 6 n-3), however, which is found 
abundantly in the nervous system, is a high-affimty-hgand for B-FABP [304] 
All FABP structures determined until now by NMR or crystallography showed two 
α-helical regions (reviewed in [10, 280]) To investigate the structural and functional role 
of this conserved helical domain of FABPs, a helix-less variant of rat I-FABP was 
engineered by deleting residues 15-31 and inserting a Ser-Gly linker after residue 14 [143] 
CD measurements and NMR spectra indicated that this I-FABP variant has a high ß-sheet 
content and a ß-clam topology similar to that of the wild type protein [143] The variant 
was less stable to guanidine than wild-type I-FABP Oleate bound to the helix-less I-FABP 
with a dissociation constant approximately 20-100 fold higher than that for wild-type I-
FABP [50] The fatty acid-protein interactions of the helix-less mutant were similar to those 
of the wild-type I-FABP at the carboxylate end of the fatty acid, but not at the methyl end 
Ligand association rates for the helix-less variant and the wild-type protein were 
comparable, but the dissociation rate was 16-fold lower for the wild-type protein [50] It 
was concluded that the α-hel ices of I-FABP are not required to maintain the integrity of the 
fatty acid binding cavity but may serve to regulate the affinity of fatty acid binding by 
selectively altering the dissociation rate constant 
A frameshift mutation into the coding region of L-FABP cDNA led to amino acid 
sequence rearrangements in the C-terminal region of the recombinant protein, starting with 
amino acid position 104 This resulted in a premature termination of translation, causing a 
mutant protein which also lacks amino acid residues 118-127 [163] This L-FABP mutant 
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showed a significant decrease in binding affinity to oleoylaminohexylamino Sepharose. 
Information on the ligand binding domain of FABPs has initially been obtained by 
the use of sulhydryl modification of the two cysteinyl residues of A-FABP [40] and arginine 
modification and enzymatic degradation of H-FABP and L-FABP [32, 204, 239]. Chemical 
modification of the cysteine residue of L-FABP did not affect fatty acid-binding activity, 
but reaction of Cys-117 in A-FABP with sulfhydryl reagents caused a large decrease in 
oleate binding affinity [40, 202] Modification of Cys-1 of A-FABP had no effect. At 
blocking of arginines of H-FABP and L-FABP, a strong inhibition of fatty acid-binding 
activity was detected [32, 204, 239]. These results suggest that Cys-117 in A-FABP and 
arginine(s) in H-FABP and L-FABP reside in the ligand-binding domains of these proteins. 
The tertiary structures of My-FABP, I-FABP, A-FABP, and H-FABP types have 
been elucidated using X-ray analysis (reviewed in [10, 227]). Their overall structural 
features are similar. Apo- and holo- structures are comparable for I-FABP and A-FABP 
based on their X-ray diffraction analysis [228, 229, 305] and for H-FABP on base of NMR 
spectroscopy and Trp fluorescence [152, 214]. The structures of apo- and holo-forms of L-
FABP studied by CD and NMR appeared to show conformational differences [156]. 
Characteristic amino acid residues important in fatty acid binding are Arg-106 and Arg-126. 
Only one of these arginine residues, Arg-122, is conserved in rat L-FABP and Il-FABP, 
whereas the other Arg, (at position 102), is replaced by threonine and serine, respectively 
The marked 4-6 residues gap in the region between ß-strands G and H only found in ileal 
and L-FABP [164, 280], and the absence of Arg-106 may relate to their affinity to other, 
more bulky hgands than fatty acids 
The three-dimensional structure of human H-FABP with bound fatty acid was 
resolved and refined by X-ray diffraction to 2.1 Â resolution [311]. The carboxylate group 
of the fatty acid is located in the interior of the protein, where it forms hydrogen bonds 
with the side chains of Туr-128 and Arg-126 and several ordered water molecules (Fig. 2). 
V > r ARC 126 \кг( ^ ^ A R G 126 
фш T>R 1ZB - » s TYR 128 
V ^ N ^ ~£?J X^ytt^ ^^J 
• o^f ARG l06 j ψ 
•λ A 
_ ,. ƒ ARG 106 _ ^ / ARC ΙΟβ 
• · ТИК 40 · · THR 40 
Fig. 2. Stereodiagram of the fatty acid-binding site of human muscle FABP. The ammo acid residues 
involved in the binding are given as empty circles, the fatty acid and the seven solvent (water) molecules as 
filled circles. Hydrogen bonds are represented by dashed lines This figure was taken from ref. [311] 
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In this network of hydrogen-bonds, Arg-106 and Thr-40 are indirectly involved in ligand 
binding The fatty acid has a U-shape conformation in the binding cavity of H-FABP High 
resolution X-ray studies on complexes of H-FABP with oleate, elaidate, and stéarate 
showed that these fatty acids are bound in a similar fashion [308] In contrast to its U-shape 
conformation in H-FABP, complexed oleate shows an extended conformation in the binding 
cavity of I-FABP [232] 
Recently, the first naturally occunng mutation was detected in I-FABP This 
Ala54Thr mutant of I-FABP showed a twofold larger affinity for fatty acids [9] The amino 
acid mutated is located in a tight turn between ß-strands С and D, which is critical m the 
conformational adjustment between the apo- and holo-form of I-FABP [107, 108, 230] 
To study the structure-function relationship of FABPs more systematically, sue 
directed mutagenesis has been used to introduce point mutations in FABP cDNAs and 
subsequently, produce mutant FABPs for in vitro studies Conserved residues in the amino 
acid sequence alignment are putative targets for mutagenesis Furthermore, target amino 
acid residues were chosen on base of the putative importance of their side chains in fatty 
acid-binding or for the conformational structure, based on the elucidated or postulated 
(forL-FABP) three-dimensional structure Various single-amino acid mutants of members of 
the FABP family have been prepared and studied for ligand specificity and affinity and 
stability (Table 4) The highly conserved Arg-106 and/or Arg-126 residues in I-FABP, A 
FABP, H-FABP, and B-FABP appeared to be important for binding affinity and ligand 
specificity Mutation of Arg-106, Arg-126, and Tyr-128 of H-FABP affected markedly 
fatty acid binding and conformational stability [214] Replacement of Arg-106 by Gin in rat 
I-FABP caused a 20-fold increase of the dissociation constant for oleic acid with a 6-fold 
decrease of the enthalpic contribution to the free energy of binding [121] This mutant 
protein showed, in contrast to the wild-type, a high affinity to retino! Also for rat L-FABP, 
mutation of argimnes indicated a major role of these amino acids in ligand binding [261] It 
is remarkable that an extracellular segment of the fatty acid translocase (CD36) region 
comprising amino acids 127-279 exhibits significant homology to H-FABP throughout 73% 
of its sequence [1, 249] The amino acids Arg-126 and Tyr-128 in H-FABP known to 
interact with fatty acid carboxyl group are conserved in CD36 as Arg 272 and Tyr-275 
[249] 
Hydrophobic amino acid residues may play a role in ligand affinity and/or 
specificity by forming Van der Waals contacts with the acyl chain of the bound fatty acid 
Amino acid residues Phe-16 and Phe-57 of H-FABP are both near the putative fatty acid 
entry The phenyl ring of Phe-16 may form a key determinant in ligand specificity and 
affinity of H-FABP [311] In the refined structures of H-FABP, A-FABP, and I-FABP, 
Phe-57 or Phe-55 are located in a ß-turn between ß-strands С and D [232, 305] This 
position may change the side chain's orientation on ligand binding [10] Results of 
mutations of Phe-57 in B-FABP and H-FABP indicate that this residue is not a major 
contributor to the FABP/ligand interaction [214, 304] Mutation of Gly-33 of B-FABP, 
which is adjacent to the opening of the binding pocket, into a bulkier amino acid could 
preclude ligand binding by preventing its access to the binding pocket and by occupying 
part of the volume normally used by the ligand [304] 
Acetylation and substitution of external lysine residues of H-FABP and A-FABP 
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Table 4. Effect of mutations on binding affinity and stability of FABPs 
F ABP type Mutation Binding affinity Stability Reference 
I-FABP ТгрбТуг 
Trp82Tyr 
Ile23Cys 
Ser53Cys 
Val60Cys 
Leu72Cys 
Leu89Cys 
Alal04Cys 
Argl06Gln 
Ala54Thr 
Leu64Ala 
Leu64Gly 
Gly65Ala 
t 
1 1 
i i 
i i 
i 
[223,224] 
[124] 
[121] 
[9] 
[144] 
A-FABP 
H-FABP 
L-FABP 
B-FABP 
Thrl25Gln 
Argl26Gln 
Tyrl28Trp 
PhelóSer 
PhelóTyr 
PhelóVal 
Thr40Glu 
Thr40Val 
Thr40Gln 
Phe57Ser 
Phe57Val 
Argl06Thr 
Argl26Lys 
Argl26His 
Argl26Gln 
Tyrl28Phe 
Phe64Ser 
Lys22Ile 
Lys22Glu 
Thr28Lys 
Lys5911e 
Phe3Trp 
Phel8Trp 
Cys69Trp 
Thrl02Gln 
Argl22Gln 
Argl22Lys 
Arg 122 Ala 
Argl26Lys 
Gly33Phe 
Gly33Ile 
Phe57Ala 
Arg 106 Ala 
Argl26Ala 
* i 
i 1 
i i 
i 
i 
i i 
i 
i 
i 1 
1 
i i 
i i 
i i 
i 
i 
i i 
i i 
i i 
i 
i i 
* i 
i 
i 
1 
[241] 
[214] 
[282] 
[102] 
[263] 
[262] 
[261,262] 
[261] 
[304] 
Binding was studied with oleic acid, ш-раппапс acid or DAUDA; stability by heat or urea denaturation. 
i i , strong decrease; 1, decrease, -, no change. For abbreviations of amino acids see Table A, page 8. 
General introduction 
located on ß2 turn and helices α-I and α-H did not change binding affinity of fatty acid, but 
changed transfer rates of 2-(9-anthroyloxy)palmitate to phospholipid membranes [102, 103] 
Conformational stability of wild-type and mutant FABPs have been tested by 
measuring the effect of dénaturants as urea and guamdine [42, 214, 223, 261] or heat [224] 
on intrinsic fluorescence (Table 4) The intrinsic fluorescence of H-FABP arises primarily 
from Trp-8 and Trp-97, which are not involved in the fatty acid-binding centre on the base 
of their positions in the protein Denaturant-induced unfolding curves of mutant proteins 
have been used to calculate the concentration of dénaturant at which 50% of the protein is 
unfolded This parameter is used as a measure for the conformational stability of the protein 
tested The conformation of all wild-type FABPs tested is remarkably resistant to dénatu-
rants Proteins keep also their capacity to refold, when dénaturant is removed Significant 
changes in conformational stability have, however, been detected in site-specific mutants of 
I-FABP, H FABP, and L-FABP (Table 4) Most mutants of H FABP and L-FABP show a 
decrease of binding affinity and conformational stability, some only a loss of stability I-
FABP mutants have been prepared in which cysteine residues were modified with the bulky 
reagent fluorescein [74] All six proteins so modified could refold, suggesting that the 
protein can accomodate major disruptions in the structure and still fold 
Recently it was shown by analysis of mutants of I-FABP that the highly conserved 
region between the two adjacent antiparallel strands ßD and BE that are not within hydrogen 
bonding distance appears to be involved in stabilization of the native structure and in the 
slow refolding process [144] A series of single, double, and triple mutations of the 
sequence Leu-64/GIy-65/Val-66 that include mutation of Leu-64 by Gly resulted in a large 
decrease of oleic acid binding and loss of stability A single mutation at Gly-65 affected the 
stability slightly 
1.4 Role of FABPs in uptake and metabolism of fatty acids 
Most eukaryotic cells are capable of taking up long-chain fatty acids to be used for a variety 
of cellular processes Literature data indicate that the uptake of fatty acids may occur both 
by passive diffusion and by protein-mediated binding and/or translocation mechanisms 
Cellular uptake of these hydrophobic molecules is well possible by simple diffusion across 
the plasma membrane, an extremely fast first-order process also called flip-flop [105, 129, 
310] Uptake into adipocytes involves the passive diffusion of protonated long-chain fatty 
acids [53, 268] Tissues as intestine, cardiac muscle, and adipose tissue specifically and 
efficiently take up and/or release fatty acids in a regulated fashion In these tissues, facilita-
ted processes may also contribute to fatty acid uptake In cardiac myocytes and adipocytes, 
an integral plasma membrane fatty-acid transport protein (FATP) functions as a long-chain 
fatty acid transporter [233, 234] Several other membrane-bound proteins with affinity to 
fatty acids have been isolated from heart [76], adipocytes [1], skeletal muscle [45], kidney 
[77] and intestine [209] A 88 kDa membrane protein called fatty acid translocase (FAT), 
isolated originally from rat adipocytes [1] showed high homology (85%) to the human 
leucocyte differentiation antigen CD36, a receptor protein present among others on 
monocytes and platelets, and thought to be involved in adhesion phenomena and ìntracel-
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lular signalling. FAT was found to be co-expressed with FABP in rat heart and skeletal 
muscle [278], in bovine mammary gland [249], and in intestine [209]. FAT is not expressed 
in rat liver or kidney [1]. Transfection of FAT cDNA in fibroblasts resulted in a higher 
fatty acid uptake rate in the FAT-expressing clones, compared to mock-transfectants [115]. 
Plasma membrane fatty acid-binding proteins of 40-43 kDa have been partially purified 
from and/or shown to be present in hepatocytes, myocytes, keratinocytes, enterocytes, 
adipocytes, and endothelial cells (reviewed in [211, 240, 280]. The significance of all types 
of membrane-associated fatty acid-binding proteins is unclear, including their possible 
interaction with extracellular albumin and intracellular FABP [277]. The rates of dissocia-
tion for long-chain fatty acids from membranes are sufficiently rapid (although much lower 
than the flip-flop rates) that complex mechanisms (e.g. protein-mediated) may not be 
required for their desorption at the cytoplasmic side of the plasma membrane [313]. 
I. '• NUCLEUS 
ENDOTHELIAL \ Ç 
CELL 
@ Plasma membrane 'a l ly acid binding piolnn 
V Albumin i tof i tor 
Fig. 3. Schematic representation of the fatty acid transfer from blood to cellular organelles and systems of 
lipid synthesis. 
Abbreviations: FA, fatty acid; VLDL, very low density lipoproteins; chylos, chylomicrons; ECF, extracellular 
fluid; FAR. putative FA receptor; FARE, FA receptor element. This figure was taken from ref. [280/. 
Fatty acid transport across and dissociation from the plasma membrane may be followed by 
binding to the cytoplasmic FABP and transfer to cellular organelles (Fig. 3). In fact, the 
cytoplasmic mobility of lipid-like molecules as fatty acids is dependent on the ratio of the 
membrane-associated fraction and the soluble fraction, which is determined by the presence 
of cytoplasmic binding proteins [297]. Since lateral diffusion within membranes is very 
slow, fatty acids solubility in the aqueous phase limits fatty acid diffusion. FABP increases 
fatty acid solubility and in this way cytoplasmic diffusion. FABPs appeared to increase 
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considerably [14C]fatty acid transfer in experimental systems, composed of various 
combinations of liposomes, phospholipid monolayers, mitochondria, or microsomes [37, 
205]. In a theoretical model for intracellular fatty acid transport in the hepatocyte it was 
calculated that FABP enhanced the fatty acid overall transport (diffusion) through the 
aqueous cytoplasm by at least one order of magnitude [265]. In a model cytosol system, an 
increase in fatty acid transport was found when H-FABP was added [252]. Using data on 
binding characteristics and myocardial content of FABP for rat heart, others calculated that 
FABP can enhance the rate of intracardiomyocytal transport of fatty acids about 17-fold 
[288] Uptake of photoactivable radiolabeled fatty acids was accompagmed with labeling of 
FABP in HepG2 cells, rat hepatocytes, and 3T3 adipocytes [269, 289, 290]. Inhibition of 
binding of a fatty acid analogue [12-N-methyl-7-nitrobenzo-2-oxa-l,3-diazol-amino stéarate 
(NBD-stearate)] to L-FABP reduced proportionally its cytoplasmic transport in hepatocytes 
[165]. 
Fatty acid transfer by FABPs has also been studied with the help of fluorescent 
anthroyloxy-labeled fatty acids (AOFAs) and phospholipid vesicles [253]. Members of the 
FABP family transfer these fatty acids to phospholipid membranes via distinct mechanisms 
[113, 141, 142, 302, 303]. AOFAs are transferred from I-FABP, H-FABP, and A-FABP 
by collisional interaction of the protein with an acceptor membrane since the rate of transfer 
increases linearly with the concentration of acceptor vesicles L-FABP transfers fatty acid 
to membranes in an aqueous diffusional manner involving an initial and obligatory release 
of ligand to the aqueous milieu. The transfer rates differ markedly for the FABP types, e.g 
the transfer rate of 12-(9-anthroyloxy)oleic acid to phospholipid vesicles is for A-FABP > 
H-FABP > > I-FABP > > L-FABP [253]. The rate of transfer increases markedly for A-
FABP and H-FABP when membranes contain anionic phospholipids, suggesting that 
positively-charged residues on the surface of the FABP are involved in ionic interactions 
with membrane phospholipids [303]. Neutralization of surface lysine residues of A-FABP 
and H-FABP by acetylation decreases the AOFA transfer rate, and transfer was then found 
to proceed via aqueous diffusion rather than collisional interaction [102, 103, 303]. Site-
specific mutagenesis of surface lysine residues has further shown that the helix-turn-helix 
domain, and especially Lys-22 of H-FABP is critical for interaction with anionic acceptor 
membranes [102]. In addition, direct interaction of A-FABP, but not acetylated A-FABP 
with anionic membranes has been demonstrated [253]. Thus, cytosolic FABPs may not only 
function in intracellular transport of fatty acids by decreasing their membrane association, 
but they may also target fatty acids to specific subcellular sites of metabolic utilization. 
A relation between fatty acid oxidation capacity and cytosolic FABP content was 
found in heart and various muscles of the rat [284]. Other tissues (kidney, brain, adrenals) 
do not show such a relation, since they are involved in more or other pathways of fatty acid 
metabolism. Effects of FABP expression on fatty acid oxidation have mostly been studied in 
cells which show an increased or decreased FABP level caused by change of endogeneous 
FABP [280, 283]. Induction of L-FABP by the peroxisome proliferators perfluorodecanoic 
acid (PFDA) and Clofibrate, has been shown to accompany induction of peroxisomal ß-
oxidation in primary rat hepatocytes [126, 274] as well as rat liver [284]. 
To establish the role of FABP in the cellular uptake and metabolism of fatty acids, 
various FABP cDNAs have been transfected in different cell types (Table 5), most of which 
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Table 5. Effect of FA Β Ρ cDNA transferiert on fatty acid uptake and esterification 
Cell type FABP type Uptake Esterification Reference 
HepG2 cell 
Mouse L-cell fibroblast 
Caco-2 cell 
CHOcell 
Yeast 
3T3 preadipocyte 
COS7 cell 
Rat L6 myoblast 
L-FABP (antisense) 
L-FABP 
l-FABP 
I-FABP 
A-FABP 
H-FABP 
H-FABP 
H-FABP 
H-FABP 
H-FABP 
H-FABP (antisense) 
A-FABP 
η 
Τ (PL>TAG) 
Î (TAOPL) 
-
Τ 
-
0 
о 
τ 
-
[221] 
[185] 
[216,217] 
[8] 
[241] 
[237] 
[233] 
[233] 
[54] 
(Chapteró) 
I . decrease, f , increase. - , no change * Total amount of L-FABP and l-FABP is not proportional to FA 
transport 
do not express endogenous FABP. The results were variable. Marked differences were 
observed between mouse L-fibroblasts transfected with L-FABP or I-FABP cDNA, in the 
fatty acid uptake and the esterification into triacylglycerol and phospholipids [185, 216, 217]. 
A change of FABP content by cDNA transfection did not affect, however, fatty acid uptake in 
many cell types (Table 5). FABP synthesis in Xenopus laevis oocytes injected with FABP 
mRNA had also no effect on uptake of oleic acid [70]. We conclude that the effect of FABP 
increase on fatty acid uptake may be related to FABP type and cell type studied. 
Esterification of radiolabeled fatty acids has been studied with cultured cells, 
transfected with cDNAs coding various FABPs. Esterification of oleic acid was increased in 
both L-FABP and I-FABP cDNA transfected fibroblasts [185, 216, 217]. The type of FABP 
cDNA transfected influenced the targeting of fatty acids to triacylglycerols or phospholipids 
and to PC or PE. Alterations in plasma membrane lipids and/or structure were found in 
transfected fibroblasts expressing L-FABP [117, 123, 301]. Their PC/ΡΕ ratio increased at a 
higher content of L-FABP. Increase of H-FABP content in rat L6 muscle cells by transfection 
with H-FABP cDNA did not change fatty acid oxidation and incorporation into 
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triacylglycerols and phospholipids (Chapter 6) The palmitate incorporation into the various 
neutral lipid and phospholipid species differed between L6 cells transfected with H-FABP or 
A-FABP cDNA (Chapter 6) 
1.5 Regulation of expression of FABPs 
Several physiological conditions are known to influence the expression of FABPs both on 
mRNA and/or protein level Differentiation of human skeletal muscle cells in culture is 
accompanied by an increase in the concentration of H-FABP [19] Cell lines of mouse and rat 
skeletal muscle also show this differentiation-dependent expression of H-FABP [226](Chapter 
6) A differentiation-stage dependence has also been observed for other FABPs in their 
respective cell types An increase of L-FABP was found during mitosis in hepatocytes [16. 
24, 59] L-FABP and I-FABP levels increased in enterocytes during their translocation from 
the upper crypt to the base of the intestinal villi and during their migration to the apical 
extrusion zone [57, 225, 242, 256, 257] A strong increase in A-FABP expression was found 
when cultured preadipocytes are induced by dexamethasone and insulin to differentiate to 
adipocytes [23] This increase is concomitant with an increase in other late markers of adipose 
differentiation, e g acyl-CoA synthetase, glycerol-3-phosphate dehydrogenase, glucose 
transporter-4, hormone-sensitive lipase, adipsin, and fatty acid translocase [2] Expression of 
B-FABP in radial glia throughout the developing central nervous system is strictly correlated 
with the differentiation and migration of neurons upon these cells [69] E-FABP (LP2) 
content in bovine lens increases strongly upon differentiation [122] E-FABP mRNA was also 
found in high concentrations in the rat lens, and at lower levels in rat skin [149], retina, and 
lung [295, 298] In situ hybridization analysis localized E-FABP to the lens epithelial cells 
and to the glial cells of the retina, regions that are expected to be most active in cellular 
differentiation [298] Primary keratinocytes cultured for at least 8 days under conditions that 
promote incomplete terminal differentiation, revealed a 9-fold upregulation of E-FABP [195] 
During postnatal development of liver, heart, muscle, and kidnev the content of the 
FABP increases [284] Distinct patterns of developmental change in H-FABP mRNA 
accumulation were documented in heart, placenta, brain, kidney and testes [104] In 
agreement with the developmental regulation of H-FABP mRNA expression, the content of 
H-FABP showed a significant increase with the pre- and postnatal development of rat heart 
and skeletal muscle [58, 199, 284] Expression of H-FABP mRNA became evident in brain 
after birth, with a gradual increase and confined to the gray matter, suggesting that the 
expression of H-FABP mRNA is neuron-specific [198] Three members of the FABP family, 
H-FABP. E-FABP, and B-FABP, show a spatio-temporally differential expression in 
developing and mature brain [198] Mammary epithelial proliferation and H-FABP gene 
expression appear to be developmentally regulated [11, 150] Virgin mouse mammary gland 
(primarily adipocytes) express A-FABP, whereas glands of pregnant and lactating mice 
express H-FABP [11, 187] 
Cold acclimation of striped bass, Morone saxatilis, from 25°C to 5 С caused an 
increase in FABP concentration in aerobic skeletal muscle [161] Authors suggested that the 
increase of FABP could compensate for its predicted lower diffusion coefficient at 5°C 
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Furthermore, electrostimulation and treadmill running have been reported to increase H-FABP 
content in rat muscles (m extensor digitorum longus and m plantaris) by 4- and 1 8-fold, 
respectively [62, 135] 
Some diseases have been observed to change the synthesis of FABPs Three weeks 
after the induction of hypertension in rats, the expression of H-FABP decreased 20-fold in 
aorta, but it did not change in heart, skeletal muscle, or kidney [231] Streptozotocin-diabetes 
markedly decreased the level of A-FABP mRNA and protein in rat adipose tissue [175], and 
the content of L-FABP in liver [35, 186, 285], whereas H-FABP levels in rat heart and some 
skeletal muscles increased [46, 81, 285] Analysis of protein patterns of keratinocytes revealed 
a high up-regulation of some low-molecular-mass proteins in psoriatic skin [168] Among 
these proteins, a new FABP type was identified, by the authors called psoriasis-associated 
fatty acid-binding protein, later termed E-FABP [168, 244] 
Endocrine effects also seem to play a role in FABP expression Especially L-FABP 
synthesis has been shown to change by the influence of hormones like oestrogens, 
testosterone, and glucocorticoids [186, 279] Furthermore, hypophysectomy caused a 
significant drop of L-FABP levels The effect of hypophysectomy was not significantly 
altered by Cortisol administration, but was greatly decreased by growth hormone [24, 245] L-
FABP levels decreased significantly in 12-22 month old rats compared to growing and 4-11 
month old rats [245] Pregnancy and lactation caused an increase of L-FABP in rat liver by 
effects on the transcriptional level [26] Also transforming growth factor beta-1 (TGFßl) 
appears to regulate the expression of L-FABP and I-FABP [72] Gene-targeted TGFßl -
deficient mice had 25% less L-FABP when compared to control mice This effect was 
developmentally related and specific to the liver Only I-FABP was decreased 3-fold in the 
proximal intestine of the TGFßl-deficient mice 
Intestinal FABP expression may be not constitutive as previously suggested [15] In an 
intestinal cell culture system, induction of I-FABP in the presence of limiting serum was 
prevented by the addition of insulin [94] 
Recent observations have shown that both natural and nonmetabolized long-chain fatty 
acids regulate the expression of various lipid-related genes in preadipocyte cell lines as well 
as in rat preadipocytes This includes the gene encoding A-FABP [6, 66, 92] Fatty acid-
înduced A-FABP transcription was specific for preadipocytes It was not observed in two 
mouse myoblast cell lines [4. 66] We did not detect H-FABP induction by addition of high 
fatty acid concentrations to cultures of rat L6 myoblasts or myotubes (Chapter 6) Ileal FABP 
is upregulated after bile infusion (6 times a day for 3 days) into the terminal ileum of male rats 
or when differentiated Caco-2 cells are cultured in the presence of 5% human bile [133] In 
the same way, upregulation of the L-FABP gene was reported to occur by long-chain fatty 
acids Using a well-differentiated FAO rat hepatoma cell line, a 4-fold increase in the L-FABP 
level was detected 16 h after addition of a medium containing C,6-C20 fatty acids [176] This 
upregulation was also found with cultured rat hepatocytes [176] High-fat diets induce L-
FABP mRNA expression and L-FABP synthesis in liver and small intestine [14, 25, 169. 284] 
like peroxisomal proliferators as benzafibrate, Clofibrate, di(ethylhexyl)phtalate (DHEP) and 
perfluorodecanoic acid (PFDA) [15, 27, 36, 199, 274, 284] For the L-FABP gene the 
induction by peroxisome proliferators has been explained by the presence of a peroxisome 
prohferator-response element (PPRE) in its promoter [119] Benzafibrate and ETYA, strong 
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PPAR activators, induce L-FABP mRNA in primary hepatocytes [36] and FAO cells, 
respectively [176] In addition, PFDA and clofibnc acid compete with long-chain fatly acids 
for binding to FABP The ability of a fatty acid to induce peroxisomal ß-oxidation and L-
FABP appears to correlate inversely with the rapidity of its intracellular metabolism [126] 
Thus, the lack of effect observed after exposure of cultured hepatocytes to monocarboxylic 
fatty acids, such as oleic and palmitic acids, may be due to their efficient intracellular 
metabolism under normal conditions Oleic acid or its metabolites, can induce peroxisomal ß-
oxidation and L-FABP in hepatocyte cultures if mitochondrial ß-oxidation is concurrently 
inhibited at the level of carnitine palmitoyltransferase I [127] Long-chain fatty acids are 
mediators of L-FABP expression in liver, independent of unsaturation [176] In contrast, only 
polyunsaturated fatty acids repress the hepatic genes encoding lipogenic and glycolytic 
enzymes In this case, PPAR does not appear to be the response factor [56, 125] 
Thiazolidinediones, antidiabetic drugs, exert potent effects in preadipose cells on the 
expression of genes encoding proteins involved in fatty acid metabolism [146] A new 
thiazohdinedione insulin sensitiser, BRL 49653 (5-(4-[2-methyl-N-(2-pyndyl)amino)ethoxy] 
benzyl)-thiazolidine-2,4-dione), has been shown to induce A-FABP gene transcription in a 
similar way as natural or nonmetabohzable fatty acids [116, 201] These observations suggest 
similar mechanisms of action for thiazolidinediones and fatty acids This idea is supported by 
the demonstration that both molecules activate, in a heterologous trans-activation assay, the 
same nuclear receptor, FAAR [116] BRL 49653 addition to the diet led to a significantly 
increased FAAR (PPARy2) and A-FABP expression in high-lat-fed. but not in high-
carbohydrate-fed rats [201] 
The expression of B-FABP mRNA and E-FABP mRNA, but not H-FABP mRNA 
were markedly elevated in the hippocampus at 48 h after systemic kainate treatment [197] 
Systemic administration of kainic acid is known to change the content of unestenfied tatty 
acids in the brain 
1.6 Relation of FABPs to growth and differentiation 
The expression of FABP mRNA and the synthesis of FABP are dependent on cell 
differentiation for various FABP types in different tissues, as intestine [242], liver [247], heart 
[104], brain [69], and mammary gland [11, 150] Members of the FABP family appear also to 
be connected with the modulation of cell growth (Table 6) An exellent review was published 
on the modulation of mitogenesis of liver and hepatoma cells by L-FABP [247] L-FABP 
cDNA transfection increases the efficacy of the utilization of unsaturated fatty acids, 
especially linoleic acid This leads to a higher proliferation rate of cultured hepatoma cells 
[136. 137] In addition, it promotes the maintenance of integrity and fluidity of membranes 
and the preservation of the morphology of the cell L-FABP is required for the induction of 
cell multiplication of hepatoma cells by two classes of carcinogenic peroxisome proliferators 
[139 Moreover, the ability of eight different prostaglandins to bind to L-FABP correlates 
with their relative growth-inhibitory activity [138] 
Other members of the FABP family have been implicated in some cases in the 
regulation of growth and differentiation (Table 6) Expression of L-FABP and I-FABP in 
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transfected mouse L-cell fibroblasts did not change the growth characteristics 
{185, 216, 217]. Expression of bovine H-FABP in yeast caused inhibition of growth [237]. In 
chapter 6, we report an increase of the proliferation rate and a blockage of fusion of rat L6 
myoblasts after transfection with A-FABP cDNA L6 cells transfected with H-FABP cDNA 
Table 6. Effects of FABPs on growth and differentiation 
Cell type 
Mammary carcinoma 
cell line (human) 
Breast cancer cells 
(human) 
Mammary epithelial cells 
(Bovine and human) 
Embryonic stem cells 
(mouse) 
Mammary epithelial cells 
(mouse) 
Yeast 
Cultured cardiomyocyles 
(rat) 
L6 muscle cells 
(rat) 
Hepatoma 
(rat) 
Cerebellar glia cells 
(mouse) 
FABP type 
H-FABP/MDGI 
H-FABP/MDGI 
H-FABP/MDGI 
MDGI 
H-FABP/MDGI 
H-FABP 
H-FABP/MDGI 
H-FABP 
A-FABP 
L-FABP 
B-FABP 
Mode of 
addition 
E 
I 
E 
E 
E 
1 
E 
1 
I 
I 
E 
Effect on 
growth differentiation 
i 
1 
1 
I 
1 τ 
1 
Ì 
-
τ ι 
τ 
τ 
Reference 
[31,153] 
[114] 
[153,312] 
[300] 
[306] 
[237] 
[44] 
(Chapter 6) 
[137] 
[69] 
1, decrease, Τ, increase, -, no change Abbreviations E , extracellular or I , intracellular 
showed no changes in growth or differentiation compared to mock-transfected cells. Porcine 
Il-FABP stimulated the growth of gastrointestinal epithelial cells in culture [181, 292]. 
Cellular retinol-binding protein I and cellular retinole acid-binding proteins are associated 
with the cessation of cell multiplication that accompanies differentiation [38, 39, 155]. B-
FABP may be involved in regulation of neuronal differentiation, not proliferation [69]. B-
FABP has been detected and appears also to function in the extracellular space, since anti-B-
FABP antibodies block glial and neuronal differentiation in primary cell cultures, but have no 
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effect on cell proliferation or adhesion [69] 
Mammary-derived growth inhibitor (MDGI) was isolated from bovine lactating 
mammary gland as a factor that inhibited growth of various normal and transformed 
mammary epithelial cells [31, 153] It was recently identified as a mixture of A-FABP and H-
FABP [248] MDG1/H-FABP cDNA transfection reduces the proliferation rate and 
tumongenicity of human breast cancer cells in nude mice [114] Furthermore. MDGI is a 
potent inhibitor of bovine, mouse, and human mammary epithelial proliferation in cell and 
organ culture [153, 306, 312], and stimulates its own and ß-casein gene expression in organ 
culture when it is added to the medium [153, 306] Synthetic peptides corresponding to the 
MDGI/H-FABP sequence of residues 121-131 mimic the regulatory properties of MDGI [291, 
306] In cultured cardiac myocytes, 5 nM extracellularly added H-FABP seems to induce 
hypertrophy [44] In addition, MDGI blocked the induction of the ß-adrenergic 
supersensitivity of cultured rat heart cells [291] The mechanism by which FABPs as II-
FABP, B-FABP, and H-FABP may leave or enter cells is unknown FABPs lack a signal 
peptide for secretion and also no cell surface receptor for FABP has been identified 
Although both the DNA labelling index, ß-casein mRNA levels, and H-FABP mRNA 
levels in the mammary gland of mice are developmentally regulated, they do not correlate 
with each other during early pregnancy [28] Overexpression of H-FABP in 'ransgemc mice 
did not affect the DNA labelling index or the levels of ß-casein mRNA, an established marker 
of differentiation of the mammary epithelium, at this developmental stage 
An integral plasma membrane glycoprotein of epithelial cells, CD36 seems to be 
involved in cellular growth and differentiation, and lipid transport and metabolism, possibly 
in association with H-FABP in the bovine mammary gland [249] This glycoprotein was 
identified in adipocytes, heart, and skeletal muscle as a fatty acid translocase (FAT) [1] H-
FABP may interact with CD36, in the mammary gland, in two different ways It can form a 
complex with CD36 on the cytoplasmic side of the plasma membrane Complexes of CD36 
and H-FABP have been identified in fat globule membranes of bovine milk [249] Secondly, 
external H-FABP may bind to the thrombospondin domain, ι e to the ecto-domain of CD36, 
and cause in this way the inhibition of cell proliferation The presence of the Vall23-Cys-rhr 
sequence and the hydrophobicity of the C-terminal portion (residue 121-127) of FABP, as in 
the type-I repeat of thrombospondin, suggest that the inhibitory effect of FABP on cell 
proliferation might be exerted through its interaction with CD36 The expression of CD36 is 
related to the state of mammary cell differentiation, like for H-FABP, since it reaches its 
maximum during lactation and declines during the involutionary period [249] 
1.7 Indirect role of FABPs in signal transduction 
Fatty acids, their CoA and carnitine esters and other lipid mediators, such as eicosanoids and 
lysophosphohpids, may influence directly or indirectly various cellular processes by their 
interaction with enzymes, membranes, ion channels, receptors, or genes (see [82, 83, 91, 254, 
281, 283] and references therein) By the modulation of the free fatty acid concentration, 
FABPs may have an indirect effect on these parameters FABPs have no similar affinities for 
the whole range of fatty acids Differences in ligand affinities were found between L-FABP 
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and H-FABP [167] B-FABP has a much higher affinity for docohexaenoic acid (22 6, n-3) 
than for mono-unsaturated fatty acids [304] Therefore, distinct FABPs may differentially 
affect processes that can be influenced by free fatty acids Examples of (indirect) regulation of 
processes by the modulation of the free fatty acid concentration are given below 
Free fatty acids may influence and disturb membrane structure and cell function, when 
not properly modulated In addition to their transfer function FABPs may therefore have 
cytoprotective effects, if fatty acids are taken up, or released by lipolytic enzymes, e g in the 
cardiomyocyte [82, 84] 
The availability of fatty acids may influence the activities of enzymes involved in fatty 
acid and lipid metabolism as mitochondrial and microsomal acyl-CoA synthase and acyl-
CoA glycerol 3-phosphate acyltransferase, acetyl-CoA carboxylase, acyl-CoA cholesterol 
acyltransferase, diacylglycerol acyltransferase (see references in [79, 200, 283]) 
Fatty acids and acyl-CoA esters modulate many steps of the cascade of reactions 
involved in signal transduction [91, 254] Fatty acids and/or acyl-CoA esters were shown to 
be involved in the modulation of phosphohpases, G-proteins, adenylate cyclase, adenine 
nucleotide translocase, guanylate cyclase, calmoduhn-dependent protein kinases, and cAMP-
dependent potein kinase (see references in [79, 200, 283] Enzymes of both cyclic AMP and 
protein kinase С pathways are regulated by fatty acids [254] and fatty acids have been shown 
to activate soluble protein kinase С [140] 
Arachidonic acid and other fatty acids directly regulate Na~, К Cà , and Cl -ion 
channels [196], but it is not always known whether this is caused by interaction with the 
channel protein or by modulation of its lipid environment [134, 196] For example, 
arachidonic acid interacts directly with voltage-dependent К channels in oocytes or with a 
closely associated component [286] Free polyunsaturated fatty acids showed effects on the 
binding of the ligand batrachotoxin A 20a-benzoate to the voltage-sensitive Na channels of 
neonatal rat cardiac myocytes [134] The modulation of human muscle Na channels by 
intracellular fatty acids appeared to be dependent on the channel isoform [299] A significant 
degree of similarity was established between a 131-residue domain of the N-methyl-D-
aspartate (NMDA) receptor (residues 263-393) and various members of the FABP family 
[207] The modulatory activity of fatty acids on receptor binding has been established for 
nuclear T3, angiotensin, glucocorticoid, insulin, and opioid receptors [283] 
Fatty acids are known to exert an effect on the transcription of genes, especially those 
genes which code for proteins involved in lipid metabolism, e g FABP, acyl-CoA synthase, 
stearoyl-CoA desaturase [6, 56, 64, 66, 176] Two different mechanisms exist for this fatty 
acid-regulated gene expression The first mechanism for transcriptional modulation is similar 
to the peroxisome prohferator-activated induction of gene expression [30, 154, 238] Chronic 
exposure of a preadipose cell line to palmitate led, in a dose-dependent manner, to a strong 
stimulation of cell differentiation [5] The authors proposed that fatty acids per se, stimulate 
gene transcription by means of nuclear receptors A nuclear fatty acid-activated receptor 
(FAAR or PPARy2) with homology to peroxisome prohferator-activated receptors (PPARs) 
has been cloned and sequenced from fatty acid-treated preadipocyte cells [7], and from 
adipocytes [266] The idea is now generally accepted that PPARs are also activated by 
physiologically occunng activators as free fatty acids, e g arachidonic or linoleic acid [30, 
154. 238] On base of the effects of differentially ß-oxidizable fatty acids and inhibitors of 
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fatty acid metabolism, it was concluded that ß-oxidation was apparently not required for the 
formation of the PPAR-activating molecule This molecule may be a fatty acid, a CoA ester, 
or a further derivative of the activated fatty acid prior to ß-oxidation of the acyl-CoA ester 
[30] Fatty acids and thiazohdinedions, antidiabetic drugs, are able to change myogenic cells 
into adipose-like cells, probably via PPAR action [201, 259] In contrast to the action of fatty 
acids, independent of unsaturation grade, repression of hepatic genes encoding lipogenic and 
glycolytic enzymes by polyunsaturated fatty acids was found not to be mediated by PPARs 
[56, 125] 
In 1987, Bemier and co-workers first identified the phosphorylation of a 15 kDa protein 
(ppl5) by the insulin receptor tyrosine kinase in cultured 3T3-L1 adipocytes [22] This 
phosphorylation took place after insulin stimulation and only when cells were treated with 
phenylarsine oxide (PAO), an agent that inhibits tyrosine phosphatases The 15 kDa protein 
turned out to be A-F ABP [111] The phosphorylation was subsequently characterized m vitro 
with a reconstituted system containing insulin receptor from 3T3-L1 cells and A-FABP The 
amino acid residue phosphorylated turned out to be Tyr-19, which is in a consensus sequence 
for tyrosine kinase phosphorylation [41, 112] Fatty acid binding enhances susceptibility to 
tyrosine phosphorylation of A-FABP [41, 112], but phosphorylation blocks ligand binding 
[42] It has been suggested that A-FABP might have dynamic conformational flexibility 
allowing transient access to Tyr-19, which is inaccessible in the crystal structure [10] 
Because the extent of phosphorylation in adipocytes is only about 1% [41,49], a clear function 
of A-FABP phosphorylation is still speculative H-FABP, My-FABP, B-FABP, and E-FABP 
contain the same consensus sequence surrounding Tyr-19, like A-FABP, and therefore may be 
substrates for tyrosine kinase activity too Nielsen et al proved the formation of phosphory-
lated H-FABP in rat cardiomyocytes and mammary epithelial cells, in response to insulin 
stimulation [187, 188] In vitro phosphorylation of H-FABP by the insulin receptor tyrosine 
kinase upon stimulation with insulin happens to a slight extent (<0 1%). and only in the 
presence of PAO [215] Isolated rat soleus muscle shows, however, at incubation autophosp-
horylation of insulin receptors but no detectable phosphorylation ol H-FABP after insulin 
stimulation [215] 
Two membrane-bound ppl 5 tyrosine phosphatases from 3T3-L1 adipocytes (PTPases 
HAI and HA2), catalyze the hydrolysis of phospho-Tyr-19 of A-FABP [157] Both enzymes 
are inhibited by PAO and exhibit substrate preference for A-FABP compared to other 
phosphotyrosine-containmg proteins The ppl5 PTPase HA2 is expressed in 3T3-L1 
preadipocytes and expression increases abruptly during the induction of differentiation into 
adipocytes [158] Constitutive vector-driven overexpression of PTPase HA2 in transfected 
3T3-LI preadipocytes blocked differentiation into adipocytes Treatment with vanadate (a 
potent PTPase inhibitor) restores their capacity to differentiate [158] Essential tyrosine 
phosphorylation event(s) appear to occur during the preadipocyte differentiation program, 
which is vital to the expression of adipocyte genes e g the A-FABP gene, and for 
accumulation of cytoplasmic tnacylglycerols It has to be established which phosphoproteins 
are involved in the phosphorylation-dephosphorylation events which regulate early steps in 
differentiation No comparable PTPases in heart, muscle and mammary gland have been 
identified yet Together with the very low level of H-FABP phosphorylation detected this 
suggests that no clear function for phosphorylated H-FABP can be anticipated 
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1.8 Implications of FABPs in medicine 
Because of their small size, high solubility, and tissue-specificity, FABPs are supposed to be 
promising candidates as a biochemical marker for tissue injury under experimental and 
pathophysiological conditions Human H-FABP can be determined in extracellular fluids as 
plasma and urine [145, 193, 271, 287] FABP released from the heart after acute myocardial 
infarction (AMI) is quantitatively recovered in plasma and so, FABP is a useful biochemical 
plasma marker for the estimation of myocardial infarct size in humans [80, 145] To discrimi­
nate AMI from skeletal muscle injury, the serum myoglobin/FABP ratio can be applied [276] 
H-FABP appeared to be a sensitive marker of tissue damage in human cardiac autopsies [145, 
148, 293] Release of FABP in serum and/or urine was also observed in renal failure, liver 
disease, and experimental ischaemia of intestine 
[86, 89, 128, 130-132] I-FABP has potential as a biochemical marker to facilitate the early 
detection of mesenteric ischemia [86, 87] Also acute intestinal allograft rejection could be 
detected earlier with I-FABP as serum marker compared to other markers, like hexosamini­
dase [171, 179] 
Human myelin P2 protein (My-FABP) induced experimental autoimmune neuritis 
(ΕΑΝ) in Lewis rats [296] In fact, synthetic peptides, corresponding to residues 53-78 or 62-
78 of bovine My-FABP mimiek the effect [93, 243] Therefore, (part of) this protein may act 
as a candidate autoantigen in inflammatory demyehnating diseases of the peripheral nervous 
system [43. 93] P2 peptide-induced experimental autoimmune neuritis may represent an 
useful model to investigate axonal degeneration A testicular FABP contains the same stretch 
of amino acids as My-FABP, that has been implicated in the induction of experimental 
autoimmune neuritis [194] 
FABP content and synthesis have been shown to change in cancer, in a FABP- and cell-
dependent way A-ГАВР synthesis was only detected in lipoblasts in both hpoblastoma and 
hposarcoma, but not in other benign adipose tissue tumours and malignant connective tissue 
or epithelial tumours [21] In contrast, A-FABP expression by normal bladder urothehum was 
lost at various stages of carcinoma progression [48] In addition, low-grade tumours contained 
more A-FABP than their high-grade counterparts Evidence for decreased expression of 
MDGI/H-FABP was found in human breast cancer [114] Breast cancer cell lines failed also 
to express the H-FABP gene [114] Rat hepatoma cells showed a decreased level of L-FABP 
[177, 222, 255], and rat and human colon carcinoma contained a decreased content of L-
FABP [47, 60] and I-FABP [61] The presence of L-FABP in human hepatoblastoma and 
hepatocarcinoma was related to the differentiation stage [255] Undifferentiated or immature 
areas did not show L-FABP immunoreactivity Upregulation of E-FABP (Mal-1) mRNA was 
found in benign papillomas and malignant skin squamous cell carcinomas [149] 
Up to now, linkage of genes to phenotypes has only been found for I-FABP A 
Thr54Ala polymorphism in I-FABP was associated with differences in fat metabolism in two 
aboriginal populations [9, 101 ] An association was not found between I-FABP gene variation 
and non-insulin dependent diabetes mellitus, but with some less favourable NIDDM-related 
intermediate phenotypes as body mass index, percent body fat and plasma tnacylglycerol 
concentration [9, 101, 178] 
Mice with a null mutation in the A-FABP gene were developmentally and metabohcally 
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normal [110] On a high-fat high-caloric diet they developed obesity, but, unlike control mice, 
they did not develop insulin resistance or diabetes Unlike their obese wild-type counterparts 
they failed to express in adipose tissue tumour necrosis factor-α A-FABP appears to be 
central to the pathway, that links obesity to insulin resistance [110] 
FABPs with high similarities to mammalian H-FABP were isolated from parasites like 
schistosomes [18, 180], Echinococcus granulosus [67] and Fasciola hepática [220. 246] The 
parasites cannot synthesize fatty acids de novo Since FABPs may be important for fatty acid 
uptake and transport in the parasite life cycle, these proteins have been suggested as 
candidates for vaccin preparation [18, 260] Mice infected with F hepática indeed develop 
antibodies to FABP [106] These antibodies also gave heterologous resistance to schistosomes 
[106. 260] 
1.9 Aim and outline of this thesis 
The FABP family consists of proteins with very similar three-dimensional structure 
Conservation of stretches of nucleotides and amino acids for the different FABP types in the 
evolution indicates their importance The amino acids whose side chains extend into the 
cavity vary between different members of this family Variations in hgand specificity and/or 
binding affinity may arise from the different amino acid side chains in the binding cavity and 
contribute to differences in functional and physiological properties 
The main body of work presented in this thesis is on several aspects of human and rat 
H-FABP and A-FABP H-FABP is more generally present than any other type of FABP It is 
thought to be of utmost importance for proper functioning of the heart and skeletal and 
smooth muscles Using biochemical and molecular-biological approaches we tried to get a 
more detailed understanding of the relationship between structure and function of this protein 
A-FABP is specifically expressed in adipose tissue and this may have consequences for its 
properties Some of the aspects studied for H-FABP are, therefore, also studied for A-FABP 
In the past the question arose if H-FABP, like A-FABP could be phosphorylated by the 
insulin receptor after insulin stimulation Both proteins contain amino acid residue Tyr-19, 
which is the target for phosphorylation in A-FABP In Chapter 2 we studied the possibility of 
phosphorylation of human H-FABP in vitro, and ex vivo in rat m soleus. a slow-twitch (type 
I) skeletal muscle, which contains a high level of H-FABP 
On base of the three-dimensional structure, recently solved by crystallography, 
presumptions were made about the role of specific amino acid residues for functioning of H-
FABP By utilization of site-directed mutagenesis and recombinant expression of the mutant 
proteins, we were able to study the effects of different ammo acid substitutions on hgand 
binding and conformational stability (Chapter 3) 
Beside the strong conservation in their overall protein structures, there exists a marked 
conservation of the FABP gene structure The locations of the genes coding for different 
FABPs, however, are scattered through the genome In Chapter 4, we isolated a lambda clone 
with a part of the gene coding for human A-FABP and established the chromosomal 
localization of the A-FABP gene 
In an attempt to clone human H-FABP gene sequences, we isolated and sequenced a 
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gene with high similarity to the H-FABP encoding sequence, and with many features of a 
processed pseudogene The chromosomal localization of this H-FABP processed pseudogene 
was performed (Chapter 5) 
The occurrence and the tissue distribution of the different FABP types may reflect 
distinct functions and/or cell environments Little is known about the function of FABP in the 
cell Therefore, we started to study H-FABP in a cell culture model We followed the 
approach of increasing the FABP content (overexpression) or inhibiting the FABP expression 
(antisense) in rat L6 myoblasts to get an idea of the role of this protein in the fatty acid uptake 
and metabolism and cell growth and differentiation Also A-FABP, a non-muscle type FABP 
was expressed in these cells to address its effect on cellular behaviour and fatty acid metabo-
lism (Chapter 6) 
Chapter 7 gives a survey and summary of the results described in this thesis 
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No significant phosphorylation of M-FABP 
SUMMARY 
As suggested by the work on adipocyte fatty acid-binding protein (FABP), other FABPs 
with a tyrosine kinase consensus sequence could possibly be phosphorylated by the insulin 
receptor tyrosine kinase Upon stimulation with insulin, recombinant human muscle fatty 
acid-binding protein (M-FABP) was phosphorylated in vitro by the insulin receptor tyrosine 
kinase only to a slight extent (<0 1%) Rat soleus muscle shows at incubation 
autophosphorylation of insulin receptors but no phosphorylation of M-FABP after insulin 
stimulation Vanadate and phenylarsine oxide (PAO) had no effect on the extent of 
phosphorylation of M-FABP in vitro and in soleus muscle Our results do not indicate that 
tyrosine phosphorylation of M-FABP is an important physiological phenomenon 
INTRODUCTION 
Cytosolic fatty acid-binding proteins (FABPs) are a group of low-molecular-mass proteins 
which bind long-chain fatty acids and are thought to play a role in the intracellular 
transport and solubilization of fatty acids [1,2] The FABP family includes at least seven 
members with a high sequence similarity, adipocyte FABP (A-FABP) one of them The 
FABP originally found in muscle (M-FABP) and heart (H-FABP) is also present in many 
other tissues as kidney, lung, brain, placenta, and testis [3-6] M-FABP and H-FABP 
appeared to be identical proteins [7] M-FABP has a high Ugand specificity for long-chain 
unsaturated and C16-C18 saturated fatty acids [8] and may mainly serve as a protein that 
provides for energy-delivering substrate 
Several years ago, Bernier and co-workers [9] first identified the phosphorylation of 
a 15 kDa protein by the insulin receptor tyrosine kinase in cultured 3T3-L1 adipocytes 
This phosphorylation took place after insulin stimulation and only when cells were treated 
with phenylarsine oxide (PAO), an agent that inhibits tyrosine phosphatases Previous 
studies had shown that PAO blocks insulin-stimulated glucose uptake without affecting 
insulin binding to its receptor, insulin receptor autophosphorylation, or the receptor's 
capacity to catalyze protein substrate phosphorylation [9-11] As later was established, the 
15 kDa protein was adipocyte fatty acid-binding protein (A-FABP) [12], a member of the 
cytoplasmic FABPs The phosphorylation was subsequently characterized in vitro with a 
reconstituted system using WGA-Sepharose eluate containing insulin receptor from 3T3-L1 
cells and homogeneous A-FABP [13,14] Fatty acid binding activates phosphorylation of 
A-FABP [15], but phosphorylation blocks ligand binding [16] Because the extent of 
phosphorylation in vivo is only about 1% [9,12], a clear function of A-FABP 
phosphorylation is still speculative 
M-FABP contains the same amino acid sequence surrounding tyrosine 19, like A-
FABP (Fig 1)[7], and therefore, may be a substrate for tyrosine kinase activity too [17,18] 
Nielsen et al proved recently the formation of phosphorylated FABP in rat cardiomyocytes 
and rat mammary epithelial cells, in response to insulin stimulation [19,20] No 
investigations were performed on M-FABP phosphorylation in vitro or in intact tissues 
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1 10 20 30 
HM-FABP MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQ 31 
RM-FABP MADAFVGTWKLVDSKNFDDYMKSLGVOFATRQ 31 
HA-FABP MCDAFVGTWKLVSSENFDDYMKEVGVGFATRK 31 
* *** ****** * ******* ******* 
Fig. 1. Partial amino acid alignment of the consensus sequence for protein-tyrosine kinase of human M· 
F ABP, rat M-FABP and human A-FABP. The residue numbers start after the methionine on the first amino 
acid position. * Indicates identity in the three proteins. The position ofTyr-19 is shaded. 
The present report describes attempts to establish if M-FABP can be phosphorylated 
in vitro and in rat soleus muscle. The soleus muscle of young rats is a sensitive, 
physiological preparation commonly used for ex vivo studies [21]. Under defined 
conditions, constant rates of pyruvate, palmitate, and glucose oxidation were measured in 
intact muscle for at least 2 h [22]. A marked insulin stimulation of glucose oxidation and 
lactate formation was observed in intact soleus muscle. Because PAO does not affect 
autophosphorylation of insulin receptors purified from rat soleus muscle [23], the PAO 
blockage of insulin-dependent glucose uptake in soleus muscle may be post-receptor, as in 
the 3T3-L1 adipocytes. 
In this report we show that phosphorylation of M-FABP could be obtained in vitro, 
with a very low efficiency, but not in rat soleus muscle neither without nor with insulin 
stimulation. 
EXPERIMENTAL 
Materials 
[32P]Orthophosphate (carrier-free, 10 mCi/ml) and2 [γ- P]ATP were obtained from 
Amersham Corp.,'s-Hertogenbosch, The Netherlands; phenylarsine oxide (PAO) from 
Aldrich,Bornem, Belgium; sodium orthovanadate (Na3V04), Ponceau S and insulin from 
Sigma, St. Louis, U.S.A.; 4-nitro blue tetrazolium chloride (NBT) and 5-bromo-4-chloro-
3-indolyl-phosphate (BCIP) from Boehringer; phosphotyrosine mouse monoclonal antibody 
PY20 from ICN, Zoetermeer, The Netherlands; anti-mouse IgG alkaline phosphatase 
conjugate was from Dakopatts, Glostrup, Denmark; anti-rabbit IgG alkaline phosphatase 
conjugate from Sigma; protein A Sepharose CL-4B from Pharmacia, Uppsala, Sweden. All 
other chemicals were reagent grade. Rabbit anti-rat M-FABP(H-FABP) and anti-human M-
FABP sera were prepared previously [3,24]. 
Preparation and purification of human M-FABP 
The human M-FABP cDNA was cloned in the pET-8c vector and expressed in E coli 
strain BL21(DE3), and the purification of M-FABP was performed as described in [8]. The 
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protein content was determined according to Lowry et al.[25] with bovine serum albumin 
(BSA) as standard. FABP was delipidated with the Lipidex procedure and loaded with 
palmitic acid (molar ratio protein/fatty acid 1:10) as previously described [26]. 
In vitro phosphorylation assay with WGA-purified insulin receptor 
The insulin receptor was partially purified by use of WGA-Sepharose from a Chinese 
hamster ovary (CHO)-denved cell line overexpressing human insulin receptor [27]. The 
insulin receptor content of the WGA-preparations used in this study was approx. 10%-40% 
as judged from Coomassie Brilliant Blue stained PAGE gels. The receptor preparations 
were tested for insulin-stimulated autophosphorylation of the receptor and tyrosine 
phosphorylation activity using the synthetic peptide poly-[Glu.Na,Tyr](4:l)[28]. In a total 
volume of 10 μΐ, 1 μg WGA-purified insulin receptor was incubated with 3.5 μg FABP and 
20 ¿ig BSA in 50 mM Tris-HCl (pH 7.5)/10 mM MgCl2/0 1% Triton X-100/1 mM 2-
mercaptoethanol/0.3 M N-acetylglucosamine. Incubations were performed in the absence 
or presence of 1 μΜ insulin and 25 μΜ PAO. After 60 min incubation at 22°C 2.5 μΐ [γ-
32P]ATP (150 μΜ; 10 μΟ) and 1.5 μΐ 50 mM MnCl2 were added to the incubation mixture 
and the incubation was prolonged for 30 min at 22°C. The reaction was terminated by 
addition of trichloroacetic acid (10% final concentration) and the proteins were pelleted 
The proteins were separated by SDS-PAGE and visualized by autoradiography. 
Phosphorylation assay of rat soleus M-FABP 
Soleus muscles were isolated from young male Wistar albino rats (60-70 g). Each muscle 
(about 15-25 mg) was incubated in 2 ml phosphate-free Hepes-buffered saline (10 mM 
Hepes/126 mM NaCl/2 mM MgSCyiO mM NaHCO,/5 mM KCl/ 1.8 mM CaCl and 20 
mM D-glucose (pH 7 6)) and labeled for 2 h with 1 mCi 32Pi in the presence or absence of 
1 mM orthovanadate at 37°C in a 5% C02/95% air atmosphere. After the labeling period, 
PAO was added to a final concentration of 35 μΜ, and incubation continued for 10 min 
Subsequently muscles were incubated in the presence or absence of 1 μΜ insulin for 20 
min. Labeling and stimulation were terminated by washing the muscles three times with 
ice-cold phosphate-buffered saline, after which whole homogenates (5%, w/v) were 
prepared by hand homogenization using a teflon-glass Potter-Elvejhem tissue homogemzer 
and two pestles with different diameter (0.12 and 0.05 mm, respectively). The 
homogenization buffer contained 250 mM sucrose/2 mM EDTA/10 mM Tris-HCl (pH 
7 4)/35 μΜ PAO/1 mM Na3VO4/10 mM ATP/10 mM NaF/1 mM phenylmethylsulfonyl 
fluoride (PMSF) and 0.1% NP40. Homogenates were centrifuged for 1 h at 105,000 χ g at 
4°C and the supernatant (cytosol) was stored at -80°C. 
Immunoprecipitation, gel electrophoresis and immunoblotting 
Ten μΐ of rabbit antiserum against rat M-FABP was incubated with 10 μΐ of a 50% (w/v) 
protein A-Sepharose suspension in buffer A (500 mM NaCI/0 1% NP40/10 mM Tris-HCl, 
(pH 8.0)). This mixture was rotated end-over-end for 2 h at 22°C. After this step the 
Sepharose was pelleted and washed three times with buffer A, followed by an incubation 
with 10 μΐ of the 105,000 χ g supernatant of soleus muscle homogenate and 0.5 ml of 
buffer В (100 mM NaCl/0.1% NP40/10 mM Tris-HCl (pH 8.0)). This mixture was 
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incubated for 2 h at 4°C and washed thrice with buffer В The pellets were resuspended 
with SDS-PAGE sample buffer, and boiled for 5 min The entire supernatant was applied 
to a 15% SDS-polyacrylamide gel Proteins separated by electrophoresis were visualized by 
staining with Coomassie Brilliant Blue and the phosphoproteins located by autoradiography 
at -80°C using Kodak XAR5 film To determine the amount of 3 2P incorporated, the protein 
bands were quantitated by densitometnc analysis of the autoradiogram utilizing a LKB 
scanning densitometer 
Blotting of SDS-PAGE separated proteins was performed using a Biorad Mini 
Protean II electrophoresis system, according to the manufacturer's instructions Proteins on 
the blot were visualized with Ponceau S, to mark the molecular mass marker proteins 
Detection of rat M-FABP was performed using anti-rat M-FABP serum (1 250) and anti-
rabbit IgG-alkaline phosphatase conjugate (1 1000), with BCIP/NBT as substrate 
Application of anti-phosphotyrosine monoclonal antibody 
In this study, soleus muscles were incubated in Hepes-buffered saline as above, but 
containing 1 mM phosphate with 35 μΜ РАО for 10 mm without or with 1 mM 
orthovanadate and subsequently with or without 1 μΜ insulin for 20 min Homogenates 
and cytosols were prepared as described above Immunoprecipitation of 100 μΐ cytosol was 
performed with 50 μΐ of rabbit antiserum against rat M-FABP and 50 μΐ of a 50% (w/v) 
protein A-Sepharose suspension in buffer A in the presence of 1% BSA The 
immunoprecipitation and washing was performed as above described After SDS-PAGE 
and blotting, detection of phosphotyrosine proteins was performed with mouse monoclonal 
antibody PY20 (1 1000) and anti-mouse IgG alkaline phosphatase conjugate (1 1000) 
RESULTS 
In vitro phosphorylation of recombinant human M-FABP 
Recombinant human M-FABP was incubated in vitro with the tyrosine kinase of the insulin 
receptor purified from membranes of an insulin receptor-overexpressmg CHO cell line In 
the first experiments M-FABP was incubated following in vitro phosphorylation conditions 
with insulin stimulation for 5 min (as for the synthetic peptide) After analysis of the 
proteins by SDS-PAGE, no phosphorylation of M-FABP was visible (results not shown) 
Long-term phosphorylations (24-48 h) were suggested to maximize the yield of 
phosphoprotein [16] However, when we extended the phosphorylation period to 6 h, a 
heavy background became visible in the whole lane of the autoradiogram After stimulation 
with insulin, we could not distinguish any specific phosphorylation signal in the 15-kDa 
region No differences were observed in the phosphorylation of delipidated, palmitic acid-
loaded or original preparations of recombinant M-FABP 
Since addition of РАО to 3T3-L1 adipocytes led to a marked accumulation of 
phosphorylated A-FABP after insulin activation [9,12], we used this inhibitor of tyrosine 
phosphatases in the in vitro phosphorylation assay In vitro incubation during 30 min in the 
presence of РАО and insulin caused a strong autophosphorylation of the 95-kDa tyrosine 
kinase subumt of the insulin receptor and a weak, but specific phosphorylation of a protein 
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of about 15 kDa representing M-FABP (Fig.2). This phosphorylated M-FABP was present 
to the same extent in the incubation without PAO, showing that the addition of this 
phosphotyrosine phosphatase inhibitor had no effect on the level of M-FABP 
phosphorylation. This result indicates that our receptor preparations are relatively free of 
tyrosyl phosphatase activity. With longer exposure periods of the autoradiogram, also a 
basal level of phosphorylation of M-FABP in the absence of insulin became visible. The 
extent of phosphorylation was quantitated by densitometric analysis. The M-FABP signal at 
insulin stimulation in the presence of PAO was about 2% of the autophosphorylation of the 
95-kDa kinase subunit. Taken into account the existence of 3 main autophosphorylation 
sites of the receptor kinase after insulin stimulation [29], a rough estimation could be made 
of the proportion of phosphorylated M-FABP in the insulin-stimulated reaction. Only about 
0.1% of the added M-FABP appeared to be phosphorylated during the in vitro 
phosphorylation reaction. 
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Fig. 2. Autoradiogram after SDS-PAGE of the in 
vitro phosphorylation products of human M-
FABP. Incubations were performed in the absence 
or presence of 1 μΜ insulin or 25 μΜ PAO. 
Fig. 3. Autoradiogram of the immunoprecipitates 
with anti-rat M-FABP of soleus cytosol after 
incubation with p2P]phosphate and PAO. The 
presence of vanadate and insulin at incubation are 
indicated. Lane 1: '*C molecular-mass markers; 
lane 2-5: immunoprecipitates (equivalent to 100 μΐ 
cytosol); lane 6: 5 μΐ cytosol without immuno-
precipitation. 
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Phosphorylation of M-FABP in rat soleus muscle 
First, an attempt was made to demonstrate M-FABP in rat soleus by immunoprecipitation 
with anti-rat M-FABP serum. Since the content of M-FABP in rat soleus muscle is 
relatively high (about 2% of cytosolic protein [3]), this approach appeared satisfactory. 
Soleus muscles were preincubated with [32P]phosphate with and without vanadate and 
incubated with and without insulin. The inhibitors fluoride and vanadate were added to the 
homogenization buffer to prevent phosphatase action. The cytosols were 
immunoprecipitated with anti-rat M-FABP and the immunoprecipitated proteins were 
separated by SDS-PAGE. The phosphoproteins were visualized by autoradiography. Only a 
labeled 95-kDa background protein could be located and no phosphate label on M-FABP 
was detected (Fig.3, lane 2-5). The cytosol (105,000 χ g supernatant) of the rat soleus 
shows a clear labeling of proteins of 185, 95, 45-kDa and a strong low-molecular-mass 
signal after insulin stimulation, but also no labeled 15-kDa protein (M-FABP)(Fig.3 lane 
6). The 185-kDa phosphoprotein is probably the insulin receptor substrate I (IRS-I) and 
was previously identified as a physiological substrate for the insulin receptor tyrosine 
kinase in rat muscle [30]. Furthermore, we did also not observe a labeled 15-kDa 
phosphoprotein in cultured rat myotubes incubated for 20 min with or without 1 μΜ insulin 
after 3 2P labeling (not shown). 
A a n t i - r a t M-FABP В anti-phosphotyrosine 
vanadate, 1mM + - + - + _ + _ 
i n s u l i n , ΙμΜ + + - - + + . . 
Fig. 4. Immunoblots, incubated with anti-rat M-FABP serum (A) and anti-phosphotyrosine monoclonal 
antibody (B). The 105,000 χ g fractions of rat soleus muscle were incubated in the presence or absence of 
vanadate and insulin as indicated and subjected to immunoprecipitation (anti-rat M-FABP) and electrophoresis 
as given in Experimental. Lane 1-4: immunoprecipitate from 100 μΐ cytosol; Lane 5: immunoprecipitate of 2.5 
ßg rat M-FABP. 
We applied another way to investigate phosphorylation of FABP in rat soleus 
muscle by using anti-phosphotyrosine monoclonal antibodies for detection. This procedure 
had the advantage over the radioactive procedure that the 2 h-preincubation of the soleus 
muscle with [32P]phosphate to obtain labeling of ATP could be omitted. At 
immunoprecipitation 1 % BSA was included to prevent aspecific precipitation. We observed 
no differences in the phosphoprotein patterns detected with the anti-phosphotyrosine 
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antibody of the preparations incubated in the presence or absence of 1 μΜ insulin and/or 1 
mM vanadate (Fig 4B) No 15-kDa phosphoprotein was visualized with this method even if 
the staining time of the blot was prolonged in comparison to the usual procedure In the 
same 105,000 χ g supernatants we could detect M-FABP by lmmunoblotting with anti-rat 
M-FABP serum in high quantities (Fig 4A) The staining in the high molecular region of 
the blot is due to the recognition of the heavy chains of the rabbit antibodies (50-77 kDa) 
which were used in the lmmunoprecipitation, by the anti-rabbit IgG antibodies used for the 
immunodetection 
DISCUSSION 
Adipocyte FABP was previously identified as a cellular target of the însulin-
activated tyrosine phosphorylation [12] This tyrosine phosphorylation was performed by 
the insulin receptor tyrosine kinase Skeletal muscle comprises the main bulk of însulin-
sensitive tissue m the mammalian body Therefore, we were interested in testing the 
possibility whether M-FABP would be phosphorylated by the insulin receptor tyrosine 
kinase the same way as A-FABP 
In the present study, we demonstrated a slight extent of phosphorylation of 
recombinant human M-FABP by the insulin receptor tyrosine kinase in vitro at insulin 
stimulation in the presence and absence of PAO In contrast with the incubation time 
necessary for phosphorylation of the synthetic peptide, we had to considerably prolong the 
incubation periods to detect any phosphorylation of FABP The detected small amounts of 
phosphorylated M-FABP were in agreement with other results [13,15], who reported a 
slight percentage (< 1%) of insulin-dependent phosphorylation of recombinant A-FABP by 
the 3T3-L1 insulin receptor 
Lane and co-workers demonstrated that A-FABP was phosphorylated following 
insulin addition to РАО-treated monolayers of 3T3-L1 adipocytes [9,12] Only about 1% 
of the cellular A-FABP content was phosphorylated In rat cardiomyocytes and mammary 
epithelial cells, only a minute fraction ( < 0 2%) of phosphorylated H-FABP of the total 
pool of FABP was found after insulin stimulation in the presence of PAO [19,20] We 
were not able to detect any phosphorylation of FABP in rat soleus muscle ex vno or in 
cultured rat myocytes Dephosphorylation during the isolation procedure is not probable, 
since a mixture of phosphatase inhibitors was present and the insulin receptor and other 
proteins were well phosphorylated 
After incubation of rat cardiomyocytes in the presence of insulin, phosphorylated 
H FABP was isolated as a minor fraction from the large pool of H-FABP [19] 
Phosphoamino acid analysis and radiosequencing of the major tryptic phosphopeptide 
revealed Tyr-19 as the phosphorylated amino acid of H-FABP [19] In A-FABP, this 
residue was previously recognized as the target for the insulin receptor tyrosine kinase 
[12] Tyr-19 is located in the middle of the first amphilic α-helix and preceded by a 
tyrosine phosphorylation consensus sequence Glu-Asn-Phe-Asp-Asp-Tyr in more members 
of the FABP family, A-FABP, heart/muscle FABP, myelin FABP, epidermal FABP and 
also cellular retinol-binding proteins I and II [2] The three-dimensional structures of A-
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FABP [31,32], M-FABP [33], myelin FABP and CRBP I [34] are very similar. In all these 
proteins Tyr-19 is oriented to the interior and its side chain is solvent-inaccessible. This 
makes a direct attack of the kinase unlikely. The very low percentage of phosphorylated 
FABPs detected in vitro could originate from phosphorylation of a small proportion of 
denatured or unfolded protein molecules. 
The position of Tyr-19 in A-FABP does not change significantly upon binding of 
oleic acid or stearic acid [32], although fatty acid binding seemed to increase 
phosphorylation of A-FABP [15], in contrast to our observations on M-FABP. 
Interestingly, the Tyr-19 residue of M-FABP is one of the eight hydrophobic and aromatic 
residues that make Van der Waals contacts with the bound ligand. Phosphorylation of Tyr-
19 would introduce extra charges which may result in at least two changes. First, the 
phosphate group can interfere with the Van der Waals interactions between the protein and 
the fatty acid aliphatic chain. The helix-turn-helix motif is held in place by salt bridges and 
hydrogen bonds, for instance a hydrogen bond between Tyr-19 and Leu-23 in M-FABP 
[33] or between Tyr-19 and Thr-102 in A-FABP [32]. Buelt et al. proposed a 
conformational alteration in the helix-turn-helix region resulting in the accessibility of the 
tyrosyl residue [16]. This conformational alteration is supposed to be generated by the 
association of the tyrosine kinase to the acid domain surrounding Tyr-19. On the other 
hand, phosphorylation at this tyrosine may destabilize the helix conformation, resulting in a 
reduction in binding [16] 
In conclusion, there is still a dilemma as to how phosphorylation can occur with the 
FABPs on base of their tertiary structure. The very low in vitro phosphorylation of M-
FABP may happen on a slight amount of defolded or denatured protein. Our experimental 
data on isolated muscle do not sustain the idea that phosphorylation of M-FABP is a 
physiological phenomenon in vivo. 
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Mutants of muscle fatty acid-binding protein 
SUMMARY 
Human muscle fatty acid-binding protein (M-FABP) is a 15 kDa cytosolic protein which 
may be involved in fatty acid transfer and modulation of non-estenfied fatty acid 
concentration in heart, skeletal muscle, kidney and many other tissues Crystallographic 
studies have suggested the importance of the amino acids Thr-40, Arg-106, Arg-126 and 
Tyr-128 for the hydrogen bonding network of the fatty acid carboxylate group Two 
phenylalanines at 16 and 57 are positioned to interact with the acyl chain of the fatty acid 
We prepared 13 mutant proteins by site-directed mutagenesis and tested them for 
fatty acid binding and stability Substitutions of amino acids Phe-16, Arg-106 or Arg-126 
created proteins which showed a large decrease in or complete loss of oleic acid binding 
Substitution of Phe-57 by Ser or Val and of Tyr-128 by Phe had no great effect The 
stability of the mutant proteins was tested by denaturation studies on the basis of fatty acid 
binding or tryptophan fluorescence and compared with that of the wild-type M-FABP 
There was no direct relationship between fatty acid-binding activity and stability Less 
stable mutants (F57S and Y128F) did not show a marked change in fatty acid-binding 
activity Substitution of Arg-126 by Gin or Arg-106 by Thr eliminated binding activity, but 
the former mutant protein showed wild-type stability, in contrast to the latter The results 
are in agreement with crystallographic data 
INTRODUCTION 
After their transfer across the cellular membrane, fatty acids are bound to cytoplasmic fatty 
acid-binding proteins (FABPs) and transported to cellular organelles for ß-oxidation or for 
tnacylglycerol or phospholipid synthesis [1] FABPs may also be involved in the 
intracellular modulation of non-estenfied fatty acid concentration [2] 
FABPs are members of a family of conserved intracellular lipid-binding proteins 
and comprise at least eight types liver, intestinal, heart or muscle, adipocyte, myelin, 
ileal, epidermal and brain [1-3] Their family also includes cellular retinol-binding proteins 
I and II and cellular retinole acid-binding proteins I and II All FABPs are cytosolic, have 
low molecular masses of 14-16 kDa, and display sequence similarity of between 38-70% 
Human muscle fatty acid-binding protein (M-FABP) is expressed in skeletal and cardiac 
muscle, kidney, testis and brain [4] The protein binds long-chain fatty acids with a Kd of 
about 0 5 μΜ, showing a slight preference for unsaturated fatty acids [5] 
The tertiary structures of myelin, intestinal (I-FABP), adipocyte (A-FABP) and 
muscle FABP types were elucidated using X-ray analysis [6,7] Their structural features 
are similar and the proteins are composed of 10 antiparallel ß-strands forming a β barrel, 
and of two short α-helices X-ray diffraction and multidimensional NMR spectroscopy 
yielded a great deal of information about the three-dimensional structure of heart (muscle) 
FABP types [8,9] The three-dimensional structure of human M-FABP with bound fatty 
acid was resolved and refined by X-ray diffraction to 2 1 À resolution [8] The carboxylate 
group of the fatty acid is located in the interior of the protein, where it forms hydrogen 
bonds with the side chains of Tyr-128 and Arg-126 and two ordered water molecules One 
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of these water molecules is also hydrogen-bonded to Arg-106 and Thr-40 The fatty acid 
has a U-shape conformation in the binding cavity High-resolution X-ray studies on 
complexes of M-FABP with oleate, elaidate and stéarate showed that these fatty acids are 
bound in a similar fashion [10] The fatty acid is thought to enter the interior cavity of the 
protein via a portal in its surface, while interior solvent is released through a secondary 
opening This opening is represented by the gap between ß-strands ß-D and ß-E and is 
formed by the hydrogen-bonding interactions of side chains of the îonizable residues Glu 
72, His-93 and Arg-106 Thus Arg-106 seems to be simultaneously involved in hydrogen 
bonding to the bound fatty acid and in electrostatic interactions at the secondary portal 
Two of the eight hydrophobic and aromatic residues which make van der Waals 
contacts with the bound ligand are Phe-16 and Phe-57 The phenyl ring of Phe-16 is in 
close proximity to the acyl chain and may be a key determinant of the ligand specificity and 
affinity of M-FABP [8] The other aromatic residue, Phe-57, is within van der Waals 
distance from the terminal end of the acyl chain In A-FABP, the orientation of the side 
chain of Phe-57 represents the largest difference between the three-dimensional structures 
of the apo- and holo-proteins [11,12] Probably it is involved in the exposure of the portal 
region In holo-M-FABP a similar Phe 57 lid covers the portal, reducing access to the 
opening in the protein surface [10] 
Until recently, no absolute deficiencies and no naturally occunng mutant proteins of 
the FABP family had been detected This confirms the idea that this conserved group of 
proteins is essential to the cell and to the organism [1] Very recently an amino acid 
substitution (A54T) was reported in the human I-FABP which was found to be associated 
with increased fatty acid binding, increased fat oxidation in vivo and insulin resistance [13] 
This amino acid residue is located in a tight turn between ß-strand ß-C and ß-D, which is 
critical in the conformational adjustment between the apo- and holo- forms of I-FABP [14] 
To establish the importance of certain amino acid residues for the binding of fatty 
acids and the conformational stability of the human M-FABP, an approach of site-directed 
mutagenesis was used to construct mutant proteins with single amino acid substitutions 
The sites for mutation were chosen on the basis of their possible importance for fatty acid 
binding or ligand affinity 
EXPERIMENTAL 
Materials 
Oligonucleotide primers were obtained from Eurogentec, Seraing, Belgium and Dept of 
Haematology, University of Nijmegen, in vitro mutagenesis kit Muta-Gene M13 was from 
Bio Rad Laboratories, Richmond, CA, U S A , Taq DNA polymerase was from Promega, 
Madison, WI, U S A , Sequenase version 2 0 from United States Biochemical, Cleveland, 
OH, U S A , agar, casein hydrolysate (peptone), yeast extract, isopropyl ß-D-
thiogalactopyranoside (IPTG), restriction endonucleases and urea from Life Technologies 
Ine , Gaithersburg, MD, U S A , ampicillin, kanamycin and tetracycline were from Sigma, 
St Louis, MO, USA, DEAE-Sepharose, Sephacryl S-100 Superfine and low-molecular-
mass marker proteins were from Pharmacia Biotechnologies, Uppsala, Sweden, [a-35S]thio-
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dATP (37 TBq/mmol) and [l-"C]oleic acid (204 GBq/mmol) were from Amersham 
International, Little Chalfont, Bucks , U К , Lipidex 1000 was from Canberra-Packard, 
Groningen, The Netherlands, fluorescent 2-(9-anthroyloxy)palmitic acid (2-AP) and 16-(9-
anthroyloxy)palmitic acid (16-AP) were from Molecular Probes, Junction City, OR , 
U S A Recombinant human M-FABP and liver FABP (L-FABP) were prepared as 
described [5,15] All other reagents were of analytical grade 
Oligonucleotide-directed in vitro mutagenesis 
To prepare site-directed mutations in the cDNA coding for human M-FABP, the Muta-
Gene M13 ¡и vitro mutagenesis kit instructions were basically followed The method used 
is based on the uracil selection technique [16-18] The cDNA of M-FABP in M13mpl8 
[19] was used in oligonucleotide-directed mutagenesis The target amino acid residues for 
mutation and the oligonucleotides which were used as mutagenic primers are shown in 
Table 1 Identification of the mutant cDNAs was done by sequence analysis by the dideoxy 
chain termination technique using [35S]thio-dATP and the Sequenase kit 
Table 1 Oligonucleotides used in in vitro mutagenesis 
The nucleotide positions which were targets for mutagenesis are in upper case The nucleotides in square 
brackets were mixed m equal amounts during synthesis of the oligonucleotides N indicates each of the four 
nucleotides 
Target amino acid residue Oligonucleotide used 
Phe-16 5'-gac age aag aat [TG][N][CG] gat gac tac atg-3' 
Thr-40 5'-g cet ace [GC][AT]a ate ate gaa aag-3' 
Phe-57 5'-ca cac age ace [TAG][TC][AG] aag aac аса gag-3' 
Arg-106 5'-ca ctt gtg ACg gag eta att g-3' 
Arg-126 5'-gca gtt tgc act [CA]a[TG] act tac gag-3' 
Tyr-128 5'-c act cgc act [TA]t[CG] gag aaa gag g-3' 
Cloning and sequencing of mutant FABP cDNA 
Primers derived from the muscle FABP cDNA sequence were designed so as to amplify the 
mutated coding region forward primer, 5-GCCAGCATCACCATGGTGGACGCTTTC-
3', reverse primer, 5'-ATCACCAGTGGATCCAGGTCATGCCTC-3' [5] The PCR 
amplification reactions were carried out in a total volume of 50 μΐ containing 10 pmol of 
each primer, 250 nM of each dNTP, 2 5 units of Taq DNA polymerase and 1 5 mM MgCI2 
in 50 mM KC1/10 mM Tns/HCI.pH 9 0/0 1% Triton X-100 After 5 mm denaturation at 
95 °C, 30 cycles of amplification were carried out 95° С for 1 5 min, 6CF С for 1 mm, 74 
°C for 2 mm The PCR products were purified by phenol/chloroform extraction and ethanol 
precipitation The amplified and purified mutant cDNA fragments were digested with Ncol 
and BamHl and the digested products were hgated with a modified pGEM-5Zf( + ) vector, 
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which had previously been digested with the same enzymes. The nucleotide sequences of 
the mutant coding regions were verified. Nucleotide sequencing was performed using the 
dideoxy chain termination technique with [35S]thio-dATP and the Sequenase kit either on 
double-stranded or single-stranded pGEM vectors. 
Expression and purification of mutant M-FABP 
The primers used during amplification of mutant M-FABP cDNA contain recognition sites 
for the restriction enzymes Ncol and ВатШ, which facilitate directional cloning in pET-3d 
(formerly pET-8c) [20]. The sequenced mutant M-FABP cDNAs were isolated after 
digestion with Ncol and ВатШ and ligated with pET-3d vector previously digested with 
the same enzymes. The plasmids pET-3d/mutant M-FABP were used to transform the 
Escherichia coli В strain BL21(DE3) [20,21]. A 5 ml overnight culture of cells coding the 
mutant F ABP was used to inoculate 1 litre of 2YT medium (1.6% casein hydrolysate/1% 
yeast extract/0.5% NaCl; all w/v). Large cultures were performed in 2 litre flasks 
containing 1 litre of medium. Bacteria were grown under shaking at 37 °C. At an A550 of 
0.5 to 1.0, protein expression was induced with 0.5 mM IPTG and incubation was 
continued for 3 h at 37 °C. 
The procedure for purification of the different mutant FABPs was essentially as for 
the wild-type M-FABP [5], except that ammonium sulphate was added to the supernatant 
up to 50% instead of 70% saturation. Proteins were >95% pure on basis of 
SDS/PAGE/Coomassie Brilliant Blue staining. All proteins were concentrated to 1-3 mg/ml 
and kept at -80 °C until use. Proteins were delipidated before binding studies [22]. 
Effect of fatty acid binding on quenching of tryptophan fluorescence 
The tryptophan fluorescence of 1 μΜ delipidated proteins was measured over the 
wavelength range of 300-400 nm at an excitation wavelength of 283 nm (5 nm slits) with a 
Shimadzu RF 5000 spectrofluorophotometer. The fluorescence was analysed for 1.0 μΜ 
delipidated protein in the absence or presence of 1.25 μΜ oleic acid in 1 ml 10 mM 
Tris/HCl, pH 8.0/1% ethanol at 25°C. All values were corrected for the same mixture of 
10 mM Tris/HCl, pH 8.0/1% ethanol without protein. 
Fluorescence enhancements of fluorescent fatty acids with L-FABP, M-FABP and 
mutant M-FABPs 
All fluorescence experiments were carried out using a Shimadzu-500 fluorimeter. The 
fluorescence was analysed of 1.0 μΜ anthroyloxy-labelled fatty acid in the absence or 
presence of 4.0 μΜ FABP in 1 ml 10 mM Tris/HCl, pH 8.0/1% ethanol at 25 °C. The 
fluorescence was determined between 400 and 500 nm at an exitation wavelength of 365 
nm and band width of 5 nm. 
Protein denaturation studies 
Fatty acid binding was measured at 2 μΜ [l-14C]oleic acid and 1 μΜ protein using the 
Lipidex procedure. We used urea stock solutions of 9.6 M and 11.2 M (pre-warmed at 37 
°C) to obtain urea concentrations of 0-7 M in 400 μΐ of incubation mixture. This mixture 
was prepared as follows. First a volume of urea stock solution was diluted with 10 mM 
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Tris/HCl, pH 8 0, to obtain the required final concentration of urea, then delipidated 
protein was added to a final concentration of 1 μΜ and this mixture was incubated for 10 
min at 37 °C Then [l-MC]oleic acid was added to a final concentration of 2 μΜ, gently 
mixed and incubated for 15 min at 37 °C From here on, the Lipidex procedure was 
followed [22] Curve fitting by a computer program was used to determine the 
concentration of urea giving half the initial binding activity (midpoint) 
Equilibrium unfolding as a function of dénaturant concentration was monitored by 
fluorescence spectroscopy in the presence of urea or guanidine hydrochloride (GdnHCl) 
The tryptophan fluorescence of 1 μΜ delipidated protein was measured by the shift of 
maximum emission wavelength at an excitation wavelength of 283 nm (5 nm slits) using a 
Shimadzu RF 5000 spectrofluorophotometer Stock solutions for dénaturants were 9 6 M 
for urea and 6 M for GdnHCl A mixture of urea, 10 mM Tns/HCl, pH 8 0, and protein 
was incubated for 15 min at 37 °C before measuring the fluorescence All values were 
corrected for the same mixture of urea/10 mM Tns/HCl, pH 8 0, without protein The 
emission wavelength yielding maximum fluorescence was plotted against dénaturant 
concentration for each sample to visualize the unfolding profile Curve fitting by a 
computer program was used to determine [D]50, the concentration of dénaturant at the 
midpoint of the transition 
Denaturation curve analysis 
In order to analyse the denaturation curves, the emission maximum wavelength was used to 
follow unfolding From a measurement of the equilibrium constant К (the ratio of the 
fraction of molecules in the denatured state to the fraction in the native state), the free 
energy change on conversion of a molecule to the denatured state can be calculated from 
the equation 
A G = - R T l n K (1) 
The value of AG is the fundamental measure ot the stability of a protein with respect to 
reversible denaturation The data from the denaturant-induced unfolding curves were 
analysed in this way When the dénaturants urea or GdnHCl are used to vary the solvent 
composition, AG has been found to obey the simple linear relationship 
AG = AG%p - m [D] (2) 
where AGnapp is the apparent Gibbs free energy in the absence of dénaturant and [D] the 
concentration of dénaturant The value of m (ι e d(AG)/d[D]) is determined over the 
dénaturant concentration range where values of AG can be measured AG°ápp can be 
determined by linear extrapolation of the data to zero denaturation concentration [23-27] 
Another procedure used takes advantage of the reproducibility in measuring the 
concentration of dénaturant giving 50% unfolding, [D]50 Eqn (2) may be used for 
comparison of wild-type and mutant proteins to give 
AAG = m · A[D]50 (3) 
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where A[D]S0 is the difference between the [Ό\0 values for wild-type and mutant proteins 
[23,28] The value of m used is obtained from the unfolding curve of apo-M-FABP with 
the same dénaturant Eqn (3) gives AAG, the difference in free energy of unfolding of 
wild-type and mutant proteins in the presence of dénaturant, but avoids the uncertainties 
inherent in estimating differences in AG°app values 
Other procedures 
Standard procedures were used for SDS/PAGE Protein concentration was determined by 
the procedure of Lowry et al [29] with BSA as standard A comparative assay of the fatty 
acid-binding activity of M-FABP and the mutants was performed with 1 μΜ protein at 2 
μΜ [l-14C]oleic acid according to the Lipidex procedure [22] The dissociation constant 
(Kd) for the binding of [1-иС]о1еіс acid to M-FABP and the active mutant proteins was 
determined at 0 1-2 0 μΜ fatty acid and 0 5 μΜ protein [30] Protein samples were first 
delipidated with Lipidex 1000 at 37 °C [22] The binding parameters were obtained from 
Scatchard plot analysis 
RESULTS 
Mutagenesis and expression of mutant FABPs in E. coli 
By using oligonucleotides which had 'wobbles' on the target position of mutation, we were 
able to prepare 23 different cDNAs coding for mutant M-FABPs Only for Arg-106 was a 
specific primer used The mutant cDNAs included seven mutants with amino acid 
substitutions at position Phe-16 Cys, Asp, Gly, Glu, Ser, Val and Туг, four mutants at 
position Thr-40 Glu, Leu, Gin and Val, three mutants at position Phe-57 Ala, Ser and 
Val, one mutant at position Arg-106 Thr, three mutants at position Arg-126 His, Lys and 
Gin and three mutants on position Tyr-128 Phe, Leu and Met Two mutants with double 
amino acid substitutions were isolated for positions 16 and 57 Leu/Leu and Asp/Val 
Among the 14 mutant proteins which were expressed during this study, one mutant protein 
(Y128L) was not expressed as a soluble protein in E coli, but instead accumulated in 
inclusion bodies This mutant protein was not used in this study All other mutant FABPs 
were more or less soluble and gave rise to yields comparable with those of the wild-type 
protein For all mutant proteins the same purification scheme was used as for the wild-type 
protein [5] All soluble mutants of M-FABP had comparable secondary structures to that of 
the wild type protein, as detected by Fourier-transform infrared spectroscopy (results not 
shown) This is consistent with the finding that large structural changes in proteins as a 
result of a single mutation are rare [31-33] 
Ligand-binding activity of M-FABP mutants 
Analysis by radiochemical assay 
Because oleic acid was one of the fatty acids that showed the highest affinity for M-FABP 
[5,15], this fatty acid was used in comparative binding studies Binding activities were 
measured at pH 8 0 with excess oleic acid over protein, and expressed relative to the 
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binding activity of wild-type M-FABP (Table 2). For the proteins which showed a 
relatively high binding activity, the Kd values were also determined. 
Table 2 Binding of ¡"CJoleic acid by wild-type M-FABP and M-FABP mutants 
Binding activities were measured at 2 μΜ [l-"C]oleic acid and 1 μΜprotein by the Lipidex procedure Values 
are the means ± SD of five independent assays Kd values for oleic acid were derived from three Scatchard 
plots of binding assays at 0 1-2 μΜ oleic acid and 0.5 μΜ protein. Binding activity of M-FABP amounted to 
32 + 4 nmol/mg of protein. The midpoint is the concentration of urea at which 50% of the binding activity 
was reached and was derived from the curves given in Figure 2 Values for midpoints are means ± S D for 
three independent experiments 
Preparación 
Wild-type M-FABP 
F16S 
F16V 
F16Y 
T40E 
T40Q 
T40V 
F57S 
F57V 
R106T 
R126H 
R126K 
R126Q 
Y128F 
Relative bind 
1.00 
0 01 ± 0 01 
0.25 ± 0.13 
0.35 ±0 .11 
0.09 + 0.07 
0.87 ± 0.22 
1.08 + 0.11 
1 05 ± 0 17 
1.22 ± 0 08 
0 03 + 0.02 
0.34 + 0 13 
0.25 ± 0 11 
0.04 ± 0 02 
0.78 ± 0 19 
Kd (μΜ) 
0.43 ± 0 05 
1.50 ± 0 . 3 5 
1 16 + 0 07 
0 62 + 0 19 
0.46 ± 0 23 
0.38 ± 0.09 
0.35 ± 0.08 
0 85 ± 0 03 
2 14 ± 0.87 
1 02 ± 0.38 
Midpoint (M) 
5.8±0 3 
2 3 + 0 1 
1.4±0.3 
5 4±0.2 
5 6 ± 0 2 
3 2 + 0 5 
5 3 ± 0 0 
1 9 ± 0 2 
1 6±0.3 
3.4±0 3 
Replacement of Phe-16 by polar serine resulted in the elimination of binding activity 
for oleic acid. Replacement by hydrophobic valine or polar tyrosine led to a decrease in 
binding activity. The introduction of negatively charged glutamic acid at position Thr-40 
greatly decreased oleic acid binding, whereas substitution of polar glutamine (T40Q) or 
non-polar valine (T40V) did not affect binding activity. Substitution of serine or valine for 
Phe-57 does not affect the binding activity. Substitution of polar threonine for the 
positively charged Arg-106 resulted in no detectable binding activity for oleic acid. 
Replacement of Arg-126 by other positively charged amino acids such as histidine or lysine 
decreased binding activity; replacement with glutamine eliminated it. Finally, substitution 
of phenylalanine for Tyr-128 resulted in a moderate decrease in binding activity. 
Dissociation constants (Kd) of the mutant proteins were in agreement with their binding 
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activities Mutants with normal binding activity (T40Q, T40V, F57S and F57V) showed a 
wild-type Kd, whereas mutants with decreased binding activity (F16V, F16Y, R126H, 
R126K. and Y128F) showed an increased Kd 
Analysis by fluorescence assay 
The effects of mutation of the protein were also tested using the fluorescent fatty acids 2-
AP and 16-AP These fatty acids, with hydrophobic side groups, presumably bind to the 
surface of M-FABP [15] The fluorescence increases for the interactions of M-FABP and 
the mutant proteins were much higher with 2-AP than with 16-AP With 2-AP, however, 
all mutant M-FABPs except for R106T showed no blue shift of the maximal emission 
wavelength (456 ran), as for M-FABP The fluorescence increase varied considerably (0 7-
2 2 times that of M-FABP) Mutant R106T, which has Thr at position 106 like L-FABP, 
showed a blue-shift in the emission maximum to 443 nm, like L-FABP [15], but only 50% 
of the fluorescence increase With 16-AP, maximal emission wavelengths were the same 
for all mutant proteins as for wild-type M-FABP The fluorescence increases of the mutant 
proteins showed 2 5-8 3-fold higher values than that of the wild-type, except those of F16S 
and F16Y, which were similar 
Fatty acid binding under denaturating conditions 
For this type of study, only mutants were used which showed binding activity for oleic acid 
of at least 25% of that of the wild-type The assay would otherwise be too inaccurate to 
detect the effect of urea denaturation M-FABP shows a remarkable insensitivity to urea at 
5 M urea 75% of the initial binding activity remained (Figure 1) The initial binding 
activity decreased to 50% (midpoint) at an urea concentration of 5 8 M 
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Figure 1 Effect of urea denaturation on the oleic acid binding and tryptophan fluorescence of M-FABP 
The continuous Ime shows the decrease m oleic acid binding activity upon denaiurant-induced unfolding, gi\en 
as a percentage of the minai binding activity (left y-axis) The broken line reflects the shift in emission 
maximum upon denaturation as monitored by the fluorescence emission wavelength (right y-axis) The 
exitaaon wavelength was 283 nm Curves represent the means ± S D of three independent experiments 
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|Ur«a| (M) lurea) (M) 
Figure 2 Effect of urea denaturation on the oleic acid binding activity of wild-type and mutant M-FABPs 
Binding activity is given relative to the initial binding activity of each separate mutant The wild-type M-FABP 
had a binding activity of 22 pmol/ßg protein ¡n the absence of urea In each panel, the curve for M-FABP is 
shown by filled circles Curves are shown for proteins containing mutations at position 16 (A), position 40 
(B), position 57 (C), and positions 126 and 128 (D). Results represent the means ± S D of three independent 
experiments. 
The effect of urea treatment on the binding activities of M-FABP and its mutants is 
shown in Figure 2, and the midpoints of urea denaturation are given in Table 2. The two 
proteins with mutations at amino acid position 16 showed a markedly lower stability with 
respect to binding activity than M-FABP (Figure 2A), while the two proteins with 
mutations at position 40 showed similar changes in binding activity upon urea treatment as 
M-FABP (Figure 2B). The binding activity of the F57S protein was more sensitive to urea 
denaturation than that of the F57V mutant, which had wild-type activity and structural 
stability (Figure 2C). 
Arg-126 and Tyr-128 are thought to play an important role in the electrostatic 
network by which the fatty acid is bound [8,10]. Three proteins containing mutations of 
these amino acids showed a much higher (R126 mutants) or a higher (Y128F) loss of 
binding activity upon urea treatment than M-FABP (Figure 2D). 
Effect of urea denaturation on tryptophan fluorescence 
The stability of the structures of M-FABP and the M-FABP mutants was further evaluated 
by examination of the fluorescence spectra of the proteins. The intrinsic fluorescence of M-
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F ABP arises primarily from two tryptophans, Trp-8 and Trp-97. Crystallographic studies 
on M-FABP, indicated that Trp-8 lies internally on ß-strand ßA, while Trp-97 is on strand 
ßG, just before the ß-turn between strands ßG and ßH [8]. The two Trp residues do not 
seem to be involved in the fatty acid-binding centre on the basis of their positions in the 
protein, unlike in I-FABP where Trp-82 interacts with the fatty acid and can therefore be 
used in the assessment of ligand binding in fluorescence experiments [14,34]. The 
consequences of the location of the two Trp residues in M-FABP for fatty acid binding 
were confirmed by the observation that the Trp fluorescence of the M-FABP and all mutant 
proteins did not differ significantly in the presence and absence of bound oleic acid (results 
not shown) When fluorescence was measured at 332 nm, differences in fluorescence up to 
a factor of 3 could be detected among the mutant M-FABPs. Mutants T40E, T40Q, T40V, 
F57S and R126H showed decreased fluorescence compared with wild-type M-FABP, 
whereas mutants F16V, F16Y, F57V, R106T, R126K, R126Q and Y128F showed wild-
type or slightly higher values (results not shown). 
Complete denaturation of M-FABP with urea resulted in a red-shift of the 
tryptophan fluorescence emission maximum from 332 nm to 354 nm (Figure 1). The 
unfolding transition occured in the range 5-7 M urea, like the decrease in binding activity. 
The fluorescence intensity first showed an increase at a concentration of 6 M urea, 
indicating that the tryptophan residues in M-FABP are more exposed to the solvent at this 
urea concentration (results not shown). 
Because the effects of urea on binding activity could only be studied with mutants 
having at least 25% binding activity, we used Trp fluorescence especially in denaturation 
studies with the non-binding mutant proteins. The transition profiles for M-FABP and the 
M-FABP mutants are shown in Figure 3. All curves follow similar patterns, although the 
midpoints of the transitions vary and the initial wavelength, at which the fluorescence was 
maximal, also varies. Figure 3(A) shows that GdnHCl is a much stronger dénaturant than 
urea. With both dénaturants apo-M-FABP showed a less stable structure than M-FABP 
with oleic acid as ligand. The curves for the mutant proteins F16Y, F57S and Y128F 
followed similar patterns as for apo-M-FABP, although the midpoints of transitions 
occured at much lower urea concentrations (Figure 3B). The three proteins with mutations 
at Thr-40 showed more diversity: T40E and T40Q were less stable than T40V, which has a 
wild-type transition profile (Figure 3C). The mutant protein T40E had the lowest stability 
to urea denaturation. Mutant proteins R106T and R126K showed a midpoint of transition at 
a lower urea concentration than apo-M-FABP, whereas R126Q showed a wild-type 
transition profile (Figure 3D). For most investigated mutants, the midpoints of the urea 
concentration causing unfolding ([D50]) were higher (Table 3) than the midpoints of the 
decrease in fatty acid-binding activity (Table 2). This indicates a higher sensitivity of the 
binding centre. 
Estimation of the conformational stability by reversible denaturation 
By analysis of urea and GdnHCl denaturation curves (Figure 3) it is possible to obtain an 
estimate of the conformational stability, i.e. the apparent Gibbs free energy of the protein, 
AG°app . The emission maximum wavelength was used for following unfolding. All proteins 
studied appear to closely approach a two-state mechanism in which only the native state 
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and the denatured state are present at significant concentrations in the transition region 
GdnHC 
jf » | · " " - j-X 
2 j j 
[Dénaturant] [M] [Urea| (M 
/ 
» i U » ' ; .- * J * I * 
Figure 3 Shift in the tryptophan emission maximum of wild-type and mutant M-FABPs on denaturant-
induced unfolding 
The tryptophan fluorescence of proteins was measured at 1 μΜ concentration and at an excitation wavelength 
of 283 nm Emission spectra were recorded from 300 to 400 nm. (A) Open symbols, apo-M-FABP; filled 
symbols, oleic acid-bound M-FABP, the type of dénaturant used is indicated In (B), (C), and (D), urea was 
used as dénaturant, the curve for apo-M-FABP is always given for comparison. Results represent the means ± 
S D of three independent experiments 
Two methods were used to estimate the conformational stability of the mutant M-
FABPs, and the results were compared. In the first method AG was estimated with the 
assumption that the linear dependence of AG on dénaturant concentration observed in the 
transition region continues to zero concentration [23]. There is convincing evidence that 
this linear extrapolation provides a good approximation for nearly all monomeric single-
domain proteins [24,26,27]. This method was used to analyse the data from Figure 3, and 
the results are given in Table 3. The AG values of apo- and holo-M-FABP were lower on 
the basis of the GdnHCl denaturation data compared with the urea data, indicating the 
importance of electrostatic interactions to these proteins [35]. With both dénaturants, the 
apo-protein was less stable than the holo-protein. Therefore mutant and wild-type proteins 
were compared after delipidation. Only mutants T40V and R126Q showed an apparent 
Gibbs free energy similar to the value of wild-type M-FABP, whereas the other mutants 
show a considerable lower AG°n . 
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Table 3 Conformational stability and transition midpoints for the denaturant-induced unfolding of wild-
type M-FABP and nine mutant M-FABPs. 
Equilibrium unfolding was measured by the change m intrinsic tryptophan fluorescence at 25°C in the presence 
of increasing concemraiions dénaturant (D) A&^ , the apparent free energy difference between the folded 
and unfolded forms of the protein, was determined by linear extrapolation of the data to zero denaturanon 
concentration, m is the slope of the linear denaturanon plot, -dAC/d[D]. [D]¡0 is the concentration of 
dénaturant at which 50% of the protein ¡s unfolded. For each protein d(AC) was determined by comparison of 
the free energy of unfolding around [D]¡0. The difference AAG was calculated as m • A[D]¡0 relative to apo-M-
FABP For m the value derived from the transition curve of apo-M-FABP was always used (see the text) 
'Holo ' indicates M-FABP with oleic acid as ligand. All mutant proteins were delipidated. Data are means ± 
S D of 3 independent experiments 
Dénaturant 
Urea 
GdnHCl 
Protein 
Apo 
Holo 
F16Y 
F57S 
Y128F 
T40E 
T40Q 
T40V 
R106T 
R126K 
R126Q 
Apo 
Holo 
[0]
И
(М) 
6 0 ± 0 02 
6 7+0 01 
4.9+0 01 
5 2±0.08 
5 0 + 0 05 
5 0 ± 0 08 
5 3+0 12 
6 2 ± 0 03 
4 6 ± 0 04 
4 8 ± 0 16 
6 0 ± 0 00 
1 88+0.01 
2 17+0 01 
Ag°
w
 (kJ/mol) 
45.5±5 6 
49 1±0.9 
31.1 ± 1.6 
30 3+2.5 
29.5±0 6 
31 8 ± 6 0 
27 2 ±1 7 
37 8 ± 3 7 
30 7+1.7 
26 0 ± 4 3 
42.9±6.9 
28.8±0 6 
37.0+2 7 
-m (kJ/mol.M) 
7.6±0 8 
7 3+0 2 
6 3+0 2 
5.9±0.4 
5.9±0 1 
6.3 + 1 1 
5.3+0 2 
6 2 + 0 7 
6 6 + 0 4 
5 5 ± 0 6 
7 3 + 1.1 
14 6±0.6 
16.8+1 6 
ΔΔΘ (kJ/mol) 
-5.3+0.6 
8 4 ± 0 9 
6.1 ±0 6 
7.6±0 8 
7 6 ± 0 8 
5.3+0 6 
-1.5+0 2 
10.6+1 1 
9 1±1 0 
0.0±0 0 
-4 2±0.2 
The second procedure involves calculation of the difference in the energy of 
unfolding between apo-M-FABP and holo-M-FABP or M-FABP mutants in the presence of 
dénaturant. This method takes advantage of the reproducibility in measuring [D]5l) and is 
suitable in the mutational analysis of a protein [23,24]. The stability differences between 
apo-M-FABP and each of the mutant proteins (ΔΔΰ) can be estimated by multiplying the 
difference between the [D]50 values by the m value derived from the transition curve of 
apo-M-FABP (Table 3). Using this method, the differences in conformational stability 
between apo- and holo-M-FABP obtained from the curves achieved with urea and GdnHCl 
are about the same. In general, the differences between the AG°
app values for wild-type and 
mutant proteins are similar but somewhat larger than the AAG values calculated, due to the 
uncertainty of the AG°
app values, which are obtained by extrapolation (Table 3). 
The mutant proteins with the greatest difference in AG°
app compared with apo-M-
FABP also showed the largest difference in stability (AAG). Mutants T40V and R126Q, 
which showed the smallest difference in A G ^ , also deviated least in stability by the 
second procedure: they showed nearly wild-type stability. No large differences in the value 
of m were observed among mutant proteins, but all mutants had a lower value than the 
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wild-type If an average of the m values of the mutant proteins is used to calculate the 
mutant's effect on stability instead of the m value of apo-M-FABP, as suggested by others 
[24,28] for mutant proteins, the results are the same 
DISCUSSION 
Various studies on FABPs, cellular retinol-binding proteins and cellular retinole acid-
binding proteins showed the importance of the amino acid residues at position 106 and 126 
for ligand binding (for references see [1,2]) Among the family of FABPs, Arg-106, Arg-
126 and Tyr-128 are conserved in intestinal, heart, adipocyte, myelin and epidermal 
FABPs In this study we show that Arg-106 seems essential for the fatty acid-binding 
activity of the M-FABP Furthermore, a specific role for Arg is indicated at position 126, 
since mutants with other positively charged residues (R126L, R126K) showed a 
considerable decrease of binding activity In I-FABP, substitution of Gin tor Arg-106 also 
decreases the affinity for fatty acids by 20-fold [34] Complexes between this mutant I 
FABP and oleate showed a destabilization of the electrostatic network [36] In A-FABP, 
mutation of Arg-126 to Gin caused a greatly decreased affinity for cis-pannanc acid [37] 
A 2-4-fold decrease in binding affinity for 11-dansylamino-undecanoic acid (DAUDA) 
and/or oleic acid was observed in mutants of L-FABP in which Arg-122 was replaced by 
Lys, Gin or Ala or Arg-126 was replaced by Lys [38] 
Compared with the arginine residues, Tyr-128 is more tolerant to substitution in M-
FABP, since it can be substituted with Phe without a large change in binding activity On 
the other hand, substitution of Tyr-128 by Trp in A-FABP caused a greatly decreased 
binding affinity for cu-pannaric acid [37] Tyr-128 is not so well conserved throughout the 
family of FABPs as are Arg-106 and Arg-126, since I-FABP has Phe at position 128 
Mutation of Thr-40 caused a large variation in binding activity The introduction or 
a negatively charged carboxylate (T40E) probably interferes with the capture ot the 
carboxylate group of the fatty acid in the electrostatic network in the internal cavity ot M-
FABP The involvement of Thr-40 in the hydrogen-bonding network [8] does not appear to 
be essential, because substitution of valine or glutamine for threonine does not change the 
fatty acid-binding activity 
Other mutants tested had amino acid substitutions at positions Phe-16 and Phe-57, 
which are thought to be involved in the interaction with the acyl chain of the fatty acid 
Phe-16 showed a low tolerance to substitution The phenyl ring seems to be required for 
interaction with the fatty acid, since mutation to Tyr disrupted binding The phenyl ring of 
Phe-57 seems less critical, since the replacement of this amino acid by Ser or Val resulted 
in wild-type binding activity 
The binding of the anthroyloxy-labelled fatty acids to M-FABP and the mutants 
must occur at the surface, since their fluorescence increase was low with these proteins, m 
contrast with L-FABP [15] Furthermore, we observed no shifts in the emission 
wavelength maximum upon binding, except for the mutant R106T Also, all mutant 
proteins of M-FABP, irrespective of whether they bound oleic acid, showed a fluorescence 
increase The binding affinities of fusion proteins of the A-FABP mutants R126Q and 
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Y128W did not change compared with the wild-type with 12-(9-anthroyloxy)oleic acid as 
ligand, but were decreased 30-50-fold with c/s-parinanc acid [37] This suggests a binding 
mechanism other than the carboxylate electrostatic network for the former ligand 
The binding activity of M-FABP shows remarkable stability towards a non-ionic 
chaotropic agent such as urea (Figure 1) Destruction of the external water structure 
decreases generally the hydrophobic character of proteins M-FABP and its family 
members, however, contain a folding motif which is designated an up-and-down ß-barrel 
[7] This structure, which is formed by many intramolecular hydrogen bonds, is probably 
not susceptible to destruction of the water structure around the protein Urea has its effect 
on the internal water-filled cavity, since the transition of M-FABP to the denatured state is 
concomitant with the decrease in binding activity (Figure 1) The denaturation curves 
presented in Figure 1 display no sigmoidal unfolding kinetics, in contrast to DAUDA 
binding by L-FABP in the presence of urea [38] Furthermore, our [D]50 value for M-
FABP was considerably higher than that for L-FABP [38]. 
The midpoint concentrations of urea, ι e those at which 50% of the initial binding 
activity was lost, showed some relationship with the relative binding activities for oleic 
acid, but not in all cases The F57S and R126H mutants showed similar binding activity as 
M-FABP, but their binding centre was less stable (Table 2) When the conformational 
stability of the proteins in the presence of urea was tested, the midpoint concentration was 
generally higher (Table 3) than that for inactivation of the binding centre (Table 2) Of all 
mutant M-FABPs tested, only T40V and R126Q showed wild-type stability, the former 
mutant protein showed similar binding activity and stability of the binding centre as M-
FABP, in contrast to the latter F57S and Y128F showed no or a slight change of binding 
activity compared with the wild-type, but urea affected strongly the binding centre and the 
stability of the protein 
The ionic chaotropic agent GdnHCl causes denaturation of M-FABP at lower 
concentrations than urea, since it disturbs the intramolecular electrostatic network The 
AG°
app values for apo- and holo-M-FABP calculated from the curves with urea as 
dénaturant are in agreement with the results for apo- and holo-I-FABP [39] The ДС°
арр 
values with GdnHCl as dénaturant are about 7 kJ/mol higher for M-FABP than for I-
FABP, but this could be due to the internal location of Trp-82 and its involvement in the 
hydrogen bonding network of I-FABP [40,41] The apparent Gibbs free energy found for 
the unfolding of apo-A-FABP is approximately 3 times lower [42] than we found for apo-
M-FABP, although their structures share several characteristics such as the location of the 
Tip residues and the electrostatic network of Arg-106, Arg-126 and Tyr-128 [10,11] 
In conclusion, the assays of oleic acid binding and conformational stability showed 
distinct differences between the mutant M-FABPs tested, and also between mutants with 
different amino acid substitutions at the same position There was no clear relationship 
between fatty acid-binding activity and stability Mutants T40Q, T40V and F57V showed 
no change in either fatty acid binding or stability, R126Q had a similar stability to that of 
M-FABP but no binding activity, and F57S and Y128F showed only a large decrease in 
stability, with little or no effect on binding These results are in agreement with 
crystallographic data on the importance of Arg-106, Arg-126 and Tyr-128 for the 
electrostatic network of M-FABP and on the role of Phe-16 in the interaction with the fatty 
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acid. The implications of the mutations for other properties of M-FABP (e.g. fatty acid 
transfer) remain to be explored. 
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Chromosomal localization of FABP4 
Adipocyte fatty acid-binding protein (A-FABP), also known as aP2 and adipocyte 
lipid-binding protein (ALBP), is a member of a well-characterized conserved family of 
intracellular lipid-binding proteins, constituting the so-called fatty acid-binding proteins 
(FABPs) and the retinoid binding proteins FABPs are thought to bind fatty acids after their 
translocation to the cytoplasmic side of the plasma membranes and transport these hgands 
to cellular organelles for ß-oxidation or for tnacylglycerol or phospholipid synthesis [10] 
Currently, eight FABP types have been identified and are named by the tissue in which 
they were first detected [10] No structural mutants of FABPs have been identified except, 
recently, an alanine to threonine substitution in the human intestinal FABP, which is 
associated with increased fatty acid binding and transport, increased fat oxidation, and 
insulin resistance [1, 2] In contrast to all other cells, adipocytes show a flux of fatty acids 
in two directions, from the plasma membrane to the cell organelles and, upon hormone 
stimulation of lipolysis from the lipid stores, back to the plasma membrane 
Several genes coding for human as well as murine FABPs have been isolated All 
exhibit a four-exon/three-intron structure, but the sizes of the introns may vary 
considerably [10] The chromosomal location of the genes shows a very dispersed pattern 
For instance, the human genes coding for liver, intestine, ileum, heart, and myelin FABPs 
are located on chromosomes 2, 4, 5, 1 and 8, respectively [6, 10] A similar dispersed 
location of FABP genes is found in the mouse We report here that FABP4 (nomenclature 
according to the Genome DataBase), the gene coding for human A-FABP, maps to 8q21 on 
the basis of PCR screening of a panel of human-rodent somatic cell hybrids and 
fluorescence in situ hybridization on normal human metaphase spreads 
Human A-FABP was purified and its cDNA cloned and sequenced previously [3] 
To establish the chromosomal localization of FABP4, two primers (5'-AGC ACC ATA 
AGC TTA GAT GG-5', З'-АТА CTC TCT CGT ATT CGG TTC-5') were developed to 
PCR amplify FABP4 intron 3 and flanking parts of exon 3 and exon 4 from human 
genomic DNA Sequence analysis of the amplified 650-bp fragment using the Sequenase kit 
(USB) revealed identity to FABP4 intron 3 This fragment was used as a probe to screen a 
human genomic library in λ EMBL3 One positive clone (A181) of approximately 14 kb 
was obtained Direct sequencing on its DNA using the finol DNA Sequencing system 
(Promega) and the primers mentioned before revealed the sequences of intron 3 and 
flanking parts of exon 3 and exon 4 of FABP4 Clone Al81 DNA was subjected to 
Southern blot analysis using three different human FABP4-speciñc probes, the FABP4 
intron 3 fragment, the entire FABP4 cDNA, and an oligonucleotide that contains codons 7-
13 (exon 1) of the FABP4 coding region All three probes hybridized to the A181 clone 
DNA 
A somatic cell hybrid panel, which consists of monochromosomal hybrid cell lines 
of the NIGMS mapping panel 2 (Coriell Cell Repository), was analyzed by PCR using the 
FABP4 intron 3-specific primers A strong signal of the expected size was detected in the 
monochromosomal cell line containing human chromosome 8, and a minor but reproducible 
signal m the DNA of a monochromosomal cell line containing human chromosome 20 (not 
shown) This minor signal could be due to a low-frequency presence of (parts of) other 
human chromosomes in this hybrid line No background signal due to endogenous FABP4 
gene amplification was detected in the mouse and hamster DNAs To confirm the 
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chromosomal location, we used fluorescence in situ hybridization (FISH), performed 
essentially according to published procedures [8, 9]. Briefly, λ EMBL3 DNA (1 μg) was 
labeled with biotin-14-dATP (Gibco, Life Technologies) and the chromosome 8 centromere 
probe (D8Z2) with dig-11-dUTP (Boehringer) using a nick-translation kit (Gibco, Life 
Technologies). A total of 250 ng λ EMBL3 DNA and a 50-fold excess of Cot-1 DNA 
(Gibco, Life Technologies) were dissolved in 6 μ\ of a hybridization mixture (2x SSC/10% 
dextran sulfate/1% Tween-20/50% formamide). Prior to hybridization, the probe was heat-
denatured and then incubated at 37°C for 30 min allowing preannealing. For D8Z2 20 ng 
DNA in 6 μΐ hybridization solution was used per reaction, and no competitor DNA was 
added. Metaphase spreads were prepared according to standard procedures. After 
denaturation of the slides, probe incubations were carried out under a 20 χ 20-min 
coverslip in a moist chamber for 48 h. Immunocytochemical detection of the λ EMBL3 
probe was achieved using fluorescein isothiocyanate (FITC)-conjugated avidin (Vector 
Laboratories), followed by two amplification steps using rabbit-anti-FITC (DAKO) and 
mouse-anti-rabbit-FITC (Jackson Immunoresearch Lab.). The D8Z2 probe was detected 
using anti-digoxigenin-rhodamine Fab fragments (Boehringer) and donkey-anti-sheep-Texas 
Red (Jackson Immunoresearch Lab.). Counterstaining of the chromosomes was done by 
4',6 diamidine-2' -phenyl indole dihydrochloride (DAPI). A Zeiss epifluorescence 
microscope equipped with appropriate filters for visualization of Texas Red, DAPI, and 
FITC fluorescence was used. Digital images were acquired using a high-performance 
cooled CCD camera (Photometries) coupled to a Macintosh Quadra 950 computer and 
further processed using the BDS-Image FISH software package (Oncor). Twenty normal 
metaphases were analyzed, and over 75% showed a signal for the centramene probe of 
chromosome 8 and an additional FABP4 signal in the region 8q21 (Fig.l). No signal was 
observed on chromosome 20 in any of the chromosome preparations studied. 
Fig. 1. Localization ofFABP4 to human chromosome 8q21 by FISH. (A) Computer-enhanced merged image of 
fluorescein signals and DAPl-stained chromosomes in which specific hybridization (symmetrical double spots) 
of the genomic FABP4 probe to chromosome 8 is marked (arrow). Chromosome 8 centromeres were visualized 
by a chromosome 8 centromeric probe (D8Z2). (B) Two chromosomes 8 of A have been enlarged. For 
comparison to the cytogenetic banding pattern an idiogram of chromosome 8 is shown. Chromosome 8 
centromeres were visualized by a centromeric probe (upper signals). 
Interestingly, the PMP2 (peripheral myelin protein 2, myelin FABP) gene maps to 
the same chromosomal region (8q21.3-8q22.1) [4]. Phylogenetic studies have revealed a 
high degree of similarity between the human myelin and adipocyte FABPs [7], and 
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comparison of the coding sequences showed a 73% homology [10] Using PMP2 cDNA as 
a template, the primer set did not yield any amplification product Furthermore, the 
amplified FABP4 intron 3 fragment was 650 bp while intron 3 of the PMP2 gene was 
reported to be approximately 1200 bp [4] From this, we conclude that the coinciding 
chromosomal locations do not result from cross-hybridization of FABP4 and PMP2 gene 
sequences 
There exists an extended synteny between human chromosome 8 and mouse 
chromosome 3, and the localization of FABP4 on human chromosome 8 is consistent with 
the localization of the mouse FABP4 (Ap2) gene on chromosome 3 [5] In both cases, the 
FABP4 gene has been found in close proximity (2 2 cM in mouse) to the carbonic 
anhydrase II gene The latter gene is located on human chromosome 8ql3-q22 1 [11] 
These data confirm the syntemc origin of this chromosomal segment 
We localized the FABP4 gene to human chromosome 8q21 using somatic cell hybrid 
and fluorescence in situ hybridization techniques More detailed mapping of the FABP4 and 
PMP2 genes should shed further light on their genomic organization and their possible 
common origin 
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Identification of a human heart FABP pseudogene 
SUMMARY 
The fatty acid-binding proteins (FABPs) constitute a conserved group of cytosolic low 
molecular mass proteins, which consists of several types: liver, heart, myelin, epidermal, 
adipocyte, brain, intestinal and ileal type. The FABP gene structure is well conserved 
during evolution and exhibits a four-exon/three-intron structure. In the past, multiple 
hybridizing fragments were detected upon Southern blot analysis using heart FABP (H-
FABP) cDNA as a probe. The origin of these fragments was not clear. We screened a 
human genomic library and isolated an intronless gene (FABP3-ps) with 85 % similarity to 
the human heart FABP (H-FABP) cDNA and high similarity (76 and 79%) to the H-FABP 
cDNAs of mouse and bovine, respectively. By means of fluorescence in situ hybridization 
this processed pseudogene could be assigned to chromosome 13ql3-ql4, whereas the gene 
for human H-FABP (FABP3) resides on chromosome Ip32-p33. No expression of the 
processed pseudogene could be detected in skeletal muscle or fetal brain. 
INTRODUCTION 
Human heart fatty acid-binding protein (H-FABP) is a member of a family of intracellular 
fatty acid-, retinoid- and bile acid-binding proteins [1,2]. FABPs seem to control the flux 
of fatty acids between the plasma membrane and cell organelles. They may also modulate 
different cellular functions. Eight types of FABPs have been described These proteins are 
found in tissues of vertebrates and invertebrates [1,3-6]. 
Heart type FABP exhibits a more general tissue distribution than any other FABP 
type and is detected in heart, skeletal muscle, kidney, aorta, adrenals, testes, brain, 
placenta, lung, mammary gland, stomach and ovary There is a high degree of similarity 
between H-FABP and mammary-derived growth inhibitor (MDGI), a protein which has 
been characterized as an endogenous growth inhibitor and differentiation factor of 
mammary epithelium [7]. By many lines of evidence this protein was identified as H-FABP 
[8,9]. Recombinant human H-FABP shows preference for binding of palmitic and C18-C :2 
unsaturated fatty acids [10-12]. 
The location of the FABP genes shows a dispersed pattern along human and mouse 
genomes [2]. Within these species the genes are located on different chromosomes, but 
there exists a certain degree of synteny between these chromosomal regions in human and 
mouse [8] The gene for human H-FABP (FABP3) was previously localized by means of 
Southern blot analysis of a human-rodent somatic cell hybrid panel on chromosome lpter-
q31 [13]. Two other groups independently confirmed this chromosomal localization by 
fluorescence in situ hybridization and narrowed down the region to Ip32-lp33 and ІрЗЗ-
p35, respectively [14,15]. Low stringency Southern hybridization of chicken, rat, mouse, 
and human genomic DNA with rat H-FABP cDNA revealed multiple hybridizing 
fragments, but their origin was not clear [16,17]. It has been suggested that these loci may 
represent pseudogenes. Genetic mapping of H-FABP-related sequences assigned the mouse 
gene to chromosome 4 and a pseudogene to chromosome 10 [8]. 
In this paper, we report the isolation and chromosomal location of a human 
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ïntronless gene, with a high degree of similarity to the human H-FABP cDNA No cDNAs 
for the ïntronless gene could be detected in human skeletal muscle or fetal brain libraries 
EXPERIMENTAL 
Materials 
Oligonucleotide primers were obtained from Eurogentec, Seraing, Belgium, Taq DNA 
polymerase was from Promega, Madison, WI, USA, Sequenase version 2 0 was from 
United States Biochemical, Cleveland, OH, USA, random primed DNA labelling kit was 
from Boehringer, Mannheim, Germany, biotin-14-dATP, restriction endonucleases, T4 
DNA ligase and urea were from Life Technologies Ine , Gaithersburg, MD, USA, Seakem 
ME agarose and NuSieve (3 1) agarose were from FMC BioProducts, Rockland, ME, 
USA, [ct-35S]thio-dATP (37 TBq/mmol), [a-3P]dCTP (110 TBq/mmol) and Hybond N" 
nylon transfer membrane were from Amersham International, Little Chalfont, Bucks , UK, 
nonfat dry milk powder was from Profilar, Nutricia, The Netherlands, fluorescein 
isothiocyanate conjugated to avidin-D was from Vector Laboratories Ine , Burhngame, CA, 
USA All other reagents were of analytical grade 
Isolation and analysis of a human genomic H-FABP clone 
A AEMBL3 human genomic library was screened with a 429-bp ([a-32P]dCTP-Iabeled) H-
FABP cDNA probe [13] DNA isolated from 10 hybridization-positive clones, was 
digested with the restriction endonucleases Rsal and Pstl, separated on a 0 8% agarose gel, 
transferred to a nylon membrane, and hybridized with the H-FABP cDNA probe The 
EtdBr staimng pattern of DNA fragments in the gel and the hybridization profile were used 
to determine whether the clones contained different inserts A representative clone, 
λΜ201, was double-digested with Sail and Я/wdIII and a 1507-bp DNA fragment isolated 
and subcloned into pGEM-3Zf( + ) The clone was dideoxy sequenced using [35S]thio-dATP 
and Sequenase 2 0 on either double-stranded or single-stranded pGEM vectors Nucleotide 
sequences were analysed using computer programms supported by the CAOS/CAMM 
Centre, Nijmegen, The Netherlands 
Somatic cell-hybrid panel 
For chromosomal localization, a panel of 31 well defined human χ rodent somatic cell 
hybrids was used [18] These hybrid lines were isolated after fusion of human cells, 
obtained from different donors, with hypoxanthine phosphonbosyl transferase- or 
thymidine kinase-deficient rodent cell lines For chromosomal analysis of the hybrid cell 
lines, air-dried chromosome spreads were made according to standard procedures Of each 
cell line at least 16 metaphases were examined, using R-banding after heat denaturation 
The cells, used for chromosome analysis and DNA extraction, were always derived from 
the same culture batch 
Fluorescence in situ hybridization 
For regional localization of the ïntronless H-FABP gene, non-radioactive in situ 
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hybridization was performed on R-banded normal human lymphocyte spreads, using 
EMBL3 vector M201 as a probe Briefly, ΛΜ201 DNA was labelled with biotin-14 dATP 
by nick-translation, purified, and ethanol precipitated together with a 50-fold excess of 
herring sperm DNA and 200-fold excess of sonicated total human DNA This DNA 
mixture was then dissolved m 10 μ\ of a hybridization mixture containing 2xSSC/10% 
dextran sulphate/1% Tween 20/50% formamide Prior to hybridization, the probe DNA 
was denatured at 80°C for 10 min, followed by incubation a!t 37 С for 2 h to allow 
annealing of highly reiterated sequences Finally, the probe mixture was added to heat-
denatured chromosome spreads, enclosed under a coverslip, and incubated at 37°C for 16 
h After posthybridization washings and blocking with non-fat dry milk powder, 
immunological detection of the hybridizing probe was accomplished through the use of 
fluorescein isothiocyanate conjugated to avidin-D in one signal amplification round, as 
described [19] R-banding was obtained using Hoechst 33258 (15 min), UV light 
irradiation (364 ran for 20 min), and denaturation in Earl's solution (pH 6 5 at 87°C for 30-
120 s) Finally, the chromosome spreads were mounted in antifade solution supplemented 
with propidium iodide (1 μg/ml) for counterstaming Chromosomal slides were evaluated 
via digital imaging microscopy using a high-performance CCD camera (Photometries) 
coupled to a Macintosh II computer 
PCR analysis of expression libraries. 
Genomic DNA was prepared from blood samples as described by Miller et al [20] Primer 
pairs were designed to specifically amplify part of the coding regions of FABP3-ps (PI, 5'-
CCTGTGCACCTGGAAGCTCTCAG and P2, 5-CAGTGACAGGGCAGGCAGACG) or 
the cDNA derived of transcripts of FABP3 (P3, 5'GCCAGCATCACCATGGTGG-
ACGCTTTC and P4, 5 ' -АТСACCAGTGGATCCAGGTCATGCCTC) Conditions of PCR 
were 20 pmol of each primer, 200 nM of each dNTP, 2 5 units of Taq DNA polymerase 
and 1 5 mM MgCI, in 50 mM KCl/10 mM Tris/HCl, pH 9 0/0 1 % Triton Х-100 in a total 
volume of 50 μ\ After 5 min denaturation at 94°C, 30 cycles of amplification were carried 
out 95°C for 1 mm, 60 С for 1 min, 74 С for 1 5 min and a final 10 mm af74 С PCR 
products (1/3 of total yield) were analyzed in a 2 5% NuSieve (3 1) agarose gel 
RESULTS and DISCUSSION 
Isolation and characterisation of a human H-FABP processed pseudogene 
Upon screening a human genomic library in the EMBL3 vector with a full-length human 
H-FABP cDNA probe we isolated one type of positive clones, represented by clone 
λΜ201 A strong hybridizing SaR-Hina\\\ 1 5-kb DNA fragment of this clone was isolated 
and the nt sequence elucidated After a FASTA search to GenEMBL, this subclone showed 
a high (85%) degree of similarity to the human H-FABP mRNA [13] Southern analysis of 
human genomic DNA hybridized with the full-length human H-FABP cDNA reveals 
multiple hybridizing fragments, some of them due to hybridization to the FABP3 gene and 
others are due to hybridization to the isolated genomic 1 5-kb fragment (results not shown) 
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РАВРЗ-рз AGCATTAGCACAGTTTAGTGCCACTGCCTCAACTGGTCCTAAGGCACCAAA θ 04 
PABP3 G*G*GCC*GGGGCG*GG*CCA*GTC**********A+G*G*****TATTT* 1192 
AATTGCATCCAAT ATCGGCAGTCCAACTCCTTGCACACCTGCTCTCTCACAGC 8 57 
**GC*GCAG*CCGGGCAGGG*G*C**C***GG*GC**"****G*+********TGT*** 12 5 2 
primer 1 
TTCTTTCTCAGTCTAGGCCAGCATCACCAJÇGTAGATGCCTTCCTGTGCACCTGGAAGCT 917 
***__******C****ç**********T*****G**c**T******G************* 1310 
primer 3 • 
CTCAGACAGCAAGAATTTTGATGACTACATGAAGTTAATCGGTGCAAGTTTTGCTATCAG 977 
AGTG* *************C************* ***C*C******TGG*** ******£*** 1370 
\intron 1 
GCAGGTGGCTAGCATGACAAAGCCTACCACAATCATCAAAAAGAATGGGGACATTATCAC 103 7 
* * * * * * * * * Ç * * * * * * * * C * * * * * * * * * * * * * * * * * * Q * * * * * * * * * * * * + * * * * C * * * * 1430 
CTTAAAAACACAGAGCATGTTCAAGAACACAGAGATCAGCTTTAAGCTGGGGATGGGGTT 10 9 7 
*C*****+****ç+* **çc*** * * * * * * * * * * + * + * + * * * * * * * * * T * * * * * G * * * A * * * 1490 
CGATGAGACAACAGCAGATGACAAAAAGGTCAAGTCCATTGTGACACTGGATGGAAGCAA 115 7 
* * * * * * * * * * * * * * * * * * * * * + + Q Q + + + * * * * * * * * * * * * * * * * * * + * * * * * * + * Q * Q * * 1550 
\intron 2 
ACTTTTTCACCTGCAGAAGTGTAACGGGCAAGAGAGGACACTTGTGCCAGAGCTAAGTGA 1217 
+ ***(^*************д* *GG* ********* **CC* ******** *GG* ******T*** 1610 
TGGGAAACTCATCCTGACACTCACCCAGGGCACTGCGGTTTACACTCGCACTTATGAGAA 12 7 7 
***д*+****++*********+*****С********д****0*******+****С***** 1670 
\intron 3 
« primer 2 
AGAGGTATCGTCTGCCTGCGCTGTCACTGACTGTTCCTCT GTTACCCTTTGA 1329 
** + **C**G_AC***A****A* + **TG******AC*A****GCCAATCG*C*****C*C** 173 0 
< primer 4 
CTCAGCACCACATTGCCTCATTTATTTCCCCTGCATTTTGTATAAATCCACCTTGTTGAA 13 8 9 
*** + ** + ***** + **********_(^****'р************с******** 1780 
lEcoRI 
GAATTCTTCTGAGGTCATGTGCCTCAGAAGACTTCAGATCAATAGGTCCCAAGACGTTAC 144 9 
***********G*****i3*****A*T**CCGGGATCC*GTTCC**T*****T*GT**ATG 184 0 
ATTTTCCAATGAAGTAACAACAGACGACATATTGTGATC 14 8 8 
TGG**TTTT*TTTT*TTTTTT*ACT*CAC*CA*AG*G«GCTCTGAGGTCAATAAAGCAGA 190 0 
Fig. I. The nt sequence of the human H-FABP processed pseudogene, FABP3-ps (top). The exon sequences 
of the H-FABP-encoding gene (FABP3) are shown at the bottom (GenBank/EMBL accession No. U57623 
[21]) Introns have been omitted, but their positions are indicated. The nt identities are indicated as asteriks 
(*) Dashes indicate gaps introduced to maximize alignment Start and stop codons are underlined Positions 
of the putative TATA box and polyadenylauon signal of FAB Pi are double underlined EcoRI sites within the 
sequences are marked with a vertical arrow Positions of the primers used in PCR are indicated by horizontal 
arrows The FABP3-ps GenBank/EMBL accession No is 1172237 
86 
Identification of a human heart FABP pseudogene 
60 
HsU/ MVDAFLC-TWKLSDSKNFDDYMKLIGASFAIRQVASMTKPTTIIKK-NGDIITLKTQSMF 
H
s
 ******Q_ ****γρ* ***** * + *3L*VG**T***** ********E*-****L****H*T* 
BQ *****YG_ ** **YD*********SL*VG**T***GN********EV- ***TVII* ***T* 
j
a^
 *A* **VG- * ** *VD** ****** *SL*VG**T****** *******E*-***T**I**H*T* 
y[Q *A* * *VG- * * * *VD*** * *** **SL*VG**T***G** *******E*-***T**I****T* 
Sm *S-S**G-K****E*H***AV*SKL*V*W*T**IGNTVT**VTFTM-D**KM*ML*E*T* 
Sg VKE-*AGIKY**D*QT**EE***A**VGAIE*KAGLALS*VIELEILD**KFK*TSKTAI 
Lm VKE-*AGIKY**D*QT**EE***A**VGAIE*KAGLALS*VIELEILD**KFK*TSKTAI 
* ** ** * _ * _ * _ * * * 
120 
HS4; KNTEISFKLGMGFDETTADDKKVKSIVTLDG-SKLFHLQKCNGQERTLVPELSDGKLILT 
Hs * * * * * * * * * * Y E * * * * * * * * J ^ * * * * * * * * * * _ Q * *γ** * *^]3* + * T * * * R * * j * * * * * * * 
Bo ********* * Y E * * * * * * * * J ^ * * * * * * * * * * _ Q * *γ*γ* *^****,js**R*MV*** * ** * 
Ra *******Q* * Y E * * *γ**** J^****Y* * * * * _ Q * * Y * Y * *щз****р**ТЕ** ******** 
Mo *****N*Q**IE***V****R****L*****-G**I*V**WD***T**TR**V******* 
Sm **LSCT**F*EE***K*S*GRN***V*EKNSE***TQT*VDPKNTTVI*R*VDGDTMKT* 
Sg ****FT****EE***E*L*GR****TI*Q**PN**V*E**-GDHPTIIIR*F*KEQCVI* 
Lm ***DFT****EE***E*L*GR****TI*Q**PN**V*E**-GDHPTIIIR*F*KEQCVI* 
** * * * * * * * * * * ** * * * 
Hs\J LTQGTAVYTRTYEKEVSSACAVTDCSSVTL 147 
Hs **н****с*******А 133 
Bo * * H * * * * C * * * * * * Q A 
Ra **H*NV*S*******A 
Mo * * H * S V * S * * * * * * * A 
Sm V*V*DVTAI*N*KRLS 
Sg IKL*DL*A**I*-*AQ 
Lm IKL*DL*A**I*-*AQ 
Fig. 2. Alignment of aa sequences of H-FABPs of several species. The deduced aa sequence encoded bv 
FABP3-ps (Hsi/r), H-FABP aa sequences of four vertebrates (human (Hs), bovine (Bo), rat (Ra), mouse (Mo)), 
and three invertebrates (Schistosoma mansom (Sm), Schistocerca gregaria (Sg), Locusta migratoria (Lm)) are 
showed The aa which are conserved throughout all H-FABPs are marked by asterisks (*) below the 
alignments and a dot ( ) indicates incomplete homology but with retention of the aa family. Dashes indicate 
gaps introduced to maximize alignment The su aa residues in bold m the deduced aa sequence encoded bv 
FABP3-ps are substitutions on conserved H-FABP positions. Alignment was by the GCG package 
GenBank/EMBL accession Nos are U72237 (Ηϊψ), X56549 (Hs), X127I0 (Bo), M18034 (Ra), U02883 (Mo). 
A39818 (Sm), A42342 (Sg), and S43470 (Lm) 
The coding sequence along with 5' and 3' flanking sequences of this gene (FABP3-ps) is 
shown m Fig.l, along with that of human FABP3 coding sequences. In contrast to the 
recently sequenced functional gene, FABP3 [21], clone ΛΜ201 did not contain any introns 
and one open reading frame (ORF) of 441 nt, which is 42 nt longer than the ORF encoded 
by the FABP3 gene. Alignment of the deduced aa sequences encoded by the intronless H-
FABP gene (FABP3-ps) and human FABP3 showed a high degree of similarity (81 %), with 
24 aa substitutions (Fig. 2). Of these substituted aa, six are located on positions which are 
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conserved in seven known H-FABPs (Fig 2) At least one of these substitutions, R106P, 
would lead to a protein incapable of binding fatty acids The arginine at this position has 
previously been found to be crucial for fatty acid binding [22] In FABP3-ps, the stop 
codon was substituted by a coding codon (Ser) In this way the aa sequence was terminated 
at the next in-frame stop codon, giving rise to a predicted product with 14 additional aa 
compared to H-FABP The sequence similarity extends 133 nt downstream from the 
consensus stop codon of the functional FABP3 gene The 23 nt at the 3' end of the 1507-bp 
clone are homologous to bacteriophage AEMBL3 left arm DNA Therefore the 3 region of 
FABP3 ps was sequenced only 200 bp after its mutated stop codon In other FABP nt 
sequences and the mouse H-FABP pseudogene, the polyadenylation signal is found at 
approx 210 bp after the translation stop codon The λ clone identified did, therefore, not 
contain a 3' sequence region long enough to identify more structural characteristics of a 
processed pseudogene, ι e , a polyadenylation signal, a poly (A) stretch and/or a direct 
repeat which could be found on both sides of the intronless gene 
Nucleotides 1-225 of the cloned 1 5-kb fragment (nt -886 to -661 of the start codon) 
in the 5 region of FABP3-ps show similarities to human nt sequences known as the 
THE1A family (direct repeats), THE1B element fragments (repeat region) and the long 
terminal repeat (LTR) O-type (not shown) In order for the intronless gene to be expressed 
it would need a functional promoter Analysis of the 5' region of the intronless gene 
revealed seven potential E boxes (not shown) which are also found in promoters of human 
and mouse muscle-specific genes [23] No putative TATA box could be detected (Fig 1 ) In 
the mouse H-FABP pseudogene an intact TATA box was found in exactly the same 
position as in the mouse functional gene promoter [8] The mouse H-FABP pseudogene 
was reported to differ by only three aa from the coding region of the H-FABP gene, 
compared to 24 aa substitutions in human From our results it appears that the human H-
FABP pseudogene has a less conserved structure than the highly conserved mouse H-FABP 
pseudogene Therefore, the human H-FABP pseudogene may have been evolved earlier in 
molecular evolution than the mouse H-FABP pseudogene 
Chromosomal location of the intronless gene 
To localize the intronless H-FABP gene (FABP3-ps) on human chromosomes, the isolated 
1 5-kb fragment which contained the intronless gene, was used to screen a panel of 31 
rodent χ human somatic cell hybrids, covering all human chromosomes (results not 
shown) The lowest discordance (13%) was found for human chromosome 13 most of the 
hybrids containing chromosome 13 were positive for FABP3-ps, conversely, when this 
chromosome was absent, the signal for FABP3-ps was missing The concordance observed 
was not complete 
To confirm and refine the chromosomal localization, we used fluorescence in situ 
hybridization (FISH), performed essentially according to published procedures [19] 
Comparisons between the FISH signals and the banded chromosomes provided the precise 
localization Over 80% of the normal human lymphocyte spreads analyzed showed a 
FABP3-ps signal in the region 13ql3-ql4 (Fig 3B) No signal was detected on other 
human chromosomes 
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Fig. 3. FISH of DAPI-stained human metaphase chromosomes probed with ЛМ201 DNA. By comparison 
with the cytogenetic banding pattern of human chromosomes (A), FABP3-ps could be located in region 13ql3-
ql4 (B, arrow). 
bp 
1444 
849 
482/476 
342 
211 
P1/P2 P3/P4 J 
Fig. 4. Detection of cDNAs by PCR screening of skeletal muscle and brain cDNA 
libraries. The ORFs of FABP3-ps and FABP3 were amplified using specific primers P1/P2 (lanes 1-4) and 
P3/P4 (lanes 5-8), respectively (forprimers see Fig. I). Templates used in PCR reactions are: 0.6 ßg human 
genomic DNA (lanes 1 and 5), 0.6 ßg of human skeletal muscle cDNA in Àgili (lanes 2 and 6), 1.6 ßg of 
human fetal brain cDNA in pJG4-5 (lanes 3 and 7), and no DNA (control) (lanes 4 and 8). PCR products were 
analyzed in a 2.5% Nusieve (3:1) agarose gel and visualized by EtdBr. 
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Expression detection in cDNA libraries 
To monitor expression of the intronless gene (FABP3-ps) we used the highly sensitive 
polymerase chain reaction (PCR) technique. For specific amplification of cDNAs of the 
processed pseudogene and the H-FABP mRNA, a human skeletal muscle cDNA library 
(previously used to isolate the H-FABP cDNA) and a human fetal brain cDNA library were 
used. Amplified cDNAs of FABP3-ps and FABP3 would give rise to products of 407 and 
432 bp, respectively. No amplification of FABP3-ps was detected with skeletal muscle or 
fetal brain cDNAs, whereas amplification of FABP3 was shown with both cDNA pools 
(Fig.4). Amplification of FABP3-ps but not FABP3 was shown with genomic DNA under 
the same conditions. This control reaction shows the specificity of the primers used. From 
these results it is not likely that FABP3-ps is transcribed in human skeletal muscle or fetal 
brain. Together with the evidence discussed before, this indicates that the gene is a 
processed non-functional pseudogene. 
CONCLUSIONS 
(1) The intronless H-FABP gene (FABP3-ps) exhibits some distinct sequence characteristics 
of a processed pseudogene. The coding sequence of FABP3-ps is not interrupted by 
introns. Nucleotide substitutions give rise to aa substitutions on positions which are 
conserved through H-FABPs of different species 
(2) Although the 5' region of the intronless H-FABP gene contains seven sequence 
elements similar to the E box, no functional TATA box was present in the 5' region and, 
therefore, no indications for a functional promoter have been found. 
(3) No polyadenylation signal or poly(A) stretch could be detected in the 3' region, 
probably due to the small size of the 3' region cloned in the EMBL3 vector 
(4) The ORF is conserved (85% identity) and might encode a 142-aa protein However, we 
were not able to detect any expression of the intronless H-FABP gene in human skeletal 
muscle or fetal brain. 
(5) The intronless H-FABP gene was assigned to human chromosome 13ql3-ql4 by FISH 
analysis. A chromosomal location different from that of the functional gene is another 
characteristic of processed pseudogenes. 
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FABP cDNA transfections of L6 myoblasts 
SUMMARY 
We studied the significance of FABP for growth, differentiation and fatty acid metabolism of 
muscle cells by lipofection of rat L6 myoblasts with rat H-FABP (S) or (AS) cDN A or with 
rat A-FABP (S) cDNA The cDNAs were isolated by RT-PCR and cloned in eukaryotic 
expression vectors under control of a SV40 early promoter Stable transfectants showed 
integration into the genome for all constructs and type-specific overexpression at mRNA and 
protein level for the clones with H-FABP (S) and A-FABP (S) cDNA constructs Introduction 
of the H-FABP (AS) cDNA construct did not decrease H-FABP expression compared to 
mock transfection The proliferation rate of myoblasts transfected with rat A-FABP (S) 
cDNA was 2-fold higher compared to all other transfected cells In addition, myoblasts with 
the H-FABP (AS) or A-FABP (S) cDNA constructs showed a disturbed fusion and 
differentiation, based on morphology, CK activity, and palmitate oxidation Uptake rates of 
palmitate were equal for all clones, in spite of different FABP content Palmitate oxidation 
over a 3 h period was similar in all clones from growth medium Mock and H-FABP (S) 
cDNA transfected cells showed after cultunng in differentiation medium a lower fatty acid 
oxidation m contrast to H-FABP (AS) and A-FABP (S) cDNA transfected clones 
Incorporation of [MC]palmitic acid into total cellular lipids and different lipid species differed 
after 24 h incubation between myoblasts and myotubes PC/ΡΕ ratios of H-FABP (AS) and 
A-FABP (S) cDNA transfected clones changed in opposite direction in differentiation 
medium compared to mock and H-FABP (S) cDNA transfected clones In conclusion, 
transfection of L6 myoblasts with H-FABP (AS) and A-FABP (S) cDNA affects fusion and 
differentiation but not fatty acid uptake The fusion defects may relate to changes of 
phospholipid metabolism 
INTRODUCTION 
Fatty acid-binding proteins (FABPs) belong to a conserved family of intracellular lipid-
binding proteins with low molecular mass (14-15 kDa)[l-3] Eight different FABP types have 
been described, including heart, liver, adipose, myelin, intestinal, epidermal, brain and ileal 
type FABPs Many FABP cDNAs have been isolated, cloned and the proteins expressed in 
bacterial systems In this way, large amounts of proteins became available for three-
dimensional analysis by crystallography and/or NMR (reviewed in [1, 3]) All FABPs studied 
thus far contain a folding motif which is designated an up-and-down ß-barrel [3] 
The main function of FABP is thought to be intracellular binding and targeting of 
fatty acids FABPs may also have a modulatory role on the effect of fatty acids on various 
metabolic enzymes and receptors and cellular processes as signal transduction and gene 
expression [1.4] The functional significance of the different FABP types is rather unclear 
and may vary with the tissue and the physiological condition Adaptations may relate to 
metabolic requirements of the cell, ligand trafficking and/or modulatory functions 
A relation was observed between the fatty acid oxidation capacity and FABP content 
of various rat tissues and of various human and rat muscles [5-7] The FABP content of 
muscle did not show changes at various physiological conditions, except an increase in fast-
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twitch muscles upon chronic electrostimulation and endurance training [7] H-FABP content 
and fatty acid oxidation capacity increase in skeletal and heart muscle at postnatal 
development [7, 8] Some indications have been obtained for a role of H-FABP in regulation 
of growth and differentiation Mammary-derived growth inhibitor which appeared to be 
identical with a mixture of H-FABP and A-FABP [9], causes specific growth inhibition and 
terminal differentiation of mammary epithelial cells [10,11], and a modest antiproliferative 
activity in human breast cancer cells [12] The protein appeared also to be an inducer of 
hypertrophy of cardiac myocytes [13] Bovine H-FABP expression in yeast transformants 
retarded growth [14] 
Much of our previous work was related to the in vitro characteristics of FABPs in 
general and H-FABP in particular [1, 4, 15] In studies with cultured human primary skeletal 
muscle cells, we observed that the FABP content increases with the maturation grade of the 
cells [16] This increase was however not accompanied by a raise in palmitate oxidation 
capacity In a mouse skeletal muscle cell line, H-FABP expression raises 60-fold upon 
differentiation [17] A 5- to 7-fold increase of fatty acid oxidation was found upon L6 
myoblast differentiation [18] In an abstract Claffey et al reported a larger fatty acid uptake 
and esterfication in these cells containing overexpressed H-FABP [19] Fatty acid oxidation 
was not studied in these transfected cells 
Transfection studies of liver FABP (L-FABP), intestinal FABP (I-FABP), and A-
FABP were performed in fibroblasts [20-25] and Chinese hamster ovary (CHO) cells [26], 
which express no or very little FABP We used the L6 rat skeletal muscle cell line to study 
FABP function in a cell culture model marked by changes of the endogenous FABP content 
Myoblasts of this cell line are able to fuse and differentiate if the culture conditions are 
changed We studied the effect of transfection with rat H-FABP (S) or (AS) cDNA on their 
growth and differentiation and fatty acid uptake and metabolism Furthermore, we studied the 
effect of the presence of a second, non-muscle FABP by the introduction of A-FABP (S) 
cDNA in this cell line 
EXPERIMENTAL 
Materials 
Oligonucleotide primers were obtained from Eurogentec, Seraing, Belgium, Taq DNA 
polymerase and RNasin were from Promega, Madison, WI, USA, Sequenase version 2 0 
DNA sequencing kit irom United States Biochemical, Cleveland, OH, USA, Superscript 
RNase H reverse transcriptase (RT), restriction endonucleases, agar, bacto yeast extract, 
casein hydrolysate, isopropyl ß-D-thiogalactopyranoside (IPTG), Ultroser G and guanidine 
isothiocyanate were from Life Techologies Ine , Gaithersburg, MD, U S A , TA Cloning 
system was from Invitrogen Corp, San Diego, CA, U S A , Lipidex 1000 was from 
Canberra-Packard. Groningen, The Netherlands, transfection-reagent (DOTAP), creatine 
kinase NAC-activated monotest kit and the random primed DNA labeling kit were from 
Boehnnger Mannheim GmbH, Mannheim, Germany, puromycin dihydrochlonde and bovine 
serum albumin were from Sigma, St Louis, MO, U S A , Dulbecco's modified Eagle medium 
(DMEM) was from Gibco, Hoofddorp, The Netherlands, fetal calf serum was from Integro 
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Zaandam, The Netherlands. Hybond N\ ECL Western blotting analysis system, [a-35 S]thio-
dATP (1000 Ci/mmol), [a-32P]dCTP (3000 Ci/mmol), [l-14C]oleic acid (55 mCi/mmol), [1-
'
4C]palmitic acid (55 mCi/mmol) and [6-3 HJthymidine (5 mCi/mmol) were from Amersham 
International. Little Chalfont, Bucks, U K , Aqualuma Plus was from Lumac LSC, 
Groningen, The Netherlands, trypsin was from Difco laboratories, Detroit, Michigan. U S A . 
TLC aluminium sheets silica gel 60 F,5J were from Merck All other reagents were of 
analytical grade 
Culture media and buffers 
Dulbecco's modified phosphate-buffered saline (D-PBS) contained 145 mM NaCl/5 4 mM 
KC1/5 mM NaiHPO.,/25 mM glucose/25 mM sucrose (pH 7 3) Growth medium was 
composed of Dulbecco's modified Eagle medium (DMEM) with 10% fetal calf serum (FCS) 
Differentiation medium contained 0 4% Ultroser G and 10% rat brain extract in DMEM [ 16] 
Cell culture 
L6 myoblasts were proliferated in growth medium Before confluency was reached the cells 
were washed with D-PBS, treated with 2 mM EDTA (in D-PBS) during 1 min, and 
trypsinized (0 05% trypsin in D-PBS for 7-10 min at 2ГС) , collected by centrifugation and 
seeded again in fresh growth medium Medium was changed every 2-3 days To induce 
fusion, the medium was changed to differentiation medium at confluency of the culture Cells 
were grown m this medium for 3-9 days Routinely, mycoplasma control was performed 
using fluorochrome Hoechst 33258 staining of air-dried cultures Cultures of cells, grown on 
differentiation medium were photographed (Zeiss Pan-Neofluar lOx lens) after staining with 
haematoxylin solution Primary rat muscle cells from 10 day old rats were cultured in the 
same media as the L6 cells 
Cloning and sequencing of rat heart and adipocyte FABP cDN A 
Rat heart- and adipocyte FABP mRNAs were reverse transcribed and amplified using rat 
poly(A) RNA isolated from adult rat quadriceps muscle as a template The primer sets used 
are for the rat H-FABP cDNA sequence forward primer, 5'-TCTCATT-
GCACCATGGCGGACGCCTTT-3', reverse primer, 5'-AGTGACGGGGGATCCAGGT-
CACGCCTCCTT-3' For rat A-FABP cDNA the primers were derived from the mouse and 
human A-FABP cDNA sequences forward primer, 5'-GGCCATATGTGTGATGCY-
TTTGTRGG-3', reverse primer, 5'-CATGGATCCGGCTYATGCYCTYTCATAAAC-3' 
Reverse primers (20 pmol) were used to reverse transcribe 1 μg of rat muscle mRNA with 20 
units of Superscript RNase H RT in 50 mM Tris/HCl, pH 8 3/75 mM KC1/3 mM MgCL/5 
mM dithiothreitol (DTT)/1 mM of each dNTP/40 units of RNasin in 1 h at 42°C The PCR 
amplification reactions were earned out in a total volume of 50 μΐ containing 20 pmol of each 
primer, 1 unit of Taq DNA polymerase and 1 5 mM MgCl2 in 50 mM K.C1/10 mM Tns/HCl, 
pH 9 0/0 1% Triton X-100 After 5 mm denaturation at 94°C, 30 cycles of amplification were 
carried out 94 °C for 1 5 min, 55°С for 2 min, 74° С for 2 min The amplified cDNAs were 
cloned using the ТА Cloning kit DNA sequencing was performed using Sanger sequencing 
on either double-stranded or single-stranded pCRII plasmids 
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Expression and purification of rat H-FABP and A-FABP 
Coding sequences of rat H-FABP and A-FABP were hgated in bacterial expression vectors 
pET-3d and pET-lla, respectively The recombinant plasmids were transformed to 
Escherichta coll BL21(DE3) cells and expression of the FABPs was induced by the addition 
of 0 5 mM IPTG [27,28] The procedure for purification of the rat H-FABP and A-FABP was 
essentially as for the human H-FABP [15,28] The binding affinity for [l-MC]oleic acid was 
analyzed with the Lipidex method [29] K¿ values were derived from Scatchard plots of 
binding assays at 0 1 -2 0 μΜ oleic acid and 0 5 μΜ protein Polyclonal rabbit anti-rat H-
FABP and anti-rat A-FABP sera were prepared following standard procedures [6] 
Construction of eukaryotic expression constructs 
The constructs were based on the pSG5 expression plasmid [30] Transcription of the cDNAs 
was under the control of a SV40 early promoter and the construct contained a rabbit ß-globin 
intron II and a SV40 poly-A signal [30] A modified pSG5 plasmid, with an extended 
multiple cloning site and a 1,7 kb рас cassette (puromycin acetyltransferase) hgated in the 
Sail site of the multiple cloning site was used as expression construct Rat H-FABP and rat 
A-FABP cDNAs in the pCRII vectors were cut out by EcoRl digestions and inserted in the 
EcoRl site of the multiple cloning site of the pSG5-pac expression plasmid The orientation 
and size of the cloned cDNAs was verified by PCR using a T7 promoter (forward) primer and 
a cDNA specific (reverse) primer or a SV40 poly(A) addition signal (reverse) primer and a 
cDNA specific (forward) primer 
Introduction of plasmids into rat L6 myoblasts by lipofection; selection of transfected 
cells 
L6 myoblasts were seeded at a density of 5xl05 cells per 60 mm dish, and cultured for 18 h 
The medium was refreshed and after 6 h lipofection was started 5 μg of linearized plasmid 
DNA was mixed with 37 5 μΐ transfection reagent DOTAP, added to the cells and incubated 
for 18 h at 37°C/5% C02 Selection with 5 μ§ puromycin/ml growth medium started 24 h 
after lipofection [31] One week after transfection, separate colonies were picked and grown 
to check for clonal variation 
Southern analysis 
Genomic DNA of non-transfected and transfected L6 myoblasts was digested during 18 h 
with £coRI and Я/ndIII The digestion products were separated on a 0 8% agarose gel and 
blotted onto Hybond N+ filter Southern hybridization was performed using 32P-labeled рас 
cassette (1,7 kb) as a probe in a mixture of 0 5 M sodium phosphate, pH 7 2/1 mM EDTA/7% 
SDS and 100 μg/ml denatured herring sperm DNA Hybridization with the labeled probe was 
performed in the latter mixture for 16 h at 65°C Blots were washed with high stringency in a 
solution containing 40 mM sodium phosphate, pH 7 2/ 0 1% SDS at 65°C 
Northern hybridization 
Total RNA was isolated by the RNAzol method 15 μg of total RNA was separated on 
agarose/formaldehyde gels and blotted onto Hybond N+ filters Northern hybridization was 
performed using j2P-labeled cDNA probes for rat H-FABP cDNA, rat A-FABP cDNA or 
98 
FABP cDNA transfections of L6 myoblasts 
murine GAPDH cDNA The hybridization and wash conditions were as described for 
Southern analysis After exposure (1-3 days), the nylon membrane was dehybndized and re­
used for subsequent hybridizations 
SDS/PAGE and immunoblotting 
Cell extracts were analyzed for FABP expression by separation of 20 μg protein on a 15% 
SDS/acrylamide gel and blotting Rat H- or A-FABP were detected with polyclonal rabbit 
antisera and the ECL detection system (Amersham) 
Cell proliferation 
Cell proliferation was assayed by means of [3H]thymidine incorporation Myoblasts were 
seeded at a density of 10,000 cells per 35 mm dish (five dishes were assayed for each clone) 
and proliferated in growth medium for 36 h After medium change, cells were pulsed for 24 h 
with 3 μΟ [6-3H]thymidine per dish Cells were washed three times with PBS, fixed with 
methanol and air-dned Cells were solubilized by the addition of 1 0 ml 0 5 M NaOH, 
neutralized and radioactivity was determined 
Assay of palmitic acid uptake 
L6 myoblasts were plated on 35 mm dishes in growth medium After 36 h growth, sub-
confluent myoblasts were washed 2 times with 2 ml D-PBS. and 1 75 ml DMEM was added 
After 1 h equilibration period, 0 25 ml of a solution containing 600 μΜ [l-MC]palmitic acid 
(1 4 μΟ/μπιοΙ) bound to 120 μΜ albumin in 0 9% NaCl was added and incubation was 
prolonged After 1-30 min this solution was removed and the cells were washed three times 
with ice cold PBS containing 0 5% fatty acid-free BSA Cells were lysed with 1 ml 0 5 M 
NaOH, neutralised with 6 M HCl and radioactivity was determined in 10 ml Aqualuma by 
liquid scintillation counting At each time point three plates were assayed Values were 
corrected for a blank which was determined by aspirating the fatty acid-containing solution 
immediately after addition The data were normalised for protein content, determined on four 
identical plates Cells were washed three times with PBS, lysed with 0 5 M NaOH, 
neutralised with 6 M HCl and used for protein determination according to Lowry et al [32] 
Assay of palmitate oxidation 
For this assay, we used a procedure previously described for the measurement of fatty acid 
oxidation of human myotubes [33] Cells were cultured m 24 wells plates on growth and 
differentiation medium The medium was removed and the cells were washed three times 
with PBS Wells with cells in 0 5 ml buffer containing 119 mM NaCI/4 7 mM KC1/1 2 mM 
KHiPOj/1 2 mM MgSQ,/ 10 mM Hepes, pH 7 4 were separately placed in 40 ml incubation 
vials, containing 5 ml water Incubation at 37°C was started by the addition of 120 μΜ [1-
HC]palmitate (I 6 μΟ/μιτιοΙ) bound to 24 μΜ fatty-acid free albumin (final concentrations) 
to wells Incubation at 37°C proceeded for 180 mm Palmitate oxidation rate was calculated 
from the production of MC0 2 and
 NC-labeled acid-soluble products [34] 
Assay of palmitic acid incorporation 
Cells were grown on 35 mm dishes in culture medium for 24 h in the presence of 120 μΜ [1-
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HC]palmitic acid bound to 24 μΜ albumin. The cells were washed three times with 0.15 M 
NaCl. and sonicated in the same medium (0.3-1 0 and 3-7 mg protein/ml for cells on growth 
and differentiation medium, respectively). Extracts were analyzed for lipids by TLC as 
described by Mazière et al. [35]. Neutral lipids were separated in hexane/ diethylether/acetic 
acid (70:30-2, v/v), phospholipids in chloroform/methanol/water/acetic acid (5030:4.8. v/v). 
The incorporation of [l-^CJpalmitic acid was determined by liquid scintillation counting of 
separated spots. 
Biochemical assays 
Cells were homogenized in a buffer containing 250 mM sucrose/2 mM EDTA/10 mM 
Tns/HCl, pH 7.4. Citrate synthase (CS) activity was measured in sonicated culture 
homogenates as described by Shepherd and Garland [36]. Units of activity of this enzyme 
represent μιτιοί coenzyme A formed at 25°C per min. Creatine kinase (CK) activity was 
determined with the CK N-acetylcysteine-activated monotest at 37°C. Units of activity 
represent μπιοί NADPH formed per min. CK isoenzymes were separated by agarose gel 
electrophoresis (procedure no. 715-EP, Sigma, St. Louis, MO, USA). The gels were scanned 
using a Bio-Rad GS-670 densitometer and analysed with Molecular Analyst software (Bio-
Rad laboratories, Hercules, CA) The content of rat H-FABP was assayed by a modified 
ELISA [6] Briefly, cellular protein (25 ng) was adsorbed to 96-well microtiter plates by 
incubation for 16 h at 4°C. The FABP was probed with affinity-purified anti-rat-H-FABP 
antibodies, and peroxidase-conjugated swine-anti-rabbit IgG was used as second antibody. 
Results were determined by reference to a standard curve (0 - 0 2 ng rat H-FABP). Protein 
content was determined according to Lowry et al. with bovine serum albumin as standard 
[32]. Intact L6 cells were washed with PBS and dissolved in 500 μΐ 2 M NaOH per well. 
Contents of 6 wells were pooled and neutralized with HCl before protein determination. 
RESULTS 
Cloning and sequencing of rat adipocyte and heart FABP cDNAs and expression of the 
proteins 
The rat A-FABP cDNA was isolated and sequenced (GenBank/EMBL accession no 
U75581). Comparison with the mouse and human A-FABP cDNA sequences [37.38], 
showed similarities of 93% and 85%, respectively. Conserved amino acid substitutions are 
the most common substitutions between the three A-FABP sequences (10 out of 17). The 
presence of Glu-45 and Val-50 discriminates rat A-FABP from both mouse and human A-
FABP. Isolated rat H-FABP cDNA showed no differences in nucleotide sequence with 
previously reported sequences [8,39], except one conserved nucleotide substitution on codon 
Val-32 (GTG to GTC). Coding parts of rat A-FABP and H-FABP cDNA were cloned into 
bacterial expression vectors pET-1 la and pET-3d. using the Ndel and Nco\ restriction sites, 
respectively, as start sites of translation. Purified recombinant rat A-FABP and H-FABP 
showed dissociation constants for the binding of [l-MC]oleic acid of 2.19 ± 0.51 μΜ (means 
± S.D. of 5 experiments) and 0.39 μΜ for rat A-FABP and H-FABP, respectively. These 
values are in good agreement with the data for tissue-derived or recombinant A-FABP 
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[38,40] and H-F ABP [41]. The FABP preparations were applied in subsequent assays as 
standards. 
Rat L6 cell line as a model 
Rat L6 myoblasts show a low H-FABP content on growth medium (about 30 pmol/mg 
protein) which increases to 50 pmol/mg protein in myotubes. No additional induction of H-
FABP was detected at mRNA nor protein level upon the addition of 20 and 200 μΜ palmitate 
or oleate, 0.3 μΜ insulin, or 6-25 mM glucose to the culture medium of L6 myoblasts and 
myotubes for 24 h (data not shown). Primary rat muscle cells show a gradual increase in H-
FABP content from myoblasts (45 ± 2 pmol/mg protein, n=2) upon culturing for 7 days on 
differentiation medium to a maximal content of 76 ± 21 pmol/mg protein (n=7). 
Transfection of L6 myoblasts and clonal variation 
The isolated rat A- and H-FABP cDNAs were used for preparation of constructs which 
contained both a FABP cDNA and а рас cassette. In this way, no co-transfection is necessary 
and all puromycin-resistent clones automatically include a FABP cDNA (except the mock-
transfectants). After lipofection of L6 myoblasts, separate colonies were picked and grown to 
check for clonal variation. 
Clonal variation was monitored by SDS-PAGE and subsequent immunoblotting of 
transfected myoblast homogenates. Among the 7 isolated clonal cell lines transfected with rat 
H-FABP (S) cDNA, only one showed a 6-8 times higher expression of H-FABP than mock-
transfected myoblasts. Clonal cell lines isolated after transfection with rat H-FABP (AS) 
cDNA (9 clones) and with mock construct (9 clones) all showed a comparable expression of 
H-FABP as the non-transfected myoblasts. The clonal variation among the latter two types of 
clones was not large. From this, we concluded that the antisense approach i.e. inhibition of H-
FABP expression, had not worked. 
kDa 1 2 3 4 5 6 
Fig I. Immunodetection ofA-FABP expression 
Total cell extracts of transfected L6 clones (20 μ& were analysed on a 15% SDS/PAGE gel. Immunodetection 
was performed with rabbit anti-rat A-FABP serum. Lane I, purified rat A-FABP (50 ng); lane 2-4, A-FABP 
cDNA transfected clones 1-3; lane 5, mock-transfected clone; lane 6, non-transfected L6 cell line. 
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All three isolated clones transfected with rat A-FABP cDNA showed A-FABP 
expression, whereas A-FABP was not detectable in non-transfected and all other transfected 
clones by Western blotting (Fig. 1). A strong signal at about 30 kDa, points to the existence 
of dimers of A-FABP in transfected myoblasts. A protein of approximately 20 kDa also 
reacted strongly with the rabbit anti-rat A-FABP polyclonal serum (Fig. 1) and also with 
affinity-purified antibodies (not shown). This phenomenon was also observed with antisera 
raised against human A-FABP in mouse and chicken as well as against rat A-FABP in 
another rabbit. Pre-adsorbing the antibodies with a homogenate of non-transfected L6 
myoblasts also did not work (results not shown). One representative clone of each type of 
transfected cell lines (mock, H-FABP (AS), H-FABP (S) and A-FABP (S)) was used in most 
of the following experiments. 
Genomic analysis of transfected L6 clones 
Selection for resistance to puromycin was an indirect test to check the stable integration of 
the constructs in the genome. A direct test for integration is Southern hybridization of 
genomic DNA isolated from the clones (Fig. 2). Indeed only transfected clones tested showed 
a positive hybridization signal with the isolated рас cassette. Different patterns occured as the 
result of concatemer formation of linear plasmids and subsequent integration in the genome. 
kb 1 2 3 4 5 6 7 8 1 2 3 4 5 6 , 2 3 
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Fig 2. Genomic analysis of transfected and non-
transfected rat L6 clones 
EcoRI or Hindlll digested genomic DNAs were 
separated on a 0.8% agarose gel. Southern analysis 
was performed using the s'f '-labeled рас cassette as 
a probe. Lanes I and 5, mock-transfected clone; 
lanes 2 and 6, H-FABP (AS) cDNA transfected 
clone; lanes 3 and 7, H-FABP (S) cDNA transfected 
clone; lanes 4 and 8. non-transfected L6 cell line. 
Fig 3. mRNA expression in non-transfected and 
transfected L6 clones 
Total RNA (15 pg) was separated on a 1% 
formaldehyde/agarose gel. Northern hybridization 
was performed using "P-labeled rat H-FABP cDNA 
(a, d), rat A-FABP cDNA (b), or murine GAPDH 
cDNA (c, e) as probes. Fig. a-c: lane 1, non-
transfected L6; lane 2, mock-transfected clone; lane 
3, H-FABP (S) cDNA transfected clone; lane 4-6, Α­
ΡΑ Β Ρ (S) с DNA transfected clones 1-3. Fig. d, e: 
lane I. H-FABP (AS) cDNA transfected clone; lane 
2, mock-transfected clone; lane 3, H-FABP (S) 
cDNA transfected clone. 
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Northern hybridization 
Total RNA of representative transfected clones was used in Northern hybridization. Clones 
transfected with the rat H-FABP (S) cDNA and rat A-FABP (S) cDNA showed a clear 
overexpression at mRNA level (Fig. За and b). Changes in the levels of messenger RNAs are 
not due to differences in the quantity of RNA loaded onto the gel (Fig. 3c and e). Northern 
analysis of total RNA of H-FABP (S) as well as (AS) cDNA transfected clones showed 
beside the H-FABP messenger, two other signals of high molecular mass, probably due to 
incorrect, plasmid-derived transcription (Fig. 3d, lanes 1 and 3). The clone transfected with 
rat H-FABP (AS) cDNA showed no change in H-FABP mRNA signal, compared to the 
mock-transfected clone. In the three clonal cell lines derived from transfection with A-FABP 
(S) cDNA, differences in length of the A-FABP transcripts were observed. This phenomenon 
is detected more often in systems for heterologuous expression and probably due to 
differences in the length of the poly (A) tail. 
Morphological and growth characteristics 
In the proliferative stage, all transfected clones were morphologically similar to non-
transfected L6 myoblasts. [3H]Thymidine incorporation studies revealed a significant increase 
in the proliferation rate of A-FABP cDNA transfected myoblasts compared to mock-
transfected L6 myoblasts (Table 1). Both rat H-FABP (S) and (AS) cDNA transfectants 
showed no significant differences in growth rate compared to mock-transfected myoblasts. 
Transfected clones were mycoplasma-negative during all culturing and assays. 
Table I [3H]Thymidine incorporation of L6 myoblasts transfected with four different constructs. 
[3H]Thymidine was added (3 μθ/dish) and incorporation measured after 24 h incubation Values are given as 
percentage of control, mock-transfected L6 myoblasts The incorporation in these cells varied between 1061-
3353 dpm/dish (8 independent experiments). Data are means ± S D. of 4-5 experiments ' P<0 01 
Clone type Percentage incorporation 
Mock transfected 100 
H-FABP (AS) cDNA 119 ± 26 
H-FABP (S) cDNA 104 + 28 
A-FABP (S) cDNA 189 ± 45 " 
After changing the growth medium to differentiation medium, morphological differences 
became visible. Both mock-transfected and H-FABP cDNA (S) transfected L6 cells show a 
normal myotube formation after 3-6 days on differentiation medium (Fig. 4a and b) The very 
dark regions in the largest myotubes are due to the typical clustering of nuclei and their 
staining by haematoxylin. L6 myoblasts which were transfected with the H-FABP (AS) 
cDNA show, however, a delayed myotube formation, with few oligonuclear (2-3 nuclei) cells 
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after 6 days (Fig. 4c). These cells fuse much later (after 6-10 days on differentiation medium) 
than mock-transfected cells. Rat A-FABP cDNA transfected L6 myoblasts, cultured on 
differentiation medium remain mononuclear and are arrested in the alignment process (Fig. 
4d). These cells are unable to fuse and form myotubes even after 9 days on differentiation 
medium (observed with three different clones). After 5-7 days the mock and H-FABP (S) 
cDNA transfected myotubes detach from the dishes, but the H-FABP (AS) and A-FABP (S) 
cDNA transfected cells remain sticked for at least 9 days. 
Fig 4. Micrographs of transfected L6 cell lines 
Confluent L6 myoblasts were cultured for 6 days on differentiation medium (a) Mock transfected (b) H-FABP 
(S) cDNA transfected (c) H-FABP (AS) cDNA transfected (d) A-FABP (S) cDNA transfected Cultures were 
stained with haematoxylin solution for 15 min Large arrows indicate myotubes, small arrows oligonuclear 
cells. The bar represents 70 pm. 
Determination of creatine kinase (CK) activity established the difference in differentiation of 
the four clone types (Table 2). After 3 - 5 days on differentiation medium, the two fusion-
incapable clones show very low CK activities, comparable to myoblast values, whereas the 
myotube-forming clones (mock- and H-FABP (S) transfected) show the usual CK activities. 
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The proportion of the muscle-specific isoenzyme CK-MM, as measure of the myogenic 
differentiation, is already over 90% of total content of CK isoenzymes in proliferating 
myoblasts. Therefore, this marker is not useful for the maturation grade of cultured L6 muscle 
cells, in contrast for the mouse muscle cell line C2C12 and primary rat and human skeletal 
muscle cells [16]. Spontaneous contractions of L6 myotubes were never observed in our 
cultures, nor reported in the literature for L6 myotubes, and therefore, could not be applied as 
differentiation marker. Citrate synthase activities do not significantly differ between the 
different clone types on differentiation medium (Table 2) and are only about twofold the 
values of myoblasts. These activities appear also to vary between the different cultures of the 
clones, leading to relatively high S.D values. 
Table 2. CK and CS activities and H-FABP content of transfected L6 cells on growth and differentiation 
medium 
Cells were cultured for 2-3 days on growth medium or 3-5 days on differentiation medium CK and CS activity 
are given in U and mil per mg protein, respectively, H-FABP m pmol/mg protein as means ± S D for the 
indicated number of cultures Statistically different from mock-transfected cells * P< 0 001 
Clone type Growth medium (6-18) Differentiation medium (10-12) 
CK CS H-FABP CK CS H-FABP 
Mock 
H-FABP (AS) cDNA 
H-FABP (S)cDNA 
A-FABP(S)cDNA 
0 05 ± 0 02 
0 05 ±0 01 
0 08 ± 0 02 
0 19 ±0 07 
42 ±23 46 ± 14 
46 ±34 49 ±15 
82 ±36 177 ±67* 
55 ±32 54 ±56 
1 35 ± 0 61 
0 07 ±0 03* 
1 18 r 0 66 
0 05 ±0.03* 
76=16 56 ±25 
86 ± 15 62 ±26 
84 = 24 127 ±38* 
77 ±15 62 ±28 
FABP content in transfected cells 
H-FABP content was estimated by ELISA. Proliferating myoblasts of the H-FABP (S) cDNA 
transfected clone showed a fourfold overexpression of H-FABP (0.26% of total protein, Table 
2). H-FABP contents of mock-, H-FABP (AS) cDNA and A-FABP (S) cDNA transfected 
myoblasts are all in the same range, and similar to those in non-transfected L6 myoblasts. In 
the H-FABP (S) cDNA transfected myotubes, H-FABP expression was also significantly 
increased compared to mock-transfected myotubes (0.19% and 0 08% of total protein, 
respectively). H-FABP contents of mock-, H-FABP (AS) cDNA and A-FABP (S) cDNA 
transfected cells were in differentiation medium slightly higher than in growth medium. 
The A-FABP content in three A-FABP (S) cDNA transfected clones was estimated as 
240-910 pmol/mg protein (0.3-1 3% of total cell protein) as means of 2 densitometry 
determinations of Western blots. The content of A-FABP could not be measured by ELISA 
because of the strong reaction of a 20 kDa L6 protein with the anti-rat A-FABP antibodies. 
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Palmitic acid uptake 
We were unable to detect significant differences in palmitic acid uptake of the transfected 
myoblast cultures (Table 3). In the first 5 min the uptake shows a high initial rate (about 2.6 
nmol palmitic acid/mg protein.min), but it slows down after 5 mm incubation (about 1.3 
nmol/mg protein.min measured over 30 min). H-FABP (AS) cDNA transfection and H-FABP 
and A-FABP overexpression did not cause an effect on the palmitic acid uptake. 
Table 3 Uptake ofll-''Clpalmitic acid by non-lransfecled and transfected rat L6 myoblasts 
Cells were used as subconjluenl cultures on growth medium, and equilibrated for I h at 37"C and 5% CO
:
 on 
DMEM without serum The assay was started by the addition of 75 μΜ [l-NC]palmilic acid bound to 15 μΜ 
albumin Values (in nmol palmitic acid/mg protein) are the means ± S D of 4-6 experiments No significan! 
differences were delected between the different clones 
Clone type Time (mm) 
1 5 15 30 
Non-transfected 
Mock-transfected 
H-FABP (AS) cDNA 
H-FABP (S)cDNA 
A-FABP (S)cDNA 
2 7 ± 1 0 
4 5 ± 1 3 
3 7 ± 1 6 
3 2 ± 0 3 
3 6 ± 1 4 
14 4± 8 0 
12 1 ±5.2 
13 1 ± 1 2 
11 5 ± 2 4 
11 5± 1 1 
24 5 ± 5 8 
202 ± 5 1 
2 6 9 * 3 1 
20 6 ±2 3 
24 5 ± 2 3 
39 3 ± 8 4 
31 7 ± 8 0 
43 4 ± 5 1 
35 0 ± 6 0 
41 9 ± 3 4 
Fatty acid oxidation 
Fatty acid oxidation assays were performed with transfected L6 cells on growth and 
differentiation medium. The assay used for measuring palmitate oxidation has earlier been 
shown to be linear over 300 min in intact myotubes [33]. 
At subconfluency. all transfected clones of myoblasts showed the same rate of 
palmitate oxidation (Table 4). Differences in palmitate oxidation became visible when the 
transfected clones were cultured on differentiation medium for 3 days. The palmitate 
oxidation rate became lower except when fusion was disturbed by transfection with rat H-
FABP (AS) cDNA or rat A-FABP (S) cDNA. These latter clones showed rates comparable to 
myoblasts. 
Distribution of [l-l4C|palmitic acid in neutral and phospholipid species 
We studied the relative distribution of [MC]palmitic acid in the lipid species of cells cultured 
for 24 h with [l-NC]palmitic acid in growth medium or on differentiation medium by TLC 
No marked differences were detected in total incorporation among the four different type of 
clones on both media. The extent of uptake varied for different experiments between 811-
1808 pmol/^g protein or 31-37% of added radioactivity for myoblasts and 215-346 pmol/^g 
protein or 58-81% of added radioactivity for myotubes. The ratio of incorporation of 
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Non-transfected 
Transfected 
Mock 
H-FABP(AS)cDNA 
H-FABP(S)cDNA 
A-FABP(S)cDNA 
13.2 ± 0 5 
11 6 ± 2 2 
16 3 ± 4 6 
l l . 0 ± 3 4 
12.1 ± 3 4 
Table 4 Palmitate oxidation of transfecied and non-transfected L6 cells on growth and differentiation 
medium 
Clone Growth Differentiation 
type medium medium 
(2-3 days) (3 days) 
3 4 ± 0 9 
4.6 ± 0 5 
10 8 ± 1 8 " 
4 7 ± 0 8 
8 4 ± 2 . 6 · * 
L6 myoblasts were grown for 2-3 days in growth medium and used before confluency Confluent L6 myoblasts 
were cultured for 3 days on differentiation medium Oxidation was measured for 3 h with 120 μΜ [1-
l4C]palmitate bound to 24 μΜ albumin as substrate Values (in nmol/h mg protein) are means ± S D of 3-5 
experiments Significally different from mock-transfected cells· * P<0 001, ** P<0 05 The ' 4CO
:
 contribution 
of the total palmitate oxidation was 59 ± 6% and 67± 7% for cells on growth medium and differentiation 
medium, respectively 
radioactivity in phospholipids compared to neutral lipids was also similar for the four clones, 
and 2.0 ± 0 1 in cells on growth medium compared to 3.4 ± 0.4 in cells on differentiation 
medium. 
Proliferating myoblasts of the four clones did not show differences in distribution of 
[14C]palmitic acid among the different neutral lipid species (data not shown). The 
incorporation in cholesterolesters (about 24%) was higher and in triacylglycerols (about 33%) 
lower compared to cells grown on differentiation medium (Table 5). Slight changes were 
observed in the relative distribution of palmitic acid incorporation of neutral lipids of H-
FABP (S) and A-FABP (S) cDNA transfected cells after culturing on differentiation medium 
(Table 5). 
Mock-transfectants show a significant change of [l4C]palmitic acid incorporation into 
PC after culturing on differentiation medium compared to growth medium (Table 6). On 
growth medium all transfected clones do not show differences of [l4C]palmitic acid 
distribution over the phospholipid species, except a higher PE and a lower PC percentage in 
the A-FABP (S) cDNA transfected clone. In cells cultured on differentiation medium, a 
significantly lower incorporation in PE is observed in H-FABP (AS) and A-FABP (S) cells 
and a significantly higher incorporation into PC in all three FABP cDNA transfectants 
compared to mock-transfectants. Incorporation in SM is lower m transfectants of H-FABP (S) 
and (AS) cDNA on differentiation medium. The PC/ΡΕ ratio of A-FABP (S), H-FABP (AS) 
and H-FABP (S) cDNA transfected cells on differentiation medium show a significantly 
107 
Chapter 6 
higher value compared to mock-transfected myotubes (Table 6). Furthermore, the palmitic 
acid incorporation into phospholipids of A-FABP (S) cDNA transfected cells on 
differentiation medium differs from that of the same cells on growth medium, but is very 
similar to the mock-transfected clone on growth medium. The PC/ΡΕ ratio of mock-
transfected cells and H-FABP (S) cDNA transfected cells decrease, whereas that of H-FABP 
(AS) and A-FABP (S) cDNA transfected cells increase upon culturing on differentiation 
medium compared to growth medium. 
Table S Distribution offl-''C/palmitic acid in neutral lipid species of transfected Lb cells cultured on 
differentiation medium 
Clone 
type 
Mock 
H-FABP (AS) 
H-FABP (S) 
A-rABP(S) 
π 
7 
5 
5 
9 
Neutral lipid 
CE 
11 1 ± 0 7 
12 0 ± 14 
1 4 2 ± 0 8 * * 
11 9 ± 2 7 
species 
TAG 
53 I ± 38 
48 2 ± 8 3 
47 0± 2 7* 
43 6 ±10 6* 
FFA 
14 3 ± 3 1 
14 6 ± 3 3 
13 0 ± 3 9 
1 9 4 ± 5 7* 
C + DG 
21 7± 1 6 
24 6 ± 3 3 
26 0± 1 2** 
25 2 ± 4 7 
Cells were cultured for 4 days on differentiation medium, the last 24 h with addition of 120 uM [l-MC]palmitic 
acid bound to 24 μΜ albumin. DG, diacylglycerols, TAG, triacylglycerols, C, cholesterol, CE, cholesterol 
esters, FFA, free fatty acids Cholesterol and 1,2- and 1,3-diacylglycerol were taken together Values (in % of 
radioactivity) are given as means ± S D of the number of cultures (n) Significantly different from mock-trans­
fected cells * P<0 05.** P<0 01 
DISCUSSION 
To study the function of H-FABP in cells which show a low endogenous H-FABP 
expression, we introduced H-FABP cDNA in rat L6 myoblasts, in both the sense and 
antisense orientation. Another approach followed by us, was to introduce a second, non-
muscle FABP into cells already expressing a FABP, as proposed by Matarese et al [42]. 
Expression of A-FABP in muscle cells may compromise fatty acid oxidation, because A-
FABP may be more involved in fatty acid utilization for triacylglycerol synthesis and 
lipolysis. The results presented here, show a clear effect of the transfections with H-FABP 
(AS) and A-FABP (S) cDNA on cell growth and differentiation by biochemical assays and 
morphological observations. The introduction of A-FABP cDNA in L6 myoblasts caused a 
marked increase of their proliferation rate. The fusion-incompetence of these cells at culturing 
for 4-9 days on differentiation medium, is also striking. The mononuclear myoblasts clearly 
enter the first stages of myogenesis, e.g. alignment and adhesion [43], but the cells arrest in 
this stage in stead of fusing to multinucleated myotubes. H-FABP (AS) cDNA transfected 
cells show a disturbed fusion upon culturing on differentiation medium, but with these cells 
fusion is delayed instead of blocked. The cause of these changes is not clear. Transfection of 
L-cell fibroblasts with L-FABP or I-FABP cDNA did not change the growth characteristics 
of these cells [21.24]. 
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Table 6 Distribution of [l-'4C]palmitìc acid in phospholipids of transfected L6 cells cultured on growth and 
differentiation medium 
Clone type 
Growth medium 
Mock 
H-FABP (AS) 
H-FABP (S) 
A-FABP (S) 
η 
4 
2 
2 
4 
Differentiation medium 
Mock 
H-FABP (AS) 
H-FABP (S) 
A-FABP (S) 
7 
5 
6 
10 
Phospholipid class 
PE 
197 ± 6 3 
20.5; 21.6 
17 7; 18 1 
31 9 + 1 9 d 
23.8 ± 1 4 
19 2 ± 2.8 e 
22 6 ± 1 0 
18.8 ± 2.4 M 
PS + PI 
12.3 ± 1.1 
13.5; 15 1 
13 6; 14.2 
12 2 ± 0 5 
13 8 ± 1 2 
13 5 ± 0 7 
13 4 ± 1.0 
12 5 ± 1.4 
PC 
57.5 ± 4 8 
49 3,51 4 
56.2; 56.6 
48.8 ± 0 9 c 
49 5 + 1.2 ь 
57 5 ± 1.8 е 
54.8 + 1.6 е 
53.5 ± 1 1 ь ' е 
SM 
0.5 ± 2 7 
13 5, 15.1 
11.7; И 8 
7 1 + 0 8 
12 8 ± 1.0 
9 7 ± 1.3 e 
9 2 ± 1.3е 
13.9 ± 2 5 b 
Ratio 
PC/PE 
3 2 + 11 
2 3; 2.4 
3.1; 3 2 
1 5 + 0 1 c 
2.1 ± 0 1 a 
3 1 ± 0.5 е 
2 4 + 0.1 ' 
2 9 ± 0 4 ь 'е 
Cells were cultured on growth (for 2-3 days) or differentiation medium (for 4 days), the last 24 h with 
addition of 120 μΜ [l-14C]palmitic acid bound to 24 μΜ albumin PE, phosphatidylethanolamine, PS, phosp-
hatidylsenne; PI, phosphatidylinositol; PC, phosphatidylcholine, SM, sphingomyelin Values (in % of radio­
activity) are given as means ± S D of the number of cultures (n) 
* P < 0 05 vs corresponding cells on growth medium, P < 0 01 vs corresponding cells on growth 
medium, c P < 0 05 vs mock-transfected cells on growth medium, P < 0 01 vs. mock-transfected cells on 
growth medium, e P < 0 01 vs mock-transfected cells on differentiation medium 
The H-FABP (S) cDNA transfected clone did not show a different proliferation rate 
compared to the mock-transfected clone in contrast to yeast, mouse mammary epithelial cells 
and human breast cancer cell lines, which show a specific inhibition of growth and exhibit a 
differentiated morphology upon H-FABP cDNA transfection [11.12,14]. The mammary-
derived growth inhibitor from bovine lactating mammary glands, now identified as a mixture 
of A- and H-FABP [9], reversibly suppresses cell multiplication in a variety of cultured 
epithelial cells [10-12]. In cultured cardiac myocytes, extracellularly added H-FABP seems to 
induce hypertrophy [13] The mechanism by which H-FABP may leave or enter these cells is 
unknown. 
Members of the FABP family appear to be connected with modulation of cell growth. 
L-FABP cDNA transfection increases the efficacy of the utilization of unsaturated fatty acids, 
especially linoleic acid, leading to proliferation of cultured hepatoma cells [44,45]. L-FABP 
specifically mediates the induction of cell multiplication of transfected hepatoma cells by two 
classes of carcinogenic peroxisome proliferators [46] Moreover, the binding of 8 
prostaglandins to L-FABP correlates with their growth inhibitory activity [47] Porcine ileal 
lipid-binding protein (ileal FABP) stimulates the growth of gastrointestinal epithelial cells in 
culture [48]. Cellular retinol-binding protein I and cellular retinole acid-binding proteins are 
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associated with the cessation of cell multiplication that accompanies differentiation [49] In 
our transfected L6 myoblasts, A-FABP expression exerts the same effect as L-FABP 
expression in hepatoma cells, e g the promotion of cell proliferation The underlying 
mechanism of this growth promotion is however not understood Binding studies of other 
ligands than fatty acids have not been conducted as extensively with A-FABP, as with L-
FABP and H-FABP [50] It has been reported that A-FABP is able to bind retinole acid in 
contrast to H-FABP [38,40] It is not clear if such difference in hgand affinities between bl­
and A-FABP could underly the increased proliferation rate of the A-FABP (S) cDNA 
transfected cells Retinole acid appears to be a potent inducer of myogenesis with retinole 
acid receptor-α and transcription factor Myf-5 as primary targets and mediators [51,52] 
The original L6 cell line, used in our studies shows a low content of endogenous H-
FABP In myotubes, the amount of H-FABP rises nearly 2-fold like in cultured primary rat 
muscle cells, but is still 30-fold lower than in quadriceps muscle [5, 6] A larger 
differentiation-dependent increase of expression of H-FABP was found in the mouse C2C12 
cell line, which shows a much lower FABP content in myoblasts [17] A low content of 
endogenous H-FABP should be an advantage to test the antisense approach, because the 
number of endogenous messengers may not titrate out the number of messengers coded by 
the H-FABP (AS) cDNA construct Nonetheless, H-FABP could still be detected by 
immunoblotting and ELISA in myoblasts of these clones m a similar concentration as in 
mock- and non-transfected clones, and so, in our hands use of antisense cDNA transfection 
did not appear an appropriate method to inhibit the expression of H-FABP Changes in fusion 
and differentiation were, however, obvious but the cause of this phenomenon is not yet clear 
Gene-targeted H-FABP-deficient mice may give better information on the importance of this 
protein for survival of cells and organism Our H-FABP-overexpressing transfected L6 
myoblasts show the same level of expression (0 26% of total protein) as the L- and I-FABP 
overexpressing fibroblasts used by others [23-25] Our A-FABP (S) cDNA transfected L6 
clones showed a higher A-FABP content ( 0 3 - 1 3%) than A-FABP cDNA transfected CHO 
cells (0 01%) [26] 
To establish the role of FABP in the cellular uptake of fatty acids, FABP cDNAs have 
been transfected in cell lines, most of which do not express endogenous FABP The results 
were variable In mouse fibroblasts overexpression of L-FABP increased the initial rate and 
extent of c/5-parinaric acid uptake by 50 and 29%, respectively [23] Expression of I-FABP 
did not influence fatty acid uptake [23, 24] In addition high L-FABP expression caused a 
larger initial uptake rate of fatty acid, compared to low-expression [25] In an abstract, Rolf et 
al reported a reduction of fatty acid uptake into HepG2 liver cells transfected with antisense 
L-FABP cDNA and a decreased L-FABP content [53] Furthermore, the total amount of L-
FABP and I-FABP in I-FABP cDNA transfected Caco-2 cells was not proportional to fatty 
acid uptake [54] CHO cell transfectants expressing A-FABP demonstrated a 1 5-2-fold 
increase in the rate of [3H]oleate uptake [26] We did not observe any effect of H-FABP 
overexpression, or A-FABP expression on the rate and extent of fatty acid uptake by L6 
myoblasts In contrast, Claffey et al reported in an abstract a larger uptake and estenfication 
of fatty acids by L6 myoblasts, which were stably transfected with rat H-FABP cDNA and 
producing the protein [19] No quantitative results of these studies were published We 
conclude that the effect of FABP on fatty acid uptake may be related to FABP type and cell 
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type studied 
The higher palmitate oxidation rate of H-FABP (AS) and A-FABP (S) cDNA 
transfected clones on differentiation medium can be explained by their presence in the 
myoblast stage The lower palmitate oxidation in our non-transfected myotubes compared to 
myoblasts, is in contrast to the data of Sauro and Strickland [18], who observed a 3-5-fold 
increase of fatty acid oxidation upon L6 myoblast differentiation These differences are not 
due to the use of different fatty acid concentrations The oxidation rates of myotubes are also 
similar (about 4 nmol/h mg protein), but our oxidation rates of myoblasts are 12 to 18-fold 
higher than theirs This is probably due to differences in assay conditions They measured 
only l4CO, production, whereas we measured also labeled acid-soluble products In our assay 
the fatty acid bound to albumin in the incubation buffer is the only energy source available, 
whereas they determined the oxidation rate in glucose- and serum-containing culture medium 
with fatty acid added together with Tween 20 
The higher uptake of fatty acid into total lipids and the relatively higher incorporation 
into triacylglycerols of L6 myoblasts compared to myotubes were also previously observed 
after 6-18 h incorporation [18] Estenfication of [3H]oleic acid was increased in both L-FABP 
and I-FABP cDNA transfected fibroblasts [23-25] The type of FABP cDNA transfected 
influenced the targeting of fatty acids to triacylglycerols or phospholipids and to PC or PE 
[23-25] A higher estenfication of fatty acids was also found in CHO cells transfected with A-
FABP [26] Expression of bovine H-FABP in yeast did not affect either the phospholipid 
composition or the fatty acid pattern of neutral lipids or total phospholipids [14] Fusion-
retardation and fusion-incompetence of the myoblasts containing H-FABP (AS) cDNA and 
expressing A-FABP, respectively, could be related to alterations in plasma membrane 
structure, as found in transfected fibroblasts expressing L-FABP [20-22] Their PC/ΡΕ ratio 
increased at (higher) expression of L-FABP [20,25] The PC/ΡΕ ratio of our fusion-disturbed 
clones increases on differentiation medium, whereas the PC/ΡΕ ratio of the two clones with 
normal fusion and differentiation decreases Future studies are necessary to reveal the slage(s) 
of myogenesis. in which the former clones are disturbed and which factors are involved 
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Survey and summary 
The low-molecular-mass fatty acid-binding proteins (FABPs), are part of a superfamily of 
lipid-binding proteins, and occur intracellularly in vertebrates as well as invertebrates 
Chapter 1 gives an overview of the diversity of these FABPs and the proposed roles they 
play in fatty acid metabolism and other cellular processes This chapter puts a special 
emphasis on structural studies performed on different types of FABPs and on cellular 
studies on the expression of FABPs and their role in growth, differentiation and cellular 
signaling Special attention was given to transfection studies with FABP cDNAs and the 
implication of FABPs in medicine 
A remarkable observation is the phosphorylation of Туr-19 of A-FABP in vitro and 
in vivo upon insulin stimulation by the group of insulin receptor kinases Phosphorylation 
of residue Туг-19 of A-FABP and also H-FABP upon insulin stimulation is thought to be 
performed by the insulin tyrosine kinase subunit of the insulin receptor, and therefore, may 
act as intermediate in signal transmission to the glucose transport system Purified H-FABP 
could be phosphorylated to a slight extent by the insulin receptor in vitro, but not ex vivo in 
rat muscle (Chapter 2) Up to now, it remains unclear how the tyrosine kinase would be 
able to exerts its action, because structural analysis of A-FABP and H-FABP show the Tyr-
19 residue pointing inwards the cavity of the protein Protein tyrosine phosphatases have 
been identified in preadipocytes but not in skeletal muscle cells or cardiomyocytes A 
possible role has been hypothesized for the phosphorylated H-FABP as a transcriptional 
regulator in the nucleus, but no evidence has been found yet 
FABP is an interesting protein to use as a model protein for structural studies, 
because of its small size, high solubility, and good hgand-binding activity Studies on this 
type of protein can give us more insight in the ligand binding mechanisms used by this 
protein In a previous study, the cDNA encoding human H-FABP was isolated Using this 
cDNA, and based on the information which came available from crystallographic studies 
on the expressed recombinant protein, we started a mutational analysis In this way we 
tried to explore the details of the interactions between the (hydrophobic) amino acid 
residues and the fatty acid's methylene groups, and also between the fatty acid's carboxy-
late and the ionic groups of the binding cavity 23 different cDNAs coding for site-specific 
mutant H-FABPs were prepared from which 14 were used to prepare mutant proteins in E 
coli (Chapter 3) We tested these mutant H-FABPs for fatty acid-binding activity, and for 
conformational stability, compared to wild-type H-FABP The assays showed distinct 
differences between the mutant H-FABPs, and also between mutants with different amino 
acid substitutions at the same position Arginines 106 and 126 proved essential in fatty 
acid-binding of H-FABP Arginines in this region also play key roles in hgand-binding in 
A-FABP, B-FABP and L-FABP We found no clear relationship between fatty acid-binding 
activity and stability of mutant H-FABPs Mutants T40Q, T40V and F57V showed no clear 
change in either fatty acid binding or stability, R126Q had a stability similar to that of H-
FABP but no binding activity, and F57S and Y128F showed only a large decrease in 
stability, with little or no effect on binding In a recently started collaboration with Dr С 
Lücke (Johann Wolfgang Goethe-Universitat, Frankfurt, Germany), the same site-directed 
mutagenesis procedure is followed to prepare mutant H-FABPs for NMR studies on the 
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role of the amino acid residues whose side chains are involved in a hydrophobic patch, a 
structural characteristic which is conserved through all FABPs. Furthermore, determination 
of the contribution of secondary structure elements in the mutant H-FABPs by Fourier 
transform infrared (FTIR) spectroscopy and crystallography are now in preparation 
Comparison of FTIR and fatty acid-binding data for mutant protein with those of the wild-
type H-FABP, will give more information which specific structural elements determine 
conformational stability and fatty acid binding 
Characterization of FABP genes and their genomic regions may be important in the 
determination, association and linkage of polymorphisms to a certain phenotype Mutations 
in the coding region and m noncoding regions like introns and promoters may affect a 
correct expression Furthermore, a gene may be recognized as a candidate gene for a 
disease by its chromosomal location Knowledge of a gene's location may facilitate 
association studies for certain diseases No sequences nor chromosomal localization were 
available for the genes coding for human A-FABP (FABP4), B-FABP, and E-FABP In 
Chapter 4, we describe the isolation of a lambda phage positive for FABP4 sequences, 
using an intron probe We did not examine the gene structure or the intronic sequences 
Using somatic cell hybrid and fluorescence in situ hybridization techniques, we assigned 
FABP4 to chromosomal region 8q21 Unlike the dispersed locations of other FABP genes, 
FABP4 was localized to the same chromosomal region as the gene coding for another 
FABP, the myelin type (PMP2) The coding parts of both genes show a very high 
similarity (73%) The evolutionary origin of these two genes has to be established by future 
closer identification of both chromosomal regions 
As a result of an attempt for cloning the human gene coding for H-FABP, we 
reported in chapter 5 the isolation of FABP3-ps (a H-FABP pseudogene) from a human 
genomic library, its sequence, and localization on chromosome 13 From several lines of 
evidence it was concluded, that this gene was a H-FABP pseudogene, and therefore not 
functional The sequence of the pseudogene may be of help for the development of PCR 
primers for the isolation and quantification of RNA messengers for H-FABP by RT-PCR 
It was concluded that confusion of localization studies by processed pseudogenes may be 
prevented by the use of noncoding, genomic probes (see also chapter 4) 
H-FABP has an almost exclusive affinity for fatty acids as ligands and therefore, a 
role for H-FABP in fatty acid metabolism is anticipated In chapter 6, we used the rat L6 
skeletal muscle cell line to study FABP function m a cell culture model marked by changes 
of the endogenous FABP content Transfection of H-FABP sense cDNA resulted in the 
isolation of a clone which showed H-FABP overexpression This clone showed no 
difference in fatty acid uptake, oxidation and incorporation or in growth characteristics 
compared to mock-transfected cells Introduction of H-FABP antisense cDNA did not 
result in inhibition of H-FABP expression This clone type did also not show differences in 
fatty acid uptake, but showed a delay in fusion and differentiation of the myoblasts 
Another approach followed by us was to introduce a foreign FABP into cells already 
expressing a FABP type, in this case L6 myoblasts with endogenous H-FABP A-FABP 
may be more involved in fatty acid utilization for tnacylglycerol synthesis and lipolysis A 
clear effect of transfection with A-FABP sense cDNA on growth and differentiation of L6 
myoblasts was noticed by assays of proliferation and CK activity, and on base of 
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morphological observations. The cause of these changes is not clear, but differences in 
ligand affinities between H-FABP and A-FABP could underly the increase in proliferation 
rate of the A-FABP cDNA transfected cells. For example, retinole acid, an important 
inducer of myogenesis, has been known to be bound by A-FABP in contrast to H-FABP 
Synthesis of A-FABP in muscle cells did not compromise H-FABP expression, fatty acid 
uptake and oxidation. Incorporation of fatty acids into neutral lipid species did not change 
markedly among the clone types. The relative distribution of [l4C]palmitic acid over the 
phospholipid classes showed a significant difference in the PC/ΡΕ ratio of the two clone 
types not capable of fusing to myotubes. The fusion-incompetence, therefore, may be 
explained by alterations in plasma membrane structure. 
Future research perspectives: 
The results of mutational analysis of the H-FABP fatty acid-binding site may have 
implications for the structural studies on the PPARs ligand-binding site of peroxisome 
prohferator-activated receptors. These receptor proteins have been reported to be activated 
by peroxisome proliferators as well as by fatty acids. Especially arginine residues seem to 
play important roles in protein-ligand interaction. Techniques used for the structure/func­
tion analysis of amino acid residues proposed in binding may be succesful in the study of 
the role of the hydrophobic patch of H-FABP, which is a conserved structure in most 
FABPs. 
The isolation and characterization of the human gene coding for A-FABP will 
encourage studies that use this gene as a candidate gene for diseases as triacylglycerol 
storage disorders, obesity, and insulin resistance. Until now, no polymorphisms have been 
found in A-FABP coding sequences, and isolation of the gene makes it possible to search 
for polymorphisms or repeated sequences in non-coding sequences of this gene. 
Our studies and those of others, indicate an association of FABPs with cell growth 
and differentiation. Rat L6 myoblast clones, derived from the transfection with A-FABP 
cDNA, showed a higher proliferation rate compared to mock-transfected cells and a 
blockage in myogenesis, e.g. the fusion of myoblasts to myotubes. Therefore, this cell line 
may be a model for the study of myogenic cell fusion, and factors involved in this process. 
The effect of addition of factors (growth factors, fatty acids) on fusion of myoblasts of 
these clones may be studied systematically. Also, comparison of the gene expression of the 
fusion-blocked cell lines with the original L6 cell line may give a better understanding of 
the proteins involved in cell fusion. Furthermore, comparative ligand binding and functio­
nal studies on H-FABP and A-FABP may give more insight in the role of these FABPs in 
L6 cell growth and fusion. 
Interesting prospects in FABP research open up by the availability of new techniques. For 
instance, the possibility exists to study in vivo interactions between FABP and other 
intracellular proteins using the yeast two-hybrid system Candidate FABPs for such an 
approach would be the My-FABP and the newly discovered testis-specific FABP which 
both have a stretch of amino acids that has been implicated in the induction of experimental 
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autoimmune neuritis and may account for interactions with membrane proteins Gene-
targeted FABP-deficient mice may serve as a model to study FABP function and complex 
cellular processes and diseases as insulin resistance and obesity Application of monoclonal 
antibody technology and phage display technology may have impact for selection of 
specific antibodies to be used for diagnostics of tissue injury 
The involvement of FABP in growth and differentiation of cells is evident The 
tumour-suppressor activity of H-FABP in breast tumour may give the possibility to use H-
FABP expression as prognostic marker of breast carcinogenesis Other FABP types may 
also be useful tumour markers The use of release of specific FABP types as markers for 
tissue damage opens possibilities for clinical applications in cardiac infarction, liver 
disease, renal failure, and intestinal ischemia and transplantation 
Different types of FABP have been observed m the nuclei of different cell types 
Up to now, no consensus exists about the function FABP may exert in nuclei Fatty acids 
show a clear regulatory role in regulation of genes involved in lipid and carbohydrate 
metabolism Different types of PPARs may be involved in this gene regulation mechanism, 
by the binding of natural fatty acids and/or peroxisome proliferators Gene expression may 
be influenced by dietary supplementation of specific fatty acids This may possibly give 
therapeutic perspectives 
FABPs may have impact for immunological aspects in disease and protection 
Human My-FABP has been considered as a candidate autoantigen in inflammatory 
demyelinating diseases of the peripheral nervous system My-FABP-peptide-induced 
experimental autoimmune neuritis (ΕΑΝ) may represent an useful model to investigate 
axonal degeneration Invertebrate FABPs are vaccine candidates for heterologous immunity 
against parasites like schistosomes and Fasciola hepática 
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Vetzuurbindende eiwitten (FABPs) met een moleculair gewicht van 13-15 kDa, behoren tot 
een familie van vetzuur- en retinoid-bindende eiwitten Sinds de ontdekking van de eerste 
FABPs in 1973, is er veel gedetailleerde informatie over deze eiwitfamilie en hun karakte-
ristieken beschikbaar gekomen Vetzuurbindende eiwitten komen voor in het cytosol van 
cellen, bij zowel gewervelde als ongewervelde dieren Oorspronkelijk werd aan deze 
eiwitten slechts een functie voor intracellulaire binding en transport van vetzuren toege-
dicht, maar de laatste jaren zijn ook andere functies onder de aandacht gekomen, onder 
meer in relatie tot een beschermende en modulerende werking van de vrije vetzuur-
concentratie in de cel 
Hoofdstuk 1 geeft een overzicht van de diversiteit van de vetzuurbindende 
eiwitten, hun structurele overeenkomsten en verschillen, en hun voorkomen en expressie 
Mogelijke functies van deze eiwitten in transport en metabolisme van vetzuren, groei, 
differentiatie, genregulatie en cellulaire signaaloverdracht worden besproken Verder wordt 
in dit hoofdstuk aandacht besteed aan transfectiestudies met FABP cDNAs en mogelijkhe-
den voor het gebruik van FABPs in medische diagnostiek 
Een opmerkelijke observatie is de fosforylenng van tyrosine 19 (Tyr-19) van 
adipocyt FABP (A-FABP) in vitro en in vivo na stimulatie met insuline, door insuline 
receptor kinases Deze reactie wordt daarom gezien als een mogelijke schakel in de 
signaaloverdracht van het glucose-transport systeem Gezuiverd hart FABP (H-FABP) kon 
in zeer beperkte mate in vitro gefosforyleerd worden door de insuline receptor, echter niet 
ex vivo in rattenspier (Hoofdstuk 2) Anderen hebben een zeer beperkte fosforylenng van 
H-FABP in cardiomyocyten en borstkliercellen aangetoond Tot nu toe is het onduidelijk 
hoe de tyrosine kinase zijn functie kan vervullen, omdat uit structurele analyse van A-
FABP en H-FABP is gebleken dat de zijketen van aminozuur Tyr-19 naar het binnenste van 
het eiwit wijst 
Vetzuurbindende eiwitten kunnen als model eiwitten worden beschouwd voor 
studies naar eiwitstructuur, vanwege hun relatief geringe omvang, hoge oplosbaarheid, en 
goede hgandbindingsactiviteit Studie aan FABPs kan meer inzicht geven in het mechanis-
me waarmee het ligand wordt gebonden aan dit type eiwit In een voorgaande studie werd 
het cDNA geïsoleerd dat codeert voor het H-FABP van de mens Met behulp van dit 
cDNA, en de informatie die beschikbaar kwam uit crystallografische studies aan het 
recombinante eiwit, werd een mutatie analyse van dit eiwit gestart Op deze manier wilden 
wij meer gedetailleerde informatie verkrijgen over de interactie tussen hydrofobe aminozu-
ren en vetzuurstaart, en ook die tussen de carboxylgroep van het vetzuur en de geladen 
aminozuren in de bindingsholte van het FABP 23 verschillende cDNAs werden gemaakt 
via plaatsgerichte mutagenese, die todeerden voor specifieke FABP mutanten Hiervan 
werden 14 mutanten verder gebruikt om recombinant mutant FABP te bereiden in E. colt 
(Hoofdstuk 3) Deze FABP mutanten werden getest op vetzuurbindmgsactiviteit en 
conformationele stabiliteit en vergeleken met het ongemuteerde FABP Duidelijke 
verschillen bleken te bestaan tussen de verschillende FABP mutanten op posities Phe-16, 
Thr-40, Phe-57, Arg-106, Arg-126 en Tyr 128, en ook tussen mutanten met verschillende 
aminozuurzijketens op dezelfde positie binnen het eiwit De arginines op 106 en 126 bleken 
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voor H-FABP van essentieel belang te zijn voor de vetzuurbinding. Arginines in deze regio 
bleken ook bepalend in mutatie analyse voor de ligandbinding bij adipocyt-, hersen-, en 
lever-type FABP. Wij vonden geen duidelijke relatie tussen vetzuurbindings-activiteit en 
stabiliteit van de FABP mutanten. Zo vertoonden mutanten T40Q, T40V en F57V geen 
duidelijke verandering in verzuurbindingsactiviteit noch in de stabiliteit; mutant R126Q had 
een stabiliteit die vergelijkbaar was met die van het ongemuteerde H-FABP maar geen 
bindingsactiviteit en mutanten F57S en Y128F toonden slechts een grote verlaging in 
stabiliteit, zonder een effect op de bindingsactiviteit. 
Door de karakterisering van FABP genen, en hun omgeving en plaats op het 
genoom kunnen mogelijke genetische variaties vasgesteld worden. Deze genetische 
variaties of polymorfismen, kunnen een handvat zijn voor de bestudering van associaties 
tussen genen en een afwijkend fenotype. Mutaties in gencoderende gebieden en ook in niet-
coderende gebieden als intronen en promoters, kunnen een correcte expressie van het 
genproduct beïnvloeden. Door de ligging van een gen op een bepaald stuk van een 
chromosoom kan een gen bovendien herkend worden als een kandidaatgen voor een ziekte. 
Kennis omtrent de ligging van een gen op het chromosoom kan associatie studies met 
bepaalde afwijkingen vergemakkelijken. Voor de genen die coderen voor humaan adipocyt 
FABP (FABP4), hersen FABP en epidermaal FABP zijn geen genomische sequenties of 
chromosomale locaties beschikbaar. In hoofdstuk 4 beschrijven we de isolatie van een 
lambda faag die positief is voor FABP4 met behulp van een tevoren gesynthetiseerde intron 
probe. De genstructuur en de intronsequenties werden niet nader gekarakteriseerd. Met 
behulp van somatische celhybriden en fluorescentie in situ hybridisatie technieken, werd 
de FABP4 locus gelocaliseerd op chromosoom 8q21. De meeste FABP genen van de mens 
en de muis waarvan de chromosomale ligging bekend is, liggen op verschillende chromoso-
men. Locus FABP4 werd echter gelocaliseerd in dezelfde chromosomale regio als het gen 
dat codeert voor het myeline-type FABP (PMP2). De coderende delen van FABP4 en 
PMP2 vertonen een erg hoge gelijkenis (73%). Door nadere identificatie van de chromoso-
male omgeving van deze twee genen kan meer inzicht worden verkregen in hun evolutio-
naire oorsprong. 
Tijdens een poging om het humane gen voor H-FABP te doneren, isoleerden we 
een H-FABP pseudogen (FABP3-ps) uit een humane genomische bank. In hoofdstuk 5 
beschrijven we de isolatie van dit pseudogen, de nucleotidevolgorde en de localisatie op 
chromosoom 13. In dit hoofdstuk worden verschillende argumenten genoemd, om 
aannemelijk te maken dat dit gen een pseudogen is. Pseudogenen zijn per definitie niet-
functioneel. De nucleotide volgorde van FABP3-ps kan behulpzaam zijn bij de ontwikke-
ling van PCR oligonucleotiden voor de isolatie en quantificatie van RNA boodschappers 
voor H-FABP met behulp van RNA-PCR. Het gebruik van niet-coderende, genomische 
probes tijdens de isolatie van positieve klonen uit een bank, kan mogelijke verwarring 
tussen genen en pseudogenen in genlocalisatie studies voorkomen. 
H-FABP heeft bijna uitsluitend affiniteit voor vetzuren als ligand en daarom is het 
niet vreemd dat algemeen een rol van H-FABP in het vetzuur-metabolisme wordt 
verondersteld. Om de functie van FABP in een celkweek model te bestuderen, werd in 
hoofdstuk 6 gebruik gemaakt van de rat L6 skeletspiercellijn en veranderingen van de 
endogene hoeveelheid FABP in deze cellijn. Introductie van het sense cDNA coderend voor 
H-FABP in de L6 cellijn met behulp van transfectie, leidde tot de isolatie van een L6 kloon 
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met een verhoogde H-FABP expressie Deze kloon vertoonde geen verschillen met de 
controle-transfectant in vetzuur-opname, oxidatie en incorporatie of groei karakteristieken 
Introductie van het cDNA (omgekeerde oriëntatie) van H-FABP resulteerde niet in de 
beoogde remming van de H-FABP expressie, ook wel antisense-remming van expressie 
genoemd Deze klonen vertoonden ook geen verschillen in vetzuuropname, maar wel een 
vertraging in fusie en differentiatie van de myoblasten Een andere benadering die door ons 
werd gevolgd, is de introductie van een "vreemd" (met-hart type) FABP in cellen die al een 
type FABP maken, in ons geval, L6 myoblasten met endogeen H-FABP Gezien de aard 
van het weefsel waarin het specifiek voorkomt, zou adipocyt FABP meer betrokken kunnen 
zijn bij het intracellulaire transpon van vetzuren van en naar de plaats waar triacylglycerol 
afbraak/synthese plaatsvindt Introductie van het sense cDNA coderend voor A-FABP in de 
L6 cellijn leidde tot een duidelijk effect op groei en differentiatie van L6 myoblasten, 
gemeten met behulp van een proliferatie assay en op basis van creatine kinase activiteit en 
morfologische observaties De oorzaak van deze veranderingen is niet duidelijk, echter 
verschillen in ligand affiniteit tussen H-FABP en A-FABP kunnen mogelijk ten grondslag 
liggen aan de toename in prohferatiesnelheid van de cellen die getransfecteerd zijn met het 
A-FABP cDNA Zo wordt bijvoorbeeld retinolzuur, dat myogenese bevordert, goed 
gebonden door A-FABP maar niet of nauwelijks door H-FABP Synthese van A-FABP in 
spiercellen interfereerde niet met de H-FABP expressie, noch met de vetzuuropname en -
oxidatie De A-FABP cDNA getransfecteerde L6 myoblasten bleken niet in staat tot fusie 
tot myotubes De incorporatie van vetzuren in neutrale lipiden door de verschillende 
getransfecteerde L6 kloons veranderde niet noemenswaardig Echter, de relatieve verdeling 
van [14C]palmitinezuur over de fosfolipiden vertoonde een significant verschil in de PC/PE 
ratio van de twee kloontypen die niet/slecht in staat waren te fuseren tot myotubes De 
incompetentie van deze klonen tot celfusie kan daarom misschien verklaard worden door 
veranderingen in hun plasmamembraan structuur 
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